var title_f17_15_17648="Periareolar abscess male";
var content_f17_15_17648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Male breast abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Before and after treatment of a male breast abscess with incision and drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17648=[""].join("\n");
var outline_f17_15_17648=null;
var title_f17_15_17649="Virilization cross section view";
var content_f17_15_17649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Virilization (cross-sectional view)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal and abnormal differentiation of the urogenital sinus and external genitalia. Diagrams of normal female and male anatomy flank a series of schematic representations of different degrees of virilization of females, graded using the scale developed by Prader for patients with congenital adrenal hyperplasia. Note the uterus persists in virilized females even when the external genitalia have a completely masculine appearance (Prader grade 5).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245. file://edrv.endojournals.org/. Copyright &copy; 2000 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17649=[""].join("\n");
var outline_f17_15_17649=null;
var title_f17_15_17650="Treatment protocols for breast cancer";
var content_f17_15_17650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17650/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17650/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17650/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17650/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17650/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17650/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/15/17650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12702398\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with breast cancer. Additional regimens may be added over time, particularly as treatment for breast cancer evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with breast cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link\">",
"       \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"       \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=see_link\">",
"       \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12702620\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12702628\">",
"    <span class=\"h2\">",
"     Regimens for HER2-negative breast cancer",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931995884\">",
"    <span class=\"h3\">",
"     TC (docetaxel plus cyclophosphamide)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56545 \" href=\"UTD.htm?2/43/2750\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931995909\">",
"    <span class=\"h3\">",
"     Dose-dense ACT (doxorubicin plus cyclophosphamide followed by paclitaxel)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef55933 \" href=\"UTD.htm?27/5/27742\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931995934\">",
"    <span class=\"h3\">",
"     AC (doxorubicin plus cyclophosphamide)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef78493 \" href=\"UTD.htm?7/47/7934\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931995959\">",
"    <span class=\"h3\">",
"     ACT (doxorubicin plus cyclophosphamide followed by weekly paclitaxel)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef69273 \" href=\"UTD.htm?25/22/25966\">",
"     table 4",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931996017\">",
"    <span class=\"h3\">",
"     Oral CMF (oral cyclophosphamide plus methotrexate and fluorouracil)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef69601 \" href=\"UTD.htm?42/50/43821\">",
"     table 5",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29982684\">",
"    <span class=\"h3\">",
"     IV CMF (IV cyclophosphamide plus methotrexate and fluorouracil)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef86827 \" href=\"UTD.htm?34/45/35549\">",
"     table 6",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29982798\">",
"    <span class=\"h3\">",
"     FEC (fluorouracil, epirubicin, plus cyclophosphamide)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef86828 \" href=\"UTD.htm?12/42/12974\">",
"     table 7",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29982691\">",
"    <span class=\"h3\">",
"     FEC followed by weekly paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef86825 \" href=\"UTD.htm?26/39/27262\">",
"     table 8",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232629016\">",
"    <span class=\"h3\">",
"     FEC followed by weekly docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef86826 \" href=\"UTD.htm?27/61/28638\">",
"     table 9",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12702676\">",
"    <span class=\"h2\">",
"     Regimens for HER2-positive breast cancer",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12702708\">",
"    <span class=\"h3\">",
"     ACTH (doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef54687 \" href=\"UTD.htm?12/23/12671\">",
"     table 10",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85677 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17650=[""].join("\n");
var outline_f17_15_17650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12702398\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12702620\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12702628\">",
"      Regimens for HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H931995884\">",
"      - TC (docetaxel plus cyclophosphamide)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H931995909\">",
"      - Dose-dense ACT (doxorubicin plus cyclophosphamide followed by paclitaxel)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H931995934\">",
"      - AC (doxorubicin plus cyclophosphamide)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H931995959\">",
"      - ACT (doxorubicin plus cyclophosphamide followed by weekly paclitaxel)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H931996017\">",
"      - Oral CMF (oral cyclophosphamide plus methotrexate and fluorouracil)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29982684\">",
"      - IV CMF (IV cyclophosphamide plus methotrexate and fluorouracil)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29982798\">",
"      - FEC (fluorouracil, epirubicin, plus cyclophosphamide)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29982691\">",
"      - FEC followed by weekly paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1232629016\">",
"      - FEC followed by weekly docetaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12702676\">",
"      Regimens for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12702708\">",
"      - ACTH (doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85677\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85677|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2750\" title=\"table 1\">",
"      TC regimen for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/5/27742\" title=\"table 2\">",
"      Dose dense AC-T breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/47/7934\" title=\"table 3\">",
"      AC regimen for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/22/25966\" title=\"table 4\">",
"      AC-T for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/50/43821\" title=\"table 5\">",
"      Oral CMF for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/45/35549\" title=\"table 6\">",
"      IV CMF for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/42/12974\" title=\"table 7\">",
"      FEC for MBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/39/27262\" title=\"table 8\">",
"      FEC plus paclitaxel for MBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/61/28638\" title=\"table 9\">",
"      FEC plus docetaxel for MBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/23/12671\" title=\"table 10\">",
"      AC followed by TH regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=related_link\">",
"      Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_15_17651="Vitamin B2 (riboflavin): Drug information";
var content_f17_15_17651=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin B2 (riboflavin): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/34/27171?source=see_link\">",
"    see \"Vitamin B2 (riboflavin): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44322?source=see_link\">",
"    see \"Vitamin B2 (riboflavin): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ribo-100 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin, Water Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary supplement:",
"     </b>",
"     Oral: 100 mg once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily intake:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;19 years: Females: 1.1 mg; Males: 1.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnancy: 1.4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactation 1.6 mg",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F218122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44322?source=see_link\">",
"      see \"Vitamin B2 (riboflavin): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: 0.3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 0.4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily intake:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 0.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 0.9 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: Females: 1 mg; Males: 1.3 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ribo-100: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14306779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Migraine prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Riboflavin may be confused with ribavirin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F218130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Genitourinary: Discoloration of urine (yellow-orange)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin deficiency: Single vitamin deficiency is rare; evaluate for other deficiencies.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13872727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Water-soluble vitamins cross the placenta. Riboflavin requirements may be increased in pregnant women compared to nonpregnant women (IOM, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13872728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Riboflavin is found in breast milk. Concentrations may be influenced by supplements or maternal deficiency. Riboflavin requirements may be increased in nursing women compared to non-nursing women (IOM, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13878290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary sources of riboflavin include liver, kidney, dairy products, green vegetables, eggs, whole grain cereals, yeast, and mushroom.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Riboflavin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $6.90",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arcavit-B!2 (AT);",
"     </li>",
"     <li>",
"      B2-ASmedic (DE);",
"     </li>",
"     <li>",
"      Beflavine (FR);",
"     </li>",
"     <li>",
"      Berivine (BE, LU);",
"     </li>",
"     <li>",
"      Bi-Love-G (JP);",
"     </li>",
"     <li>",
"      Bisanorin (JP);",
"     </li>",
"     <li>",
"      Bisulase (JP);",
"     </li>",
"     <li>",
"      Bituvitan (JP);",
"     </li>",
"     <li>",
"      Bonabon B!2 (JP);",
"     </li>",
"     <li>",
"      Butirid (JP);",
"     </li>",
"     <li>",
"      Dalivit (BR);",
"     </li>",
"     <li>",
"      Eyekas (JP);",
"     </li>",
"     <li>",
"      Flavitol (AT);",
"     </li>",
"     <li>",
"      Hibon (JP);",
"     </li>",
"     <li>",
"      Lacflavin (JP);",
"     </li>",
"     <li>",
"      Liperox (AR);",
"     </li>",
"     <li>",
"      Multiscleran (DE);",
"     </li>",
"     <li>",
"      Ribobis (JP);",
"     </li>",
"     <li>",
"      Ribobutin (JP);",
"     </li>",
"     <li>",
"      Ribon (LU);",
"     </li>",
"     <li>",
"      Riboract (JP);",
"     </li>",
"     <li>",
"      Vita-B2 (FI, PL);",
"     </li>",
"     <li>",
"      Vitamin B!2 Jenapharm (DE);",
"     </li>",
"     <li>",
"      Vitamin B!2 Jenapharm[inj.] (DE);",
"     </li>",
"     <li>",
"      Vitamin B!2 Streuli[Ampullen] (CH);",
"     </li>",
"     <li>",
"      Vitamin B!2 Streuli[Tab.] (CH);",
"     </li>",
"     <li>",
"      Vitamin B!2-Injektopas (DE);",
"     </li>",
"     <li>",
"      Vitamin B2 (PE);",
"     </li>",
"     <li>",
"      Vitaminum B2 (PL);",
"     </li>",
"     <li>",
"      Wakaflavin-L (JP);",
"     </li>",
"     <li>",
"      Werdo (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F218084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Component of flavoprotein enzymes that work together, which are necessary for normal tissue respiration; also needed for activation of pyridoxine and conversion of tryptophan to niacin",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily via GI tract; increased with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Holland S, Silberstein SD, Freitag F, et al, &ldquo;Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1346-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/15/17651/abstract-text/22529203/pubmed\" id=\"22529203\" target=\"_blank\">",
"        22529203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine), \"Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B",
"      <sub>",
"       6",
"      </sub>",
"      , Folate, Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      , Pantothenic Acid, Biotin, and Choline,\" Washington, DC: The National Academies Press,  1998.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powers HJ, \"Riboflavin (Vitamin B-2) and Health,\"",
"      <i>",
"       Am J Clin Nutr",
"      </i>",
"      , 2003, 77(6):1352-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/15/17651/abstract-text/12791609/pubmed\" id=\"12791609\" target=\"_blank\">",
"        12791609",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9861 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17651=[""].join("\n");
var outline_f17_15_17651=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218108\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218132\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218110\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218122\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218111\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218095\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218081\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218096\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14306779\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218138\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218130\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218085\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299998\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218089\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13872727\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13872728\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13878290\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570485\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038799\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218084\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218098\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9861\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9861|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/34/27171?source=related_link\">",
"      Vitamin B2 (riboflavin): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44322?source=related_link\">",
"      Vitamin B2 (riboflavin): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_15_17652="Psoriasis palmar";
var content_f17_15_17652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Palmar psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDoohna7RsoH3R2PvU8m1wuz5mztIHWjy1Usd2QcY54ApkbCPcWYKc4XHp7V9hufK7DHdcRjjbuxnHQ+9Mi+UtsUr2Bzx9RUoCtGVX5SfzPvSJG3ljJxGRjGO/rVaE2d7kkTyZAOSCeo7UKfnc5ye+aEkVVydzY6U3a7bQgwxOTk9qlldB/D4bI2k4yelRzxIsSl2YY6Y5AJp5GZMKC2DkZGOaJ2AJIUdOnYGgLaFWX92oOTj7rYHJPalUpG3mbhvLdF71LEoMfzZ5B6/yphBdiY8IF6VRFrakLuY2KEYzkhl7Go1yAjSqGf25yKsmDLbd3zcspHBzVcw7WckNkDnBpqyIafUkjLMUCqW3jaOcFacJPmRVQnHGT2PvUMTBvLAyGxgrnkH1qYiS3BSRgzYGWH9aRSLEZCy/dyO/YUssjByGHQZVhzSTMbeElDkAcgc7frTSysg+ZQD1PXP0qUjRvzHLlwFDAq3pUjYIUFiBnAA9fekiKlcgcKMc9RTfnZWXnJxyOooH0JCwL7AMN0ORxj1pyq2QxUbf54qONQoC5Yjpu60sjMucA7s4AzzSGnoJNH5ny/Mcc49KDGUYspOOpHXBp5YswAwO7f4Ux5kLbhnrgGmmKyZDESOWADdcgYFOiO93Z8cHoB09xT3diAgAGeOnOKYo2kAfw8H3pktBKqhSCzFByNvXHtUUoyok2nK/x5wQexIqeJg4JCgAZAxUYIDfxA45PYCmiZRGOokjy4DPwc/w/X2pqKTkSMcLgHnt9aWQ+UwVV2gnK5PFOP7sYK7M/kaCbIjV3Clmj3Kcgc5wPWnj7rMFG0dgCCM96UDOOvovuKcPkIO7BIznHX60ilcikw7AupJz8p/u0KA8e04256jp71IWVDkthjkgAcfWldSikgADoMCmFirDEROxXcQecgZGP61O5XcVClmOMmgExK7BFVycE9QPT8aR9z/KrjJ6nPf60PV3JS5VZDNyFTlctnaAOD+dSnaygBiGJ5YdCPQ0ixHJLn7g7Hk+v0NNDsMYByer4/Kky1fqh0u1AqrlkPI2jH5elMf5SfKdWyfmJpSrZbbgNngqcBT3qFUYSgEjYG6ueCf6fWhITZMZFEgjjz85xhhncO9KJVLFBsVEGPl6qfQ07YAh+ULzuyWyc9/wpsPyRsrp8qk5cEDdS0KV76jT+5KqSSHPJI+YHp1pqnDNFGo+VgpBPfvU5Py52hipxnHQe9Mw5iYkqDgknuMU7gNcALlQ5IY/KTgEHv9KieOJizQvkYO1tveiTeSWG3YoGOT070rbV4jfa2B8ufu+mRTIuMaMOVCsx2jgg4/Q0m5toZOFz1POPpSq4LnDlX4zxn8jQW3SbtjE84QHBH0poWg5nYDC8sfmLKe2Ocj0prD90NwHX5vL/AJUo+dGdzjd0DDGfY0z7h3JnPTA70rDuM2O0YUAeo75x2+tKkm2ZSTlWG1gB2oG5yFAwMdemaPlDBAGwOMf3fpVCuVJgWUtFGF+bBIOOPSs67KSMMOwbae3I9q1pV8uBlRt5Bz6cex9aq7dzKQrKe7A9R6GplCMlyyRUKs4S5ouzK+iSompRw3C8ZwRnk+4rQuZ1eUKoKtFuDAj3qk8SMG3gb2+YMPvD3Bqs80kcn70MQcfvWHWvn8ZgHTV4ao+ry/NY1mo1dJGzHODEGYEkcCrdrdhEzjG3nHf6Z9KwopxsIBA9+xqZZgsRIchun4V5WqPeTTR0n2sv5TyDdJvBxjgDBxVW5jVmZgBux24BrJgmZR1P59a0LWdBJ/pIIiAJO0cn2+lNSvuDVtTHv0GcjHPrWTIOOc1s3GJtzBNigFgBzgZrOuE5GBx3PvUWJk9DGu4lIYcg9Qa47xIn+pbnqRXaXJALA5wa4vxI+WiT3LV0Ujzq47wnKU1QLk4Yc4opPCkZbVFYA8DrRX0WAk1SPlMz5far0PoORfMXjhMfpTJcAbGAJbG0E4IpWGFVFOHA+bjO6kRWkBdMKyjCjPBrsOfceqrwCVBGcmnnDJlPlUDn2FRhTsDbf3mORmkmYlWHJIHAxSG3oIgAGT0/SkJkEZfOW4A7YFOBAiCsDnHSlbqAv977vvVE7CxA4LDA9QaY5DkqPu9896czEKXyd2OOOKjViqjdksc7t39KQeQPuwg52jr71JswpGMA8jJx0psmXT5MbyO60sqBwi7gP7x9aA9BsRLQhpE3YzsJ6ikMfCk5z7GnMGiR9/I9ugHbApp5CqOAoBVv6UAtUESgKHHG3oFHNLsDxs0qliepHGR71IULAAqO245wRSSZ37Acc8+tIq1lcqSbSxdRtUfK2ep9KfAqJAMj5z0A705hG0ijqg6DPek2kkqwUDdxj0HeqMra3AHzgOm04HHX86swgKGEeGVOGOec1CkJSOOOFgRgnk8UjAg7gxABwxHYVL1NFdFhhlt2MqOvPeomZWbaPXnmmxzK6lY3wuTxnnNOTlS+35ifTp70JWBu+w5lxGfmyB0HenRkgDIG7qSf61GzZkyGBK9F9ac7M7bIztJ+8aA0FbhWkOdzYPt9aMZywDEnofQU1mCNgfMFXjIyD7063kYnLZ3dSBxQF1cNqqCAxAyeRzUICtHzjHtxVnChSV5yeGBx+lRS4yq4CseB6E00waI+EPz5Ge1Ol5DLtDB/mZW6YpWUeW4wfUnGQ1QxssmF2sC3qOtFidh6bdypGACo+63b6U5pD5DOwGB94jg0siAYXhhjO4df8imMwkAjONo4yOv40D2GQqUVndWAODyeAPpUqSNKS4Ck9U7g00kBAUBAz65BqRBiMKmBnrwMA+1Aooglb5MHLIcng81FFKp2tj5i20Y52/X3qfaJHy2UYcrjvijajShyqllOSeh57n3p3Jad7j0cYY7ySvfGCc+1RqhAdw21cY5Iw1OZgzsYwCemcfrSOwMm1sFhycjgClYvoNwrSYlyQqfN6EGghSqsqhQrBQR0ZakEfEZSNw55yOn5UySQnaAFEnJIxkED2o3BKyCSRppNqrvAxnjkD2pbrJJVlAjzzxj8R602JvLiBUIS2Syr1J9qFdNm5ixAHBJ6/h2pdQIp1LgBSBwBheSf8+lTIgQoVAWML8w6H601GHyNGuSW5DNnJqOR9okAwQrbiCvOfb2/zzTJVr3GyHeJFZmyDjcRkZqF/vE4HH3vVR60jHzGDfNkg59vwpF+ZVONzsP4uAatKxk9WPkZpEGApxzjpx/jSxAh1XcHGMfN1Ht7iozlRg42gY559xinQswjY4yw5+bJyfr2oGPmRnbyyQEz0pjRqP4QW6D2xUojDHGBu6/5/wAKAkgLBRt3dye3t/hSuUlfUjkXHzOzKvbHU+9IwP3dnHTOepp2CQT/AAgZXdzmmmVMLgbnIBZegJpiInWTySWQnJyDnjPvUTlWUbSA4ODgdalnAHLbs7sEZwSP/rVFIuQCDuH160g6leURpEGcYAyAd3NQujuWDKGUgYBbr9fQ/pU/lg5RgvJyd3an4DMCuAw4GaTLiZ32UIY2TKpnlG9c9KZc3Di4IuEWIEYUYwrD2NasmM4A+oHI+tIyb42EiK0X0xn8K8/EZdTrarRnr4TNatDSXvIzYp1O3ByR2q2bvfGTwOx9qjk0lSGkt28pSOB94fl2qk1teRxqSquhOQ4PA+vpXjVsvq0ne10e9QzWhW0vZ+ZaafCMF5Yjr7VRmlJJJPNNu5JrWNHfGZBxsO7A96y579QCF5PoK42rHa6kWrjb+bZuwRjPHNcLqMxur13U5ReBXXzWs0lncXdz+6t40ZuvJ9P1rldHtPtV/BCwOGb5gPSuqhTcml3PNxFVK77HVeAtOc7pmiyvXPXFFdtYW0NtAkcS8EDt1+tFfTUYeygoo+TrTVabnLqdWkquEZZFJI249amZN8e3GWBycdMelU9O8ssZMLsQYVenPerUZ+dgpJdzuJPH5Vo1Zig7q7E4KHC4z1PUj6VGknKsMnHQ+tWJGAVF3AkdR60xV2qNwGG5GOmaQNakUgdZ0CjCleQT1p6gBVbbk4yCD6VGFbdkcp+dSli0YUrg4zwKYkA/eSLzhfb+dNwWdgD8g5FSLGF2nlT0PoKSRAnyIeCQSc0DSdhm7ym3dc+vc+gpyIoZi5OOCaauJXAzhAc5YVIBjAlAyfagEIuVctkEYxyegpZFODuAAb3/AFqTLcDaPm4zjinOVVSMg/3vapuXy6EWSI1Dg5YZG7gVXALbwMgnpntU0qgEHGf7oPb8aVmITZgFj90d/wAaL2Jeu5W2kf6vaoB5JHJqSFEVRw3vntQIBLuBIBA2EjgD3qR5Aqqg4wfvf3j7U2xRiiKRhkB0KBcf8CpszM4PllY5WHHPB+tWJQxkIPBPJPaonAA3HaEXox6NQgdyjFiJmcY3tyc+nfFXIZYZcAk59M8H3qGVVlzhcY5IBHJ9BQsjNMoH+rHUcYz6VW5mvdZbG2In5c89xSAFWY8AnnBH6Uu5QyGRm8o847j2qQfvvnY/KOBzzU3NbXK6jyxgoCWORj+VSxKdoDFjnqD1FIYf3nzbmCjjnGKZK/llvl3AYAyM0b7C21ZI5VWJkDFB83HBFREqAGZUPOQfUmn7BkFyWc9D1BqMIoZthOAcjP8AKgHcIyoUh84B45xSTurIHUctwD0C0lwflO7AHB55FLDh1w2QP4QfShdyW76DQjBeWzn7p9RUkLBX3NjJ9O1MbkhYyu0cZFDFsnZjjsBTGlYArJuKYGc4z3P0pqFkVEUDJ5Ix/KnBWURgAFhxk9x9KQLknYDvz1PY0Cd+gA7yy52nPy+/vSIu6Y+YTkHqD1qREaJeOSTk7v6UpZdu4vz0APSgaXcYY1IC42hs8nqfqKRQs0hLHhWwI84yMdPc0kuBl8r0ydvJz6UttGEUIDtKtkjv9KfQW7sPJO1Wc5VQcZ649xUSM0jq2wsv3iw4Ap0xUsYydzHgHPOc0xwY+GI3NnIxxjpSSBvUc5yyuAc9Gzgfp/WmRyHPHHUAZ+bFD/MSvzBjg4zx+FSLHlPmTBJ+YbeQO1PYNW7ojm2NJhRyeSc5/GkLhDuLE44yV6U6bdGrbiGPQ+p9z7f5zVOYtIoBYAM2QR04ppEydmNz5mS3yjOck9aQBiCqZODkZPX6f4U5RsJCBDIRjcecUSlhII8jaRtz0yf89qoy6BCnIZs5HPPUf41PEN+5sHrkbvX1H+fzqEgGMbvlwcHg5qZePMC5Ln5Rzxj0x60mXEVUEjEsCwUfNkcj/P8AnFN3EIcKW3Dqp4/H3oDhhs2jcMYC5BPbmnKhjBVTh+BwMfWkMZIGGFI+ZeMH/PNN8sE7twzk8gd/f+VD/KxyMEdUP86cXAUqpIDA547ds/40xLUgkOSNpYbeACc1ATuJw2cdGA61NJkIShA/qKjA2hueAPT+lIBibgMptHPJxnimqShYHp0BHNPZiCxGef5Uqrk5z25CnqKRaYkSAtwRgDnPT6UrMMgDkc49qV8MuQTu7n1p0JCSfOA2eOOo96AfYZCCdhU4wSM9qdwZCWQJ/Cwpdo2kj7w684zQWAXy1UKT1Y0Dv0KstlDcwhJAArnd8pwB+FUzpccbKquuCM/MmTitiP5dpY5JHIbHSo3ckBeNqnIHYZrnnhaU3dxOiOKqwXKpHG69oWr3sX2aMwJZhg2FbG49s5/lT/Dfhs6ZL59wyPLjtnj8a6eWQ72UDnIyT1x6+lUbjULa3QiWZBnsDuLD0qFh6NF8+3qVLEVqy5N/T/gFyNjI6knJHAx1Y+9FY0utK24Q27txgF+AP8aKUsbQTtzFQwGIauoHaQYj3h2HmP8AxY4xV8FX2ZBKL91hWayjztm4qAMsT6mtG2VNnUuAeWbjn/CuyXc4qd9rCspbKdOgyPSo2O0FB0B9c5qZyY0Yq53Hp34qOIBUBKALz83bNSjV72GqjJCCh4TJJPf0ptvI8ts0kuQ/JA7cdqWSRwRGuWUrk+mKCudiDPsP8afQjroWFGI92dzNg02XlSxbDDhTTl5b5Tx1FMWLdMHLk8cY9O9JMpjwpWICMrkn7o7035ztyCST61JvCsdi8HkjvSRybQTgkDoD2pajsSsQqAfjnvTGTAYbfk6k9c0E/Mzhs5GP8aRVOWGSSf8APFSXuMUbpFDD5BwcnnFOkAZ8w/vMjBz2pVGGZGUFsdT3pY1yTJnBPG4Dp+FNiQzd8ioBnI6jg+9J8saHftxng96eu0gDOCe5GKil2yTHcCM+3BFCB6BGpd1K4ZT60EbnJdAQpxihguOSdvRSBjFJI6RxF9xC9B7+tMlognUIpKjKrnGBk5NNt4QH+b5RJ1BXgntUjBo1DMcq38Q6/wD16VpRtAPQcqx7U7kNLqOVEg3gAg9SDTlZAqouQx5BpgBcBiQd3QZ61JAp2MW5elYpeQyVljIX58qc8d6GHBLE7RztHXPpTmJwWbuejDmkdI85yx5HPTmqQmNiLIzMFYZHHGMA0rJlwz7iF9KcpBYMeQePaklYYyhbKjp65/lUjS0BGFyzZA8sDB7ZqOUeWpAIHQAN/jT4zIqFGwCTggjjFBRJHVWLDapGc09hboaiCPcZCAW5+gpqhslkVvUbT1FSTKoj2dfQ1FJGY494VsAYUDrQgas7BGzDiYE8YOOTUyxtuA3YOelJDH5bZJXaece9PG47QApGOueQaGCWmoxiSTw2RjGVpJHjA+5lVPLKO9KwKqNrBgG55xzUYGTuPQ5B96EN3I8MMscnHC49PWnGZSpBDOFO0kDBPvT08sjcCykduo/+vUcsYmkG1sqM4AHP/wBenfuRZrYBuR8ElznLKwxk9gDTNglZmTC/NuOetOZjkL1x90g8NTtrSyhArbgO3GfxpiBCPvzkjLZPPQ+/v7/zoiLM+clx/dHX/wCvTXA6Z/dg8Y6fiKEKCTy8Bd65bCnHHfPp/niluNaEcro2SBkgYyOAcevpTYUzuYYyRzGT1Hb8KlZDt53Eknpz+J/z+dRxlSD5RXex5LcUxW1uyLyhzlG8wjG3PJFPiC5VTty2cjPp/WpZGVh8rkL90blycVBckq0cingHGCc0J30Fbl1HowZvlTtuww5HrQo2ykqNuMFeQPypjOxwCRvPA256d8+9STHK7XUE9OBigCPcWkXC++Dzx7/jQzs27cQSxyD0FNDhWXe7lccDOR/kVGpPmHbkEE4BOcfSqJuSRuA+SPl288d/ao3IcbmJX6dRSyFdzJgAgcqT3qJwCx4PXnJ5qQ20Gja5VQUBB4x0NK/zHKIARy3PenAfM+wYzwM8kCmSArhTn5eeR90f1plXFljXftUhhnqBigx7QG+VT154FLGoVRvGQQSMf5/ShxuAPDHsR29jSBDTgseCQBzntToxu+YseeR70mefLOVTrnHeldCCpIwv3gAP50D3A+3QdqJAHO2PI3HLAimSzQ2yASTQqD0G7kGs+XU48gWQ8yQ9WP3RWU69OCvJm1OhUqSUYouXE8cKs0rKq44yccVj3etJ92xiMrno78KKjkt3mfdcbpG689qnitAgHy4z04ryK+Zyfu01ZHu4XJkvequ7Myc3l1zczMwP8C8L+lRx2OD8ijHsOtbz2ibRnhh2qSGJY8nuOxFeVUqSm7ydz3aWHhSVoqxjraMDhsUVuxxMxCxxE5HXGcUVBryI2b8liIsMhJ4Ycg1Np7EqTJICM4b0FJqCGO3+YkY4Az3NLCvyopXCj5QN3U+tfa390/N1dVC84EkbE7QewHtTQPnLHO7GAMZWlhDFNoG44wGH+NMuWY5CcgHG5TyT6VmdLelxrYDiRlHIwR606JXI3yqAx5G2hZI1byicbcZyKVm8tjITuG3g07vYnQUpgkIw+bk+oqcKiD5mK45z1zVeHDFZGO1SpzkVYba4ABzjHXv7UmVHYRVBBOeTyM8g0PGzFVAAA5z60kW4DlQAD3PNKrFfu5JI4UnNSyvUcVO/aNgOcAE5BpA6tM5PCjj396TkRkqPnHO3sDTWQCSNNoJIJY+lCEN+V2LRgnuT0Ip7HBDAjy85NIBuDum1VXgr6kU8MGK7sKQuSB0xQxoa7bvljUbT0yKiO5cKwUkH8MVJJhQWJJA7jrUDEpwdxHYf41SJkK8m5xuACtx04FRuoV1GwFR1681LglscYI4ANICyyDJXsODk0yfUjlOMlSNufu4JqqfMdgAPLRcs3P8AStF9gPA69unPpTZ42BYZBDEdR6etCdhSjcrAKYo3CqkhyQPUVJLOgVQjgDPKk805QfMUuAyD26+1V5gJXdmQK4J2gc49qOoNtLQslmJOTzjhietKiKxY5w2O56VBEQvlCQBQPmLA8fQ1MG2RllUbSenrSBeY1Bwq5+Ue1NLFXZmX5e4z1qUKXKqAcEcfX0pdqptTKkjOQeopodmyB8MNhDYPUE9PxqTaIsJjoM5+tOCfPkfdXoPWmycIwC4VT0oFa2rGLkqBIWPGM09chAx5AHrTVcGTLfh9PpSEKDhRgk565FMFsPIJDMuVbGQ3tT425VGG3d0fPemByBjGSOm3nIpJXKbto+YL2OKTHewhAWTO8FiOgz19aAeSGGEPbn9KaiESlg/zE4Ge/tUzodoAXgEbueM07iWo1wyoFjzgg5GOQKjWZVVt+4sOAyigLKzzPI3yjAGP4acw++68qV3EAZx6ikPzGxQiMkxgkucjJyCfWhykWVIJx0Unk5PYikZmADITu6jI4Uf0pzbnjDHYJCMAkDgetFxWRFl1bOGLDnbjBHr9f88UIfO2smArEgZ/z+VOdTLhFydvBPcn61ACu8q3z5PGDjNUQ3YmX9yjshyAMfN1Az6d6ibZsKgne46kdqmYoQOQAfunoAfbFVoiHjDsGySec/z9aED3sWCMRgvjaV+VSvU98VBHsdT5jEKeFx/I08yszthduBgY5B/z6VACASVJTa2c4pWGx7gLHluHAypHP51CC4ABVVGSQoOcEf41M0hdpMKWQ8nHQj2qvK53AGMAnjHtTRMu6Fkk3EIV2454PWo8KFwDjJx8w5X/AOtSIGWRgMDJzjPXFKo8zJUYj6468f57UXEkMcj94+cOCBnrSrmQn5c7T0/wqMMSxHPHGAOCKkch1RgSdo7jpQCQbzvILduMUmCjAksTnt1FRSSKj9mx2HUn+lJ5k8nCYiXoeMmuati6VH4nqdlDAVq2sVoWZHVV+dgoGOvANUnu41Y+WsknYYHH596U2oJHmZdvfmrUNmW6KWx2xmvNq5rJ6QVj16WTR3qO5T+0XcjZjVIvwyahltriUHzZpGz1AOBW75SodpX5vQdqdFas5LMMCuCpi61TeR6VLA0ae0Tlzpig8j8afa2vlDaOB710k1siA5Kk9lHU1l3ETjAPTP5VzNu+p2RhFDI4sJyMk+tTDZGw6Fj09KV1ZUGc7emagCO2RGDnHX0qdTphFWHqu5xtGWH8TdKv2drGHaS4b7o4U9z6YqKzh28ySlR32jJq6xEZwE2Rnox6n3ppFN9CaA7jtxtBOcetFMYZi3Rgj0z1NFXcxaLWpQGUYAXJ6hv5iqlqPs525JjyAWI5B/wrUkXegOM54AP86pyxEsWj5GOc98V9gnbQ/PZwXNzE8ADBtrsWzgjpSE4y21iwPBU/rUNuxxuy7OxwU6ZFSSMA4Ugk5G4qentSKTuiu5bzM7lOT1PNSvy6oclgc5HTFDARszYXaFPy461FbRvs3ZwWOSvYU+hHkXHyCcJ8vYk8U3yyFXBIYnJx3pN7FsN93rj196eZEYjygWyMYx+tI0shS7DAIxkHtnFIhYPkDgDC56fWkVicL1z3HepUG3+EEH0pMaQpkHJTIxx9ahVsuWQ7ielSYO9jyWHI5/SgINu9DgryM9aWwO7BgwZVOFHRiKVwQCAuCxxn1FJGMybcA85ye1BlLOxfOR6UFJoYV8tPL4IzuJB5Ht9KRnJztG6PringgA/JhQeD3pJjmTDEBcdjwaBMThgDGowRxng//XprwruMm07hx8rdaXzFypkyoUfLzwD7UrqTGTkKg5OOPxpisIp3qXJYL2BHOKec4ycEfqKGyvRhuUcDP+eaiLknbIQGYk5FLcNhlwPKcfM2wDg55HtiohFII2kbdgHPXmlkLAJ1Ge+BwPX3pHn3yPDhmxgHHT2qlczdr6joUyqsx+UfwseuamWTYfLDfMR3HFQBwpUlTtXqf89qcZhK7YJ64OP6UO7KWmxKHKlgQOezf0pjFhJvdmHYgjkChZDtwTuA9ecUhYgFjwoGaQx4CPwpYHJAI7CmYIcj58d881HK6g+Yud3BOR+lSW8pf34yaaFo9BqhjlgmfcGpo1AAKnG3qGFKem3aMnsP60gG7GW2kcAE8UrjtYaMMWJVQ2e3pUMuGycDCc7gealkynMQBYgn3/GmBcBiBhmHI6nmmiXroJvQANKd2DhQO3oRU5w+3aeQD8wPJ9sUw7SAZM/KcKRSIWcvlT6LgY4/xoKV1oORioO1s5GAM4J/Cmz71XAJHODtH3hUiqsS7ydjd+B17c1WmnhV086dBkjA3gAD6djU3Q7O1kSj/VMMD5uQT0qB2GxUKAEglVPJC01720kO37RHsU7iocHJFWUkjcF1ZXbGeP4R6U01cUosjVm8lt2N56ZbOD3zTjEjFQY885LdP/11FH8smVwefvDt7U7eT5gjOCcnJzz/AI0/QnpqRzH92vmDjJyMce3+f1qs8hKFs7MjkKehz0H+fzqyiYQKwVQuW45wD2FVnwHxtwTng4x+NUiZJ7ji+BtgYjJI56U5Pl2qJAd33lIGRVd5YIUxNIqL0bHJB+lU31WMNhUMhH8X3ayqVqdP4mbUcNVqv3Y3NF32oQhA3HJJ6iqsjYYuxyueCT0rNlv7m4kYDau70HSkMTg7pHLn0zmuKpmdOPwps9Gnk1aes2kXDdxxZJcMW6BfT0psmpR7Cixswz1PFQeUx6cd6b9mG4DOc9h2rinmdSXwpI74ZLTivedxJNSm3YSFWXtuJ/pTI7iSeUiXKL1Cr0qY2jquUYZz0xUbwSIAzbuOeK56mOrSVmzop5bQptNRNC1iUDb1Pb3q2VAbZEMuRj/9VZ0LkNGQCmOpHSti32ttaNgCM53cVxXbPQikh1tapFzcE7m+7Gp5P1ParMhITYpVFH8C8D8+9PiMAVjgsxGAScCmyRqADIvHbPH5VVitBltGgO48ntmnhyBsBO334qKSQkqE+7T/AJMLvBwO2OP1pbjIXBZj5fIHfFMliBGDjPrV1laUEW6FcHkngflUbWLDazMSWGe3SlZhp1M/aJFw3VeT9KgbcOEXbHxyeTV14/Kcqeh/WnRwbQAxyD938O1JIqMrKxLp8SyfxqmASB61OGQqQFGQT8pHBqu08MY5jYMOozjiqZukLuXTdxwSa0ug3LE00allj3gg4C4yPworHk1DygyRrjPQ+goqGPlZ18bFwI2+9/IVFeo+zEa5I461NbqxyzNgA9qJVEoAYEYPUGvsb2PgWroqWyFkfbnPLEdxj+lPbaQuMq78kAVDKRG3XLN0x0A96kmZi+YgHXAGemKZCtYikOGVCffAp8YCRsvQhsAZ+9mlxlnB++wyWPQmmBvLIYhAw6knihi21J5HfZsVAW5A9QKgj3CMKjMMcY6Gn+YSDv4c53Z9KWP96VIdWJHCjqKNhvV3Ejf5ZFiG7HJxxirClgBuYgkfLnoTTFAILhcZ4z0owzPg8r/KkUtBUVw+RxjPHrSkqIxgd8e+aVWKpkEkdBUa534XDIAQSw5/CgfoKxUgqMnj5iev0ppRUXcoJHTHXFNblTtByOeKa86I4MrhRjnnH50bai30HwMzgb8KM4xnmpuFXg4YdxWdPqNlGhzMpyeNgJ5qvJrlvhNwlfjJwtZutBbs2jQqPaLNkMCfLCqU68+vrUUkflZUtvRjkHOSDWWviBFJMNvKWxxvIqhdatqE5yvlwqDkBev51lLFU11N44KtL7J0QEmxvMKsoPzFTgGq7zKZGd5UUgfLnqK5ppLhhukzI57s5xSpdOOJIQPp2rmnmKXwo6YZTKS96Rvi8t0Q5kQr6YJqBr6BYw4k/eZwRtPT1qjFdRsBxj696tQCOUDgbvT0rH+1JfynR/YsH1Yk+oW4QIpeUHnKpioxrI24igfeR1YgVM9vGVIx8veqklnznJANRLNJvRaGkclprW7Y7+15kztt19MFifxpG1i6IGYYfcEHmkSEggPyvr3qVrUuMj+VYvMar6nQsporoU5NTuif9VCnfgE0/wDtS/x+7aJBjHCVL9kIIB4qT7LgkEDNL+0KvctZTQvflKjavqIAG6JhnvHTzr16B80NvkdwpFTGzbkjljyPaoGtc9RzS/tCp3G8qovoMfXNQYhxHbn5t33TUb6zqDcZjXr8yrzg9qd9m2g7RyaheIhjnJBGf/rUPManVgspo7qI5Jr+aMh7mXaffHFIYpSctLL7/Oat2CErz096uiMHp2rGWKnL7R1QwNOO0UYb2znq8n4sarSWWeSMk9c103kKxxjJqKWFQRkCs/bz6s0+qQ7HNm0xjj8MUvlcERgqMfMAcCt2S2U8lv0qAwquQOfcjrR7eXcTwkH0MhVweWO76mnF5gf3c8ig84DkVbkj+b5R9KjeLkcDntmmsRJbMl4ODVmipLcaguWjvJlbqcnIp41O7lxHJIVOMbhwTVkwjHVevSqksIzwcVssdUas2cryyipcyiiWBCSRjJxmrKQktk8dqggTkfN2rRhXEZU8+lc0qrZ2QpJIZHEYznaGBqX5lOcKMd81P9nZsHGccmnra7kI2ZK9DWblc2UCk9y2cBVPTtmp4LlsMfJHHJGMcUG32uAMc9gCakRH2sI+OOmOvrRdluOhXlu2wSFK/wBKgM5kBSQjpjir32QSjD5GeopjaaSSQPl6VOrJcYofYWsbRMfNBZCNwduAD3qdhDCMCQSY7Jz+tU0tBbMzpy3Q46YNSxxEDO9hjt3p81iOW7NGB5mUEIqL/ebtWtbaeZl3O4J6EZ/lWREAjDcXcMOSfWtuKWVEAWNsEDJJxxVRkJxImto4Cc4GODgZNQs8aA7VOSfvOalnkypKgAj37VUbLALwRVc3YnlLSXLDup/2gMU/eHOWJ3Y7Ln8hVWBcqd8u0DrhajkmWMbSZCTzknFF9AauT3kSsu5cEg847VTeb5MZABOSPcVFNeKUZR8oP95+ayLi+BZlLc+uaTaEky9c3KhG6Lg1kXEwA3/wg4Jqne6gqg4OayLvUzt2p93Ocep9alJyL51E1ZbgeYegHXiiuOv9ZWFipy0n90dvrRWqpyMXiY3PeHlxiILkjgginMxRgB0b+dQIoRCFyS3OD1FNLEgex79K+usfDp9xlwp3qYxhV5OB1+tQwB2kn3MMEj5ewxV2KRWB24yewNZhIF40UkgCqQenb096pdjKWjTRoTEPtaFSp7Z64qoRudN7ALzwf4jVqOX5gjIMP0x/KohAqyOT/q1P15pJlyVxy5ACjGCeQaNm2QuABxgYpJpMSBVUE5yfanybcejL0BPf2ouGhO0pZPKHYckdaZIwXCyH73Qj+VUXlW2XfLMqoDnrz+FZ93rZkjZYYnUE/LI+CTnrxWVSpGnuzelTnV2RtXVwsZ3yusYXjOev0rNn1ktIfsys4HGX4BrHti7yeZIglYDA3tj8atW8MpJKvGCDwq8j8/WuCpjntDQ9Sjlqes9SSa5u5uGlIH8QjGKrJAGRS4JZuMsc1eAO9nkb94nABP5Go3hJcKpOMV51TESluz1qODjHaJW8gZICnaO46/WjyRnaV/HFW47dycjJHenoQiDdg54A71zSqtndGikV4bRDjJFPa02cqMgd6sYUdEHHfNJ5rDgHI9OxqHOxoqNyAxDB3ck847Co9g/hAqyNsrFXIHpjirH2F1jJQoSBk4YVHMzVUYoz1TDkKVGfbmrkfyqGbHTg4/WmSWxRgWPQdR2qeBXDELhl9PSjmb3B04joj58jbseYecH+KnAfK44OeD7UmQ0gUjYB/F7+tPdd20rhMjkDpSvYagivs3HoMGpIMxOFcfL61bihPltgc5yTio3iwckcigOVDZot3I5zUIj29exq/bMGHlnqKW4gPO09aL9QUSp5YYDFV3hKkkAle3FX0TbnOMdxSShc+3pQmCiZbRDoT1qF4Ay4xlutaYixnng9P8KgkVV5AIIqZFxiQWi7TjGfwq2igjJHPaoEO6Q+9WUTkkdKIsrkGbc84ORUDrukIAPWtBV8w7QMZ605bcKCcfWrE0kZ3k8EYwKjuIB5eVzn2FaLp82DwPSnQ27SvtjUseTxSsSc68e3HGe59KgIHfAz6Vv3FjwS6so9QM1QkjijzsQuP9o4xUtF6Myyij1OPSoXQHGA2O5xWkzgEFYUHt1H60Xl27Bo5wpXaQoUYAz34pJoylF9EZuBE2T26VeM/wBncM43xEZwR29R71mM5B2E7gOmO9WhKJrMJg74fx+X/wCtVIlqx1TJCVJQjdhWX/a4qxZeW1zKCNqtFuPpn+lYtncsdNhKjDqdhB6Yq7Yz+TeQb2BJV0KkdOKq4iZpFBbCKT0BxkrUAB3jCNgZ6jrT5FYuCgIBzx+NW4YlEgbaQM9M9KWtyr6FNUJH3QCO+Khm3txgj6VdPBYYJx2JpoBIOVxTaIbKAjKD5+p6U/ACjIGMVOyHAwOlZ96xUKVJHrSasZ3Lsc6GOM7lVs7TkdBVy1u4WH79ixHAHNczZ3SrLL5wAUfMCx7jtVu41OyjmciRdrruVUJ4PpQkJy6HRi5tEXf5uCTkLtAxWbd6jbqW3SFscgVyl3rSbiI0JHrms251eYZZYgO2WNXdmbkl1Oom1mEgKSQVJ4ArOu9bhONgAx6nrXGX2sSKWaaYIPQVg3GqSzttgV2J6Fv8KqMHLQxlXUTu7vXlRSGKKuetYd54igDZ83cfROaz9P8AC2p6kwe63Rp1yxrsLDwhp1mqmVDNJ3L8AfhXoUcunPV6I82tm0IaJ3OKbV5rhj5VvLJnpk9au2+ja1qQBYLbxHnnivQ4LO2twoht40x0KjFSufu7Tx1HsRXo08tpx+LU8qrmlWfw6HI6Z4LtLdvMv5GmdedqjAzRXW54+UjjpRXXHD04qyicTxFWTu5HS7g5wT83PWmSkIoOQFPNcCmu6nC5xIkpPUuMZrRtfFcryA3duoXGCFbIFTGvTfUqWHqreJ11tEI4lIbezHJJPaobyDypQ6oZGY/N3AFULXxBaS7CGKZ7MOlWJ9WsZLWQ+bmTPygDrV+2hvcn2LatYtxTZ2uG+YfKFIzg+tOmdkA3KVDdCe9YDao5AMUTFu5fgE/Sq0txNdsPPkLnoBnge1c1XG06bstTtoZfWqLXQ2vt1vHu8yQerAHPPpVO41gFStsjAjJ3OPuk1VihSMgquW9xx0qqp3jJhEg3Hd6+1cVTMW9lY9CllCXxO5BNM8zEyOGP8WTwfpWjpgZ5HWWPzlWL5kLbSB7Gq80n2p4o8KEBAA27auQMTqEghi8wqePfHHPtxXFPEuTPUp4JQCze3jKv9kMi9AJJDU/2mNiWgtVjyT1YsfoM06T5ZT50CIMYOG4PsKj8syxu6HJTB2AcBfauSVRs76dGO5YsmUlwQAWGPmHFXcIPn/d7l6gGs6FSImk6AHA5xk0/5ljCup2nsP51mpux0qkrkrvhipJU+/SkaPOMgfXNOiZZHCuOTxVkw4JCjp1yKWrNbJFP5/LI6jNNgyXOec54AqeaNlbBHvxUapknng46VL3HYmS2bOSjKM8HGaR4mjYlGyQeKkMjS4DZDAbSCcZx3qxZvHENroJGYjaD0U07rYh3JbG2kkjk3yQg4BIY4BUnsabPbeQ7KpRgvBYcg+9WxA/25GjbKv8AfJHyqvcGmXMflz7T8sQfYp9B2z9a10sZLV7me0TkkkZUj74GBmpYYJCMiNsA8g9iR/KlkyF2FnxnhelTW07xIyM5+ZcH1GKl2NNUtC5boslpIVx8hHTrimNAGBCduo60kMgVpAvyh8A9uKemGYFeCKNAUSm8YjYMAQc8VZRg49COhx1p0iBydwwB1IqMps4FS1Zg0MkjDMR0OOtVZI+1XWb8h1zUUsW75kOGHUGhglYqNtCYA57VUnJYE/xfxVoYH3s1VlOyUNjK/wAQ9ql6lxKiOckjPJ/KtKKP5Vx19D3qv5aBzs4I6x/1HtV+LiMZHUU4opkca8bsYIPNTKu5uvHueKIRliOozxV4QARbXAUjr3PtWiM5abmeyqDgAP79BSlmjbAwoxwM4qWWIAHy+Mjv1quI5MEsCB1y3U0EWHNJtB2tggZOBwfY1nzpvViYirEnleR+VXy+3qd3vjApkshccfdHPHY0nqUtNjFmtCp/eDy8jkEfrUEohiBaKAyHHLSnP5CteaPf945PrVCeMLwcEds1FrbA1zbmBeeZKMlgBjKqBgfSorC5+y3IMigxsCjg+h4/+vWtPD+6ZlVtvrisqeAEcr7YNBlJaFm1ujD5sbnKo3zDPbof6GtS0mDTQu7DftlRn9cDiuPuXntmZkO4FdpBqpb63IMxruDBSDz64z/KqXmYOVmej29+j7ixHB4xzipnv0JwMZ+lcJY3ksgJA78nNbSTZjycg4+9nNLUrmRuPfAysDjOc5HFRi/yT1x1rJ8+PcdsjAj1FRyXsUa5ab+Qp6kuSNeTUAAwCkKOmKyL6+YgkDA9fWsfUNdt4c/MWxWDc6y9wxKA7e3aqUWzGdSKNG9uWeTdI/GelMNypxtAB61hSXSMf3sqhs9M0ya6lkwtpDLKT3wQP/r1pGjJ7I5pYiMd2at1eOEbbtUY5Oa56/1SWUhIH3Huw5x9K07Lw1quqMDcZhjxn5uK67QvCun6fIhmQ3EwGSzDgfhXoYfL6k9XoebiMzpw0WrOR8PeFZ9UP2i7fZGTglvvGu307w7Y6ft8qPc45JbrW0QpzsABBztApu0rnOAD617NHDQpLRanh1sVUrfEwUDPPQDA4oByMkE9Rz1pCVBBGCD2px4VSPlPUH2roOdkZC7emDnPTikHIJHGT+Yp5QNnABZ+w/iq3eWsVvqEcE02FACzlVzsbHIHrScktBWe5T8kxnLqysegYEUVZ1WKe3utkszTHauyVudy4yD+VFCd1cpqzsc1LY7XHBIPTPaq15bKlu78AAck9q3gpmiAPQjr3FV54vNZEK5TPIx1r5VV5I+x+rxZh2NhdSQiSVgEIyE6mtBYgCoU/OCBWmIvKhYdMc01YD9pjY4wTjFKVfoVDCpO49IyCBgZ9fSrCwMoBUDOc1bEQ5zgUbWJ6YI746Vi5s7qdJJEZhVZtsh4J29c1VSx8wlowd0XXtzV9ncyMWAKsfmwMUkMcbTkjJUsSA3XFS5G8aZCYJFkDTpJuVdyHjafY5qvBaSv83T5vmOcYPpWq9pJJG7CRSpIB2t0/CphBJGipIzbR8wwMbvrikWlYzLuI+eXhB8rqNw249sVf0qMW0BnmlCJKp4T77jptGeB9aknAZD5is31fvWbNEjS5y5I/hJ6D2o2dy7cysavmwNZCEqoaFvl45wfX1570iPbvFGGDLtBBZeQfr6VRViYbgAHc2GB29MdakgkI27DncORjgn3ouEY2Nb7NDbpiORblXKsWC424/rQsjT3Q84eapwuGJOPoar2kTgNuyiN90sMqxz0q5Hcra3KkMPNBBcr0z0ximtQvYddWoeWcROAiFsBjlio/rVGS2Vl+TgfqBW1dM32tpYEDBlDMuN2OOQPeksfKnYBoY/IAyWHBU//AK6JRJ9q0jKWDguAWVRjco6fWmNEAMqCR1Gepq3MXgl3Iyl0JHHO4e4qWRo50MjRCPBGQg+7xUNIOfqOE0v9kxBZD5bSEEf3umM/SkugRCQXyFk+ZDyfrmoUhMkOwu/yNkKejE/yNXrMjdu43bevUgjvVx2DQoSFdp3IXfPUelMhjDK8ZkKn+EEcZz0q6kRMm0Y+Y5Gewp5hFwOFEYjOzJOOvQ0rFc2hWeDy5Ghc5CnGe4p0RYY3csR2/Wm3IkSV1Y5ccFscGi2ZmkKY5X5wR3HRqnqWm7FxYt2N2BxwPf1qtKjA4HRTggVeG+OPzECkDv3qkrA7t69WJ3H1qmhp3GNGScOflwTzVfcyrtHUc/hWo8Q8vcB14wRxiqM8ZRyo2tnoSOanlBMYql1+bg4wPc1Wkjw5HU45FW5NwUEkj0HQgVJHbFow/Ckkqc8HIGRRyhe2plGMEIB/rIzz6kdq1IEEtuGGB61EiD7XJkcAAkitC0iWCeSB/u9RnofSlFalOWhBaxDzSAMgHmtDyPl3OcL0z1Jqa3jVHWQYUjoSM1JsXIKc5557fStDnnO7KDxBjtRDz/E3XP0qGS1O4GRvmxnL/wCFX3Vi7EN0GOOKryxcklecd+aVhcxlyou/JLMO+OAKrMdowEz+PWrzq3PCn0IqIxHjK0GiZQkVyck8Gq0qKwznmtGZNueME8kVRmGWPQDtUNFLUzp1GCT1HGKptGDksorV8s4yQMe9QTKrZAFImS0Ofvo1J5UAegrmtW08kb4cLJ2I7+xrsrqDJ6delZk0BGQQCPQ01qc84aHO6Jq2yQW91+7kTj610cupQrEQzAY5JFcxrmmBj5kXyzDo/r7GuPu7u6kJimkcBT93pWkVfQ4ZtxO11LxLbR7khk3t7dKwJtWuLx8RluegUZNUdEgtri8C3bsF9Oma9W0Sz06K0X7PBCrdyy5NelhcF7Zczeh5mMzB0Xy21ODstC1e82tHbeWpP35DnFdHaeB3bcdQvCxUfdi7116FpcK2VwcfLwfrVhVbywMksegIzmvWp4KlHpc8Wrjq0+tjGsPDelWakrbqXA4MgzmtTyxFhdirtHA28YqZH3uFID7fu7h1NMkR2cIp3bQPlHHH1rqUIxVkrHJKUpO7dxgU8ljjHJ7YFPxgArjJ56VVn1K0t8iWdSw4AQ72H4CqTa1CdxitppGzkfLtH61nPE0ofFJI0hhas9YRbNbGxwTyc/lRJyw+XIPp2rFOsTYJFix+snX9KY2t3CqVFkDzxmSsf7Qw/wDN+Z0f2bif5TdA6k8DHWmtkknBAPTJrCHiQquHsmA/iw/UVG3iRMDZZyttHAZhimsfQf2iXl+IX2DeP7vqfqfSuiEMl4q3F1okzzOBuZJQiv8A7RB6Zrzz+353PyW0aEHq5JHWuh1V5tSvZZodd0+NJQCUy2VOBxnHT0rnq5hR0s/wf+aOijltf7S/L/Jl3Vzci+la6h8qTaMJxhFA+UUVz8+mMZmjkvTdqcHcjkq30z6UVks0glZRN/7Hm9XI0rEKYUcnqM//AFqlkh5UgHrzVeycJajOCASMelaS/MpJHSvCPoUVZRxtIHIqRFV44WHGMA0YBYhu9RENEDt7HOPas5G0DZSNeOaekYwcggdOBTLVt6hhyCMjNT723YUshqrnRFEEkAVeACKgEBWQPtyDx9auMxRz2X19akDCQYXHXoKNzSxURQFxsBGfSpY5U34KkduGqRISvJJ2+lOMCLllBGfSmFhcRynbI21ugz0/OopbNThlxj65p3lk/KTyRxih3aMKGAGP4wMY9jQON7lKSMhsMSFPFM8liq5JzngZPzVfnAdB3DHr1qBIjhQGyAeM8Ee9SlqaW0EtWudOfzJoHaMZdV3ADP171PGwdkkGGRzywGcf4c05EWQPCu0sRtAbv9PSoTbyQ4ED+S5++vO0+hNaeRmtWaFm1wYplgJjkV92QOeD0zVsW16V860mR3Jw8bAqQ3cZ6Gq9vIkMkEnzeVIoVpOoGetaUiT21hCkShs5yM58w+vXIGBTaTOao9dCsPLniKyxeXOBjyxwGOeearywywxuqpIqyEDLEEjHvVkSTNE0cgxG6biGGce4NS5zbwrJMskuC+APvjsPwpWIi3EpmPNuZm3rICBleNvSltJi7n7RKMjuR1Hvj+dSLH5txI8W5YgoyAc4PtTJItk218q2RztpWtsbKVyfaWkG3cSR0A+6PSnLPsjlE0bNkgnHQ/jRMwjn5ZmAPLKM4Oeg9sU2Fg7uyoADwO2fQCmO91qVpoyDIwHy9Rk9j396rMZI9kiAZT58evt+NaM0CorIVYbQOnI5qJkzbruGCxxkDripauaKZejcO8W18xzDeh9PUfUHioBFnzNyljuOcHpn2qDTZmRjauw2yMXgJ6CQA8fiKv2TKYFJXnOG9Rj+VUtRJtFNGlj3Ac7egbvzTcr5i4BHONuKsyIdyYJJYcn2/wAik2hok6mMEkhRyW78+lNRG5WKjjEaxuo4cEtyQBWkbRTZyOA5IfcAx4J7morzibdEQsM6LlQf0NMhJK7WOFBLAHjPtRsJ3kroqyqFvGH8LL2P4VqXEPyQTS4IYdB1IHGaa0CtcW+VYKxZGZhgcjIqw526YsEuPOifaR147Zqdh32sNtQxiV26cjkZqwSdvI74ye9R25ZUKZwvIAHQVIw3fMScnPHocf8A66EZy1HwRBowckjnJpXhyOFABGCXP9KZGqjeGLbScjnipwIginYh3H8qsztqZFzbFVBI+bGMLVUQ5kVDkHOffAramkDAfIAM1RIXfcSYGI1CL+PpUs2TdjKuIywyufXGKyp4M9+9bcxAUkNx71RlKEdRnOKlo0TZmPGc/XvULx7QfWtF8dCM1UlU9SPpUvQG7mdMu7oPx9KoXEQAOBWy4VVO8bW9KozqCCf6UiJI5m6izlG+6en1rj/EOktIfNiA3gce/tXf3sOB8wwT0zWZe226Ptj2q4s460NDypSyP/dYHoeoruvCWtMxCuCXXr9KytZ0tZSXX5ZPUdDWMlnPBycle4GRxXbh8S6LujycVhfbR5We1W7ea4YvhWwVBxzntTr3U7CwYLeXkcLYyqu3OM9RXkl3p17bvbSLM5DMqxuHORnlT/KrMMN1q2olNQlZpkQ8sew9K73mycW1HU8+OTyUknLQ9S1HUEs1Cgb53HyKp/8AHj7VnrbXl8ge5lcRtztzhT9B3rE8PK/2iRJm8xlIBZjnIHT8BXd2UYnGep6jH/1+AK4sTjp13ZOyPSwWWwoq8ldmVBpEMYGAqj1Iz/KpxaAAbEJ/2iQorXldNh53EdkGf/rCqaQGV8FYo/8AakOTXA2exCndXKElmxHDRY/36pyWkyFvmgLdvmHNb/2KJIS0txEGz0HPH5Vn3tpbHhLyPH+6aVx8qOdulcZ3JGQfTFR2turNl1B9ia2rvR4lthJ9sjLY35CnaR/jVSGIbI8t1Hb607siyexZ0147JpD9jtrjeAMTLuC/StSz1VS5B0nTuPSLFY7gK2OeOalhn2sNo74pcw/Ym4WW5naURRQjAASMYWinTmCOJTDP5rHGQU2gcdvXFFVzoj2ZUtrb5JO43ZFXVjbgdupNOsGGFUgAEck+9aMUa4wRgEUlIzcGjMNsSuec1GYiFfOd+K1HiwuC2feqsi5uOB2qJmsFqT6YMQJ02jse1XdhwCuelV7BCEZScAGrinacEceh/nTidCKbROZOOAPTpVmG3GCSVBHTsan2IwBXOffrSohIw4Zf61ehd2ESc4bDcYB6Yp8UauwULkN7+lSCVxDjg47lQcc0m5t4YLk45K9KNAV2QzQH0IYcZzVO5iPRxnPQitKSQKvzg5zgqeoqNQjLglSp7E0blpNasxRhZcPuTI4ZfWrUT+diOaNEkI2iQcfnVu8tlSMDbuQ9j1X6GqtukZ/dO4B5x5nBIpWZommgmVpl2kojxY3DH3vfIqGR5HhcvslCDIDHkDvWgYJbQBiBuGCGPzAj+6fUU24AZ47mJAgbkgjinYzZUs1d4CibsMuQp6fh/wDWra0ohPK+cbwuDxyw7/lVSwgMzusUywkAOokGVY55x6VahDdJpYEmUgehX398+lWjmqu+hZ1eZTN5a8OMbgBjI9DVFYt00flN1Y5yPuDv9RWtfxI6GS7UrL93CncPY+4NUPsXmkBXbaemeCR34pNXMoSVrEjQPbxOEJKPkOO3t9MetRNNClwhRfnOfMYsSeRyMVNbTssflJPE8RBXMn3uf8KgkJkYJL5W6MYD4wSfUmiw4vUkCW4toZISw3sNxJ4UdxUogNxG8DgYQlkYcAL6CqqyHz1E2FAPOF6j1xVmaEEo+Gb5ckLxkeo/wpofWzFmRbaO6GFCkqFVfbnqKglkUs2xP3J6d2B9fpnipIWjgQhVKtkkZbIxjuKBL5cbsscewcAnsPQUFJsg1C3j8sOQEl2hgqnJ3DofanQXGUNwi7m+5cr6nsfxqWIW00aoYh5jcs3cVTMwtZvMWEiGT5ZAB1pWsXFvYuIVjuDuxIinow/L+dQoGKOAHwDgkZyo/rV6O2MKhtyeWy7lzySoHT61FPbuIJHZvPjU53K/G76VVrLUOZXKErF5IsdMYI9eeP8AGpWVhhhjO3cCDnOamkjaUAhQpzgbRVeRsRupBDg4HPXJqWaJ3Vi4sxEcIlVmXc5wf93FI8p8uNmOQVALepHQ1Dcyf6WrKcgMeByBwaiRm+z4J+VTlRU3Cxq7lGCCSDz9aDNgYBG3ORVaIZjUg8AU8LzlgDuFO5nbuW4rhArK64PUHpSsc/dOCeOO9UtnBCPkDnDURvIuR8hz/tUXFYklJBI3KwGTnp7VUnkZYAveQlz3yO1LL5hHACqe+c8VXuXZpDkYOAPoKDSJUuZGIIHYd6rYzySeDU02Scgn8KgO8ktg7RxipbNuhHKMYAHOeKhuW2rgLluv0+tWZAwj3N97+lUXzggjJPfNJi3Kkrl2z+tRtkKcDJ9alf73UZ9KQksDt4IHGD1NTcTRl3Mbbtzk8VXfTJJrcTQMuWJDKTzkc/yrRcFyAcAHqTUJfAxzxyMdzjinFq5jUi7aHKXVv++dGXkfrVM2QkjcBcE/yrotZj8y9Mi4U7ANmaq2qDdyv1p3OeVO6ucfqN9cQPHaSbTDgYyOVIPB/PFMjuna4kkQkThTlhwef/11qeL9PZkFxEpKxkbiB90E4H61kWkChIpWG3JMZ56/WtIpNaHnzm4ysze8GXDzNIJyTIp5J6kdRmvRoNiMolZnQ8gL0IrzPRIZLHVFDAiOQAgnqT2/SvSrKPMCM7A46L1xUS0O/CPngmy21wjKVS3Rc9GJJNRzGRmyGAB/uqOtSRAR/NtRm91zip/37RYAI+bOQAMVm9TutYyJg7DDb2Pc5NUWVoX+7nB7iukFsWA/fKAeMb+ap3NoojIaZMHpzRysV0c9dFSF2hhkHcvbPtUcTEW6YzlWI+gNas1nGQ2biInqMZ5qmiBYZkyvUN7kURvch2IEcFwjFhuOM+ldRNZrp099cw2CZjEdtZo67xKx5L+5xXMJD5jhADubgAV0lzZwRW0uya6e6sJIkd2kwvP3tg7cd6pK5nN2G6rbLBqjKEWM7Ed41PCOVG4fnRS3mnPaXkmx5poCFkV2HOG5GfeinyiUtCS1j+QAjqvrWnE5EK5IxwBnsKogbVXCkZHGKnT7qZ7UkrGDkWQVIXPNQiMFnCnJHT6U+IFWAPvUkYCqXz84PfvSkjSDJrSLrgZJ5OKuLDwMDJzUdrjOQMAgYxV6NvkJO0H3HWqWxXMRiAA8flUMuU3BOpH4VdMoYAjC+uOtVpx1xVMqMilFdbXZZV46Ejt+FWVwyZIJJ+7iqtxHxkAFsdqqRvMH45Uds1HM0dCaepqDOG8xSwHQDqPxpYwshAMRkXGeeGAqnl5AGico+eQT/SmtNOpDXCFiDwwP8qdwuXZsci2kYd9r9qq3Ki5VQYgsoGWA+vXn1qSOUXCyMSZAnPXaR/jVfOXIuA/H3JF4I/GncaY5ZrgHajNJEoOEbnA9Kl+0QXFtCrfuQRgMeQpqBNx/eKA6dMjkf/WqUK5bhFeDg7T908dAexqlqTJjVjuYmTy0WVW5Dr8wOKcLsXTJE8cYcEkN0JHvVTZPA7PaGWKMnBPp7ZqSK+hncLexx7hwkir9457+tK9jJ66l2CeX7iMCo6KCenoK17J3P7yUqzxsNisOnsfaqFtAjoZo5XVVk2uyjhGPt1ApLwSwyOZfNUt/GrZB9/pVmLtJluG2MNy0qXCyPc52g445zjBqC4kVIwTGomDfOdvDHoeKz1uY1fduYuOQduRWhKySxwlJlc/xYOce9HQpQs9RkQ884KjIGPl4IHtVsRqYlXoRhlYdQR2JqskLh8rt98EZHvipVTYjvL8sQHY8k+1CY5JX3HJD5yl3JzHgHHIPoeOgqJ4mEzfaC3zDcoUfe/w+lSCQwq01uMM427geAPcUyWfeB9pjbaRhXH8R/wAaYJu4jWwESsxMT54YHnH0qxlmXMwjxGQu525yR1HbmoMhFLMPNQ+nDHI6fSnXW7CJIm0hd2OqscdPpRsD1dhqXWbiS3lbeAcxbR0I/hz61GHzHn5to5OTypPtVeSIyQySRrGmw7vlJG3FVop1kG7IQ/8ALUn17H8am99zVRXQ1ZGCsCvAccrmo5ECggFcBhx681GyNC0QY5dl3Njng9BSznbEST0I7e9JlJk0sai5kXYF2MeM9P8AOahdSsQz3PHpVi/ZRfyr6EHH4Co5CDGQeTnqKi5RLp4RHw5yp4FWHUbsFTgdu1UwG4wQB0q4pZtrHBJ45p3M5LURo4QCQ0in0qBgqyMBMp78/wCNa6yRmMbjEQOxqhdRW7HIKZB9etMlblHec7ODk9QabOuTk8knNEkcav649BTNjPnBbFK5drELI2Dkd+nvSiNImGSCVGSMdTRJC+Tl345ojhGxjIGAx1P9KE2N2K05DZJxgnOc81Qn8s5ANafkQ4IbeCemc81VmgjjGQvFJ3GrdDImUAE5xUJ+VuoyOvNX7iEKMlT6GqThACdrZ6VLTLuVpWAbkjnk4qm/C9SPTFaJjR1ygZT7CqcwA3fKelSjORRnfbLFK2PlHXHpUdsqvJL/AAlQW4780XRAh5GD29xVe1kYR3DnnCjOD05q0ZuwmuWhuLKVQrBjET09MH+lYOkaVNe2up/uWYwQC8O0ZwobaSf0r0nww1tJrmlpfLvtJHMbqOcqyMK2PC1jpsvxGvtNtG8kX2kTWuFPyu2FPP4Z/KtYzSaR5OKj7+hzEmhfa/h1o2uxIjzxs6PtYltsbYPHtV/TZBPCCh3DHHtn1rq/Bt5ZW/gLxNpawSSw2d2ybA3IWVBnn0DBj+FcHobssKozAtF8hI9jiiXc2wUtXH5nSGFCB5kiIwx8uKGitQo33Em/OMMhINQ/IxDsHJ9Q3ftV2C0tnBM0khIJ+V2wP/11nvsene25CUtSf3c6Hpxg1RvPJz8r5AORwa1pbG1VA8YZTjP36yp0RGcqW4HHNJpoLpmXMMHgE9uAaqSQ7HZmHVDg+9aE4fPDMQw6ZzVIfM5VvfqfapE2V4mJnjIIHzAA5xzXcRWt+XMd3pNvcGYqWk84L5mOhIzzXF2y/wCkxKUBJccMOOK6nVVtb+7+1RarbwqcNslJDxewHcVqtjCau7Glqthcxn7VqEXkpIcB9wwMDgHHQdqKgvtXtLi3vXRnkaUJGiOx+bbj95jtRTbQoruQRhGRQc7sEU4ANkrwAAajuFMbsc9+vrUcEpKgnj5ckVJgkX4QWeRgDjI59M1GQ7b3OMg4471Xsp2xLtI5anrcZRm6cnApdNS0mtjQsGJOTx7elXxKc9cd6ybNyc5HJx+FXhkY8xgCapWsDuLLI4IIOcVCJMHBJI6jPalkdBnaGPPU1Wn3t9zK/QUmXFlpmB4YgH3qPzEPQH6dKqqrE5YtuB6mp1T5Se+ORUmnMRSsfM3ogAqzDdSBGicDaRwcZxTvs4dcjkUxVw20fLjoD3os0NSuVrmHaxdBgH0pnnyeUcr5iKcMhPI9wavE7SSMMjcMg7GoJIsHzYmGR1z1H1FM2iyOK4aLMtkxwpy0Tcge/tWjHe2d9vwPJbAPlsepHUj1rNiUMWMAxKfvKvVfceoqlIEkeTgRt7dCf6Uc1gaTNxg8Mckscj+W2Dt7fhWLLHiQngg8jmp7W+ntljWUNLEpxj+Jc9wfTFaLJBNGbqBMxlcmNQCc/wBKp2kJLlE0e4mtYZwiZGNxDKTuqW7vXeNE3GNyuChAI/A1TM6YeIrIikA5Q52//WqN9pQbvnUHGVo5rKwlDW9iVQ2RtX5cEMwGd2e1ToiKfllQyqRtQLjPtmqyTyIoQY8oHO0/4+tSxlXWQoucHcVPDKfUetCaKcXuWobhkTa6qj78MVH3vr71bdlkhZGyoLEcNkhsdMVnSNA9uXt8rxt2MSdx9jRcM87LOjgPtGeMj8fWr5jNxuaCCG3VWJcKVyQcEkUiSRFVWNUkiQk4yd2fX3qG3kccPGhLLkYOVB9RToopSHNvt3Yyc4yw9B780yXa+o7fFjHlS+UudxJ6HPGKkdUeQkOWJ5C9jVOZXkQW5JyvVM9SP61NI5WVQCQAoXGKllWHTlUibGSzYOMYBrJuo2tp3eIZQHBX1B7VqMS+0KcjsahmUvGFxkKwyallR0ILW4XIXaMZypY849Cat3TgQZB5cj6EZrLnU21w0bAbWfI/2T9alLl12sQMEd+vPapTuWkjUmw945KqdwBOPpTJAF+Uc80qksN2V3cd6QSjdiQAnP4UALuwpU59KntpSjAMO+OfUUxgCpZajPzRlm7N1B6ZFJk3ubVqYpCfM2lj0GKklsYnIESKGPYGs63YvDz1NTIz85IUAc1fQhoWe3SNeUQH65qm/nR8RqAfQjtWogIQyyAE/wAI/lQsaAEuAXOSc9/xppEuRkm7bJ8yNScY9KhmkeQAB2QDGAPar5jiDF8YUdRjNQyRjG9QF9FxyKWo0zHleXdnz2IB7mq0ru2f3jfQHNaM/JOQSelZssbxn5AVPvSZtEilmZEIZ2KkYwRWdM4PITP41dmUudpGcfpVKQYbHb3qWi0V2l5PH0FQXMiMhOw7iOuehqZ1JfpmobgZ7UrESRi3pwoyOnesyRzGWXOFfGea2rtd2QBzjvWHqEMmwlEyfQUIxmrGrazrEtuWkIRXDMVODjJHHvWZ4J8SyWfjrStQkkaRo7jYx6sVZSuKzJL1TZNyd8ZwRj3rndPmKXYmDH5ZVbI475rePc8yuuaXyO4s/E1xa3fiCPexW/ILsWwQ6OSrHH1PFX/C161150sjF5JGLM395s8k1wMlzt1CeVo1nUs2VfOGPXBxXR+CNQ8y4dlRFBP3Y+FHHpRU1FhW4yT8j0a0dNwHmFD3GMitiIsE+V0I71j2twJ0G6GG5xktk7WIp6XNtG+2W3kXPbeRWex6jk2i/dXDRxNmQbcZ9T6VkXc6tvO/OT1AqS5uLRgdsMgJOR8+cCs2R4OcRuBnJ+elJ3GvMVpmLEqcYzzmlaLMaSTOiBhuUEZJHrSWaWrlri/l8q2AOFH3pCP4Rx9KgklM0oLsInzhQf0H0pKPUiUraCxboryJn3FdwXcPukEV1N3fPbnUoLayt/8ARFjeFTCG8yM8E+/1rnbIt5MkMm1wHY4LfKGx1zT5ZLHTdQMD3uqtd2wEfmRsoA4zgZ7c1ctEZc3MxvimZ11dm+5vjjYIBjZlR8tFYmpXMU17PJA9xJGWB3TnLk9yaKzZspWR6RdRYdTtwD196zWjIzwTx+Vb0mN/I+XGQKz5I0CEjOCTVXMOUzbVG8jdjG7J9aYgbbjHOc1r20X+iYwDkZ4HOKriMCZMDODwKQ0tx9vuXlcYNWlHcnNRQIDyThc55qyhXBGB+PpVIXXUXy1YZY4GM0iR5PzHI7D0pykk8ngDjPapVaTOATk+g5ppXG3YZ5JxypOOuRULsqsMMoPfHpRJJukwzEjocHrTtmQcKQfanYRCl1tfADEH9KZcyBssgbI7kYpSXi5wQR2bvT/tEOecYxuGeuKmxtFpEYvIkdGmjZomG2QL1A9RUc00NvcgpcLKjYw46Ee9Mmlt3VgpxuHNZseQDEyBkJ4IPQ1LujdNWNXUYRa3EcyuCj9CjYINU78gAPtI3HAfs/1p9pskhe1m2leqnGCfxoFqoBRwNvfk9aTdxXSKkZLKSrYYDpUljczWs2Yjt7FecEUksCxEYyR2IpyMQeCCPQildj5zTYR3kJa2AinXrHu+99D/AEqiu7zPkZl9frTQrI+cfKeQfSpUlLtiRFZiPvdCfrTbGpWLBZmi/ervA4+Xg01UjdhIj5jU/exgg+9BZShG5gcdKiV5I33Rt14II6j3oC91oW0uUkby5AEb+FsfKTT8GKRNwIGMBc5x/wDWqj5kf+tQja33lPOPapraYDK7gynjDc4+lUpCaLsqtDMDDNvRgGXP3foTUYuJo5ThlKuOdxxg/wD1qieUmJY2B8scoB19+aFcvERINzKDg+tXzE8vcl+14XzpYxJsBUt1+bsR+tEU/nEbHViegb5TVR2ItXRckMQSDUUUan/WMAx6Af1pcw1FGhHMBJgkqOnIqykqYcnO1h29azNzQ+UUkRlYH7w6e1JHcxPNmRGj8sZyvIJ9xSuPlL+pxxzBxn5u496wxI8UwRuMdP8ACtJ5lfLl1bceccc1m3yEnAGGxUSKhoadvOWVVPIAOKvJEHTfnn0rn7GcrHgBCeNx7j/9dbNq5OCCcfpimtRyVkXY2+Ty8jJp0aHyiD/e5H4U9EBJO3Bx0NRxP8gJ9TT6mDfYI28hiOMHrz1q2kg/iHXpVMkFxxxn9KniHAxgg8gqelMVycTMMAdA27bnFSfaAy7SD85/MelVmCg7T9KaXwwZxkDgEdqpMVkaDqrOqAKFU5JHOT/9YVNNZIYw6tnjJNZqbg25TnJycdqsJc9sg4OQKpNEsbLZq7DlQR6/xVnXtsoHlhPm6cdq2DdsqO27bxgLUMJUQmSVQWY5Y9TTdmUm0c3c26xoCp5xzxjFZktud3I6+tdLe7HZiind7DrWXOigkIfTg9qhqxtGTsYk8JTjPWqjpk9hiteYBgRjnH5Vn3EY5IFZ2Kvcz54RtJyT9RVOW3DRtjir0jgD6etQtICSO+KEzKaOG8S6W5zNbHDjkjPD47GuZLx+Q/lqyOcswz39K9MvohIjjjmuC8UaY8Ia5twcD/WKPT1q1ocNSL6EFzcRLFA8Q+bzDI2e5x/Ktu1vrdJbZrWIQYfJC9ye9cTJPlFGeBVxLsiNQGAcYwBTcW9TOMlE9bt9QSVQs6fMOkkfB/GrQum2YFxlewevOtP1gSqAkoV8chj3rROoShfvq3qc1LOiFVWOtluflP3R7hutUJrsDgt9ea5qTUTtOXA+nNZ1zqS5wZeO/NRY19qjspNWtTHBG8+142bC4yuDzn65qnPrqyXQln/eEEAKOBgetccdSiyRCFz3YmmSanFHypM0n6Crim9DCVVdz0Ma6lwhQERxH+FRjPtXRarf6na3rJbaHHPbIii3la1MjMuOMnrn615RoitrMkq3d3JYBceWY7dpd57jjpXWw+GbmTAbxjfru7GJ8/8AoVbww1ap8MWctTF0aXxSSM7xBrUiahJ9utEtJtqgwqnl7eODt9+tFGpeCY21BjJq8t8SFxPIDlsDkc56UV1LK6z1OKecUL2ue4TNgKMc7etMuEBtAR2NK8eZFBOTj8qWcMIgv94gV5Vz3+USMEWm0DkD6VTWNuNvVuATWpIw+zscZ4wMdqhhiDuAoyqgc+9PqiVomMjt2wp4pxRcbgMD+EevvVqQiMYKksegoSPzeeOfXrWiZDV9SNIWyS2CeuRVgqpXAbDHg+w9anjgY53HB9qFgKl1b7xwOSOlURy3ZQNqCNwUjPTnipxAShAPCjGRW1bWZdWOEULzvkPQVnXjKSI4pl45JUYx/jTBIxLyJVY7259/Ws54yuSDnmtt4lY5LZY9c9ageIDK4zUtXNItx2MZovmyB1HGKRwPLwVINaZiAypxjrVWWPv1qbDc31KK4UrgkEHhvStBZiwV2y38LA/zqlOuwAY60ttID8rZxULRlcxZnQbAGOVP3T6VWhOcxk4yP1rSZV2BXB4GM47etZ9wio2SMH27+9U4hzDUOCVbPtViArnJxleg9aiaMZyDhWGR9Khk+RgQenX2oasLmubm1HAJAOeRioZoVIBz3qrbyZULuwynPXjBrTkQHjg/0otdDUmjJltlZRlcDv7U2MhONuc+lX9xwVckgHHPpVOaMKRsbjOaTj2NFPuNVl3EBiueKerTLyJR93bgjt6UyRQwBGP/AK9PJIADksq++DUlc40LJkncD6ZpcOVI25/HFEBjMpDc46Ank1dTZznAA7f0ppXB1LFVQx48sbsYwakjhJX7mCVIOe9WS2Wy2ARTyu719qpITqlAqqjDBgMdQKidWIUK+e4B7VpBcphuc8ZpwtiWXABzzxS5bjVRIwHieKVmK8gYOOhFa+jyHGQCU4HPY0s8ClWZuM8g1Ah8hwy8EdR2oSsyufmR0bZ2syMGXHTpT4og9okeAMcZ9zzVS3mMkBcfN3PvT1nZWXdHkBegNWZtEdxG0RAzj3HSnQbSAJRgHuDyD2qw5hnQCJgHwPlJ/Tmqk6NEvtnoetIktoC4YEhivUZ/lTJIyg5+79aijlUKEc4xyhI6+xqYyq0OWIyTg47UBewyMEnMbZPp3pryYPQg988GlABwWGWHUimyA7gCTjvnk4qilqBl3nkjaP50jTEYTncegFRBASR8w9hTCCoZEK5PU+o+tIpIjnmYMRv+Y8EL2rNmZsEL+oq5MGjlwVDd+KikUhcvhWPRaLmmxnklRk9etV5yNmMn8qtTxMDt7nkj0qrtYEoDx60mG5k3IIbjk+9RRrvNXbnZkg8juagRUBznFRciexUuEUcAisi9gV1JI5PHSt6WBSTtw2aq3EJAwRwKu5zWueY61oTxO0tku6NuWQdR9PaobHUtSggNpaQDByMiDJ5/DrXophBkwo4PtWnaWm0ZRQpI6f1oVRoxlh1JnmWmeD9Su1DvG0AIx84wfrXT2vg9FiEc7lmHVwTmu9ggBUNjqM81ZFpkgrtwfTrWiqO2wKhBHDL4SskxvG4/7bE5qZPDVoDlYIRj/YrsJrEcgH86gMLRgEAEn2qGa8q6HLyaFAuf3CfggFRf2LEesKjHYrXWEELnqfYVVkhJ67zU3Hyox7Dw1Nes62KfNHgna4TFTf8ACIa2hzE0ikcf8fC9PTr0q4LcdGDLkgA+9bc9holsL1XtrqY2RRZW83G7d1IH1q41JLZmNSjCW6T+Rw99aa1p85hluW8xVAKsQ3HUciitzxBawW+pSR2qFINivH8xO5SMg596K2WKqrRSf3nK8DQevIvuR6EzfOgclTjHNE7BmCrj60tpHkZPO3A5pZEPmjAxgc1yWPUbQ28ZVhXb99j+dT2sZWEMe/RT1PvUUiq9yoOTGgGT9e1aaxlgcDj27AU0tTNvQrtGcjcM89cVYt4DGeVHIqdIugLKO3JpQEGSH2n25xVIVyQ5XHyhdxHJFUmLeeXh27V5zjgVNcSqIjhyzbgORwBWXNN5jMFB2FvXrTv0Eo9S9cXRnTDylvQGqOSoJHWkDZJXGD9aHHoAQPeqQ+o5csfm3cdPeo5WAbKjJp6tgYA5FNdAQeAC3IOaBlViSc/xdabs3HHQHmpHHJGeaT7uGB5FSgZSubbk+vr2rMkVo5AVHGa6JmEowxAB747+lZt7HjPHJ7VMkJXJLWYvEN2T6D2qG6XHpjGfpVa2ZlcgEgds1fKiWEgHHemtUS9Cjbt8xRuo+7j+VNuI8HOOO9I+Y5ARwR0x6VK7iRcc4Pai2lhX1K9nJhgM89K2IpCwXHPGa5qcvDKSvA9fStnTLjevGDzn61Mexd+paILBuOaUAOoVhjIzmrEibXJAwOtVTxu6EA9atod7kEibdoPTNIwyMYqwCjKD3z3pNoY4zU8oc1iiUPGfzp5mkUEElx+oqxLGfLAxyORTChOcgVPLYalcfYTq8hUndgcGtLadgZDkVz7hoXDx4Ddq09NvRM/l42ueo7fhTi+gpLqaAUsiZXnoKRJCPlBG0dTTRL+8wODjGCKYTnd6VpcW+5JKFlHOQw6VWkhzxgYz+tSBgDkHmnOwcZ6N7HrS3GtNhdLnWOfZKPkbp9a1J0Dseh+UYrBmUsu5B8w5461etLlpU3MecgGkuxXmJJCfvFQ3OAR1HuKb5j4Kh9yYxtfkVZmckH3qBmyCcgjpxTaLT0KVww24XfEV565WnQTyDBd90fTcOcUXaExschveq+1s5A2sw6L/AFqNh7o27chs7SCep96JQfNPIIHU+lYkc09uQTgqDkZ4INXYLlbhlR2CEnn3pqfQXK0XXkG3lwuT+dUppznC/MT0xV4WqEZBDkHHPOKR4kiQ7Qp7r6e9XYFJGUPMOQxwPSo5Jhuwq5J7nrV+a3J+Yvz2A4AqlPtTBjXZnhh6HvUuLNFK5BJnO5myO4FVbmRmXHyKq8AAVPI2eo5HH/16pTbg2CBkflSsFyk5bd82OvQU10PoKtFM/WmjjGRUvQTdzNZcOTgg1HMwOQfStN1Ug4xms65jJycc0XIsiKOFmuBgDaBk1q20IUYY4I4qGyH+jyE43cD3xWiUZtrbfvAEYoS6gOgZVjAUZwxBFPeXLffVfYrUUKFWclGbnk1YMZwBwuPoMVor2M9LlZzhtyM+fZcCkYMQTz77mqwQCNrumPxNRbQh+Q9OmFzSauNakJiYjJkHvUEg2EAMfbirEkj92OR2AxTWXeq5LVNg1W5UdWycZIz021rXEl1b6nGl6bNmmiWOfeuVx28zHfp0qnscBmUOVXB3AZA9M1qXkVpeSNcXVvqcUr8yRxxZVj6gnpmnYzbuc54gFwdTlF4iLKMDEZ+Xbj5dvtjFFO1uc3F87tC8ChVRI36qoGFz+FFFilsekwKY41GMMSPypLoCOZ8/eVMYFWlUFrgtgAKGA7/hWfqU/lxTyAZLg4zTZEXcitAHd33HDPx71ogcHbkD1z+dUNPXbFCnBP8AWtO3UbWTaOvGe9JbFliBQduGQHk8nipn3YVQBycZpsGwM24YAXgj1qC4l81gsSkFVLHFVexJS1SfKBVI54GKpqAFJCk9hTSxmlLAZC9AOKmBJ2j7u3nApIYmzBHy4x1zxzRsz3Bz/dFOwTyOSe9OcMkYbPHp61ou5JX8vYSR096Y/HX71OQszE5Ge9QXTnBIznNBSethpbOccGmqS2QajAYOGOSDUuMYI/WpKBBgEEnk1HdEMCD1HepS3Iz1HpUcy7lyeCP1pCM1kw/vU5LADaenNNfgk9aM5GDxjmkhSVyKdAeAODUcRwuDyRT2fHH8J5FRNjnnBpiSILtQw4HNM0+Uxzbd3GfyqweY+uazZiYp9wHFQ9GVynXpIZYlOeoqJ8E9OOlUNPud0ajPHWrxzz7+lVe6HGNiuWKsR19M9qmhZWK4yCc9ahkPQkdTzQvQigbiWTgIwY9KjyChz07VENzK38qUBm4bj1oFYR48qD6VR24mHUHPatFm+TAAPrVJ8NKMZzmpkikTNKEYCXPtIp6fWr9lIsi/3lzwwPH1qkqhoWRuDmqcchspwGZlhY8lT0/Cle2omjfdDnAAz2xUD8ZDcEdKdDOxYAsrAjIYdD9DUjhWOTjnsa0Iv3Ig4PTqB1z0pbWZY5SJEOT0Yd6ryjYePWnO7YDL1FJlGpIVKgLyMc9sVDhccHceoAFJayrLGoTBYdc+tTyDaOOavfUSZUdvlw+M+mKgnwVG047cHFTS4JOCfpTIwrEqeRjioNkU5N5ByzEEd+agQsVwwGRxyKvzqVwMc9eKrImHZWz69KhxuzQWK9ngYAOGA98Gr66sjRHz0Iz3AzWNKgy2FY470kcrx7uAcjBB/nQm4icUzpBIkkW6N1PB75qtLFHuJJBDjDAHP0NYbOyEtCxDHnI6Gp7fVB8qXseVz99B/Sr9pfcjl7FiZVA46r+ZqlNs5bk+1aYQSxeZavvA67T2+lVLhGfJUBvSq32BNFBiAoxxx3quwZjz07mpZFIPPHGagLndk4yetZPcpiySGM8kYqGR9yknoKjnm3ZzVWWUhCoP4etCMmXbSRQ7xkZWQDA9810Zw0rL8rInORxkEcVyenZM45xsyc/hXR2pZoLcrjc6KWH0GMVcCWaFlGpupNwwpAyPwqzIkZbIVFIGDwB+dJawh7vnALIAeOKtz28KKzOIwx/vL71qQ0ZMrgnG6MDoOP8A69VXCuGw4yO46YrVmEPpbgrwDgVDnbIVRoSV6Fe1DNYqxk/ZlfPy5GeuTTWtQE6jJ4Oe1aAd24aMkjOCCOTVaVnYbWQqM/3u9Z2SE+YrJuCtGJGxIQGQH72On1rWvRHBMYZtcvo3AG7Ck7T7nNYzfLggHcOc5rc8j7ci3N1pchmcZ4nCCX32nn8qXMZyXUwtc0vYLmVL2W6mg2+d5q/NtP3WBzyKKTUtRl230clt5VzOyo+TgJGuMIB/WigI7HfzMjspIILDkj04rN1h8MkHXbhashslQBlUT5jmsy6bzLuEFuT85okKJrWigsgwSy85H0q0HaN2LKOAOfrVO3fEfDYLNT8qXADEsXz83QAUDReeTy0CbxnGMgdax7+SSMPtZgzEKB7VpBo1VMklnUnJ6YrJaT7TqCkZZU4JPc96GO9kWLWLy4eRxTnXYpduhGMVYJ+4gHVs4Haq93NvmwcbVbgDrVojqSqESMO5ITqB3NU7qdpucbEJ4UdKs3DEhnwFzwB1NVUjLuAQc9cE1Qla12PRPlGWUVDMM5O04Hc9KtGMxxl2ACZ4PTNVZHMjDggZ4FUC7kBJbBAwR2pr5ALcfSrAXGc9QajnQBeeR7VLRaY1QGHWmyoeKfjB/DFNnLeXuLd6ixRRmZSwxz6iq8pKgk0+XJLYwM96jU7wc9ehJpItrQruxz9OaaD3BGfSlkBHA7d6gXODmkNIsqTgjr9KpXgyOmSelWI5OCB19aY+MYHQ0PUaQywmKuFzytdAkgeJTjtzXLgmOZW7VsWcwwE3dalaA0WpCfyppc5H93inP+8UdOOKhYbWK5HSqGiaHBcA1NGwJ5ONvc1WHEinIzxSluCcdB0ouTKNyWdAFyOD6iqLHByevrWlLjywf71USh3+2fyqZBF23LcS5bKkfN2qtqMIPXn3FXrSPc+chgOmKhvoxjOeKLe6J7mbazyQZVeV7qe9akNyJl+UFgOq9xWUrBW4qUMUkEkfX60o6EM0WIIPPbv2pFIWM9yaasiywqR3OM+h9DRJ0KjnsK0FfQLW4WK7OTgNWyzK65HDVzjqxz/WtaykRoFy370cNSTtoWo31J5EO3P8qrNGVcFe54q4d2zpkdqrsS0qk9u1NmkUIWKkgLuPf2qvN8jqyjg8H61dAznaMEDoKJIBIjHj1GfWnYdzNmiO4sW4/nVZx8x4xWuYRJbq4wD6e9Z8gDOV5zjOfSk0WncosoyQD8p/Sq0iFDsc/nV2RRngYqo+T8hH0J7VLVx2sVY7h4Jd8EjKwz0NWjqBucbQYrjHJU/K30FVZrch8kjnv61WKHP0/Sp1BxW5aa7A4lTJJ+8DjH1FMkcEFkIZageTzBiQ/P2PrVKSQxk7flPtQZsmZyzHhRVeVh0zz61C10uQH+U+vamSyrjII6VS2MJOzLVrOVnwOrDBNdJaS7iMfh7GuLs5d0xIycEAV09o4UKEJPHNTezLWp0kNw4dMZ3DtVxLpACBkNg9TyfwNYVvLgcsTmrbznGcA+xrRTHymhJKgzkLJn++MH61E7lhtEMeMZDY/wAKyDcbGAxgN1I5qfzQUyG59mxx+NCkU1YfNsU4KIO2ASKpzcNlcqPY5pLm45yAwA7nkVUlmJ6c8+tJsRI8qjBxnB5z3rSvbZdTvHvLa+t/KfGPMk2tFx0x7e1c9snnZhDC8m3qI1LY/KnpZ3xU/wChXOO37pv8KlGcomlr9xDc3jmF/MAVUMpHLlRgn8aKr+JDs1HZjb+5iyuMYOwZoq7kqOh01pdZSQtk7+PpUBl8y+K9MAECqkMnlxKeCBz9adaSE3kjA5IHJqWZrbQ3kYBQePvDGKmjOXTOcKMH3zWc8wVAeT0qdZj5oUeg6U7lak+sP5CR8HAA6VHpkRRcngk5JqlfyPcXiRsxIAGQK1I1x8uTt6k01qwbsrEk0wTYzEn5Tgiqtuu/ax5Jb8aLpjIVb7oxwParMMZURKmC3X6VSIbsR3HzbVXJO40sQVf3sxIU9AOrf/WpJHMUwXh3GR04FS28JBUk73/lWiRLZFMpufmkztAwFB6Cm+WqHao4x1rR8lTGwQnezYAA61AyKPMUr8w9T3ptApFFY8ybs4BpsqFWIYfKO/rVwfJEclQTweOlQTqCA+c8YHNJ6jTZRf5uhOe1RSOSpA6VM5CdORmqTPgnJ5POKlo2i7kMq7Tg/dNQnhiw7jBqy7b1OTyP5VBIoxx1FRYq9ypMc8ioGG09frVmdCcgDI61UbAGG5pNGiEJIIPbvTmcdTgU2Mh15PsaaM55PXjFIqw2cbsnHbJqGCVlkAGc9qnJ4INVZBg5HUHFSwRuW84OM5IIz+NSyHDA4AFULOQFRgjPWrkpyo6+4qugEkbghc9Q2Pwp753Ak8DtVRXCEHIOcVZDhkyAeOKSepViUHdbsONyH9KrlwJRk9Bn60sb/vdqniQY6d6r+bmSJT94EoT60pMnlNq1wEVc/P1pbhVZDgVFaOHb1wvpz9KtSZVOnPcVS2M5XRhSxjf6GmFipAP4VcuF+bIFUnQmTPr+lQ/ILXJIyQ3y9OpHY09rkqOPmUenUU2IrnAz0IpgX5snp0NNMiyLUUiy/dPaprZylyGIDZ4IrPSLy3Drxx+dTCT5ueCe/rTlqik7aHSgnGSPpUSxhnyeoFV7CZpYRuA3KcVZR8E4HJPbirumVHQkEIB3jGOmScVGcq+CvHUZp5fIzjr0yKYzlSWVQH9T/SqWw+upGZAkjLnO8ZXNV5I41Vgh3Z6mnXBKSKUb94p7dfrRs58vJ2jnGPvd6nqapGZNCx5HQ9PcVUlQj0BHat1lO3OeBzx0qpcW4ONwGD3BosO/cwnL7TkfKOoqsysH55B71rToqqcjrVYQheoHPXFQ0NmdLBhSQfwqpKqjGR9DWnMhGT26VQlz/dzRZGcjPuYVdCTjP8qx7mR7d8Pyrfdb+lblzkqT0IrJu0WeOSJx1/Sg55oh0mcvNKA2FBzk11tjMpTCAKnGee9eZ2V21vqTwy8fMA3vXcWt4DECMAEdqSRKlY6WOQZznmpXuAFIz0rnlvhsyW96Q3+enOaVjXmNzzlyD+tI04KnDcVhG744PHvQLwdjSWg27mq1wvY8moJJMjgd6znuQCSO1ILruTxTFexpW9zcwbjb3LwbvvFGxmrTarfovF/cZ/66Gqmmz2/2W/u7iIzpaopEOcBmY4yxHYUSRxarZSXWmxNBcQjdNa7iwK/3078dxVXsiHJMiuLuSV2eaVpJTjLMck0VD4m8m21Py4FCJ5MTBV6ZKAk0UXBM6RXKn5Tz6HvSWkrb3J4JOBVZW4UgnOKl0xh8xP8Ae4o6mEXZGx9oYbB2ODmpo5x9r4yDjr3rPBHnA857UEk3TEE5C9qLdTW9zUt3Et28qA4HHPtWuWHlBu2BnHc+lYmlvmJunQnJrTEoNuTnpirRmxJnBnG48IMVYhbzDuPypjA96qRMCxY4yTk1biACA5x1NUiXqOhjBkB4x1xWnapvljIXbznd6CqVsg+U46sPyq3Gd5KqTgfKfp6VadiWmBytyTEw3An5h296a8DAEkctjt1qxbbQ0gB+4TgUl3tT5iSO9UTczZI98ZTd8o5bjv6VE8ZVd7dPTHSriYwQilh13HgUyRgwxKzEDpgcUmXdmROCnUcNyDWfOpZtwwea1plUsNoPrzVS4j2MSRjPYUmaJ6lJ4CvIPNRFcYOeR2q5I+ByuOKr7eTkZzxUWN0m9ylKMcrzjiqcqbsMDV+YYkzjnFV5FwcgYB657VmaJFEFkkI7H0pjSZYH8DViQBehBx1xTHUOp2jG4d/aixSE2kAHGeaik+b0HrU0TEgLnINV5wQwwME1LCw62fy5B6Vp5LKxB6VkIDnnnvV+2cgrnJAOD7+lCGOlJCuBxjkVLBJ82DwuaazBgOB0xTYwOCSOnb1FHUpFmThNyH5lO4H3qpdkm8ilUnZN8w9m71b6ZHBB6fSsy9k8rZnlVfeP6iiQupvaIdwYsOT6+1ab8qzYJJHyr/U+1ZOmOgmO5sR8tgdTwOK1rdnmRpX5Zj8p7AD+lOJE0ZjqT6cVE0QPXrVm4IDED1qEOAOaWzIafQgUqk6DHepCoIIHBqtKzCQSDpnIq5bgOWOMKDTRDViudykLjjqaAQfvcj19KllHznHSoACGBHT09aokltJ2huSnXeMe9bcROBkdT3rDliyA6t8y859DWvpt0JbZDLncODz0pR0di02y2wJUZI5H1qnKzoDtBx0we9WCSCevtxUcy7iAeQKu5rEZbgrksN2773qP/rVOnOVGA6cjPR19PwqIOuR82COBgc01nIIKdR2PBoHcnJ3kbPu9MN1HtVO4ADHJGKm80MilDuGcN6/Q1BcHzDsBO9uPpQ2BQchizn+HgA+tVwnJbsKs3BUkBR8q8AnrUC4xkAA+lQU9irMAecAVmTkK2Bg1o3B67etZk6clscUiSpcqNuQDn61i3BImzjnrW3ccj2rMvYeNwFUYSOL8SKIruK4Tjf8AK34dKl03WSIxGzHI6ZqfXLX7VD5ZO0g5DY6GuRdXhlZH3K69R/hTirnLUbR3K6iuPmbcfapk1EDnd+FcPZvuuESSR9hPODXoOmeH9OuIEdxPg8MRJ1+ldNDBzr35WjjxGOjh7c1yt/aQ7N+VKdQz0atOLwvpxBU+ed3Ta/I/+tVe78OWyTtHBdXCsOSCQeD0HpWzyqstrMwWdUdnf7iuLsN1alFyB05+tV7jRbiEsEvYnxx939Kj/svU/LZomhcDtu5rF5fXX2ToWZ0GviOg0G51KO5eXSYnlZV2yIkZkUqezDpipY7TXLe5SeCwv4pkbcrrEeD/AIe1Yejw+ItN1KKe0jQvnBjD8TKeqkdx/I1cuNC8VmWaZIr2CBmykbyuxVTzjPfFL6lXW8Rf2hQvfmRLrF9dXGqPJqcRhvSqhlaPYcAcHHbiismTT9Yd98oWVzwSz5PHQc0Ungqy3iNZjQe0kd9FIWcheuOamsJMBmbIO48Gsi3lInXBIxwT61Yjm2bsk9c4NZOJspG4sm6QEcmnrKBcPg4IXBBrHiu15GT161KkuLk7ienPc0uVmvOdBanbGQv93FXElUwnPbArItJz5bqzDf2xVmCX92y9qSLcro1IzxkVbgkO05Ax938ao2zAjmraNhSPfmmKKNO325whyMYJ96sEeS4GR8pGT7VStJRHtIJwanlmUMoDZ4znFNCkStIy7x8oDng0qL5ib8lzjNVo/nYluSelTZKKQvIFaJktD2H+jZJ4fIwOoqvGqZK7jwKbJIyEADnB/M0+0+/v2ZODxRuGxRlRwWUJnbyKZPGcBSPn9BzWvINzDIwp4IAx+tUL2OQD5cBQf4e1DRtDUyLmJurlVB45qm+1QcbmI9Ola8ttxk8n3qlNEVIGAM+1Zu50RZnM24EABRnj1qnKnz4Ykj3rTkhO3JAqs8ZYYwc9M1DRqmjNdVGMjHamqOeeo6fSrbRg53Ee1Rum0+1BLZGIwGb0POM0y4jGQRzipG4QHGccVGjb2wTgdDSBEEi4HXBFLE2SR+HWiTkEenBzUSsDyOD0NS0NMukkgEZp8ThWHHAbr9ahgk529/vCpEcbiMA7lI/GgpMsZKgHryQao6kN8JTjd/WrPm71ZTjPWobgD5WPcZoewyXQbkSpuAywiCfRuldpEgSJbYAAADce5Ned6Ixg1vyf4HO8V3WnMZ3kkZicc8evanTJmupVuo8vmqMqbScY961rhgc5+8T0rOl2qTuIJPpTkQim2MfKAavw4SJc9Tzg1UIGScdeKmcleAcEioje5Mo3Qs33icYqtbjfLz0XmnzSBY89TRaErCZHONxzVMzsStxl1xnHQ9DUul4MTeWcSISTnuPeiFMgKQP3nr2NVoC0d8dnBPUHv7UO6dwRuLyAyncgH3T60EZ+VSVfrhh1/Gmw/PGZI+hPzcdDSyAY+YE5/wAmtS4lWZXjb5xn1B60zzUC/MCM9CKnlZdojfKx/wB8nOP6iqcyccDjqCpyKTNEIs2GO0qWxj05+lNZiiM2eSMYJ/lVV13Nhup5pjlsqRJhB0yOtSaCgHLMc57CmuRj0zTTLgYdfxHSmZz9wgiglsqTq2SByOo5qkzHJDct1rRnUknHpVN42+8Rn1qRFadQ68YqhKmQRnIFaphyOarTKMHFO5jI5y4gLtwpNc/qWjTXRYJGu8chieldlsIYmmCMFRtHU8mpvZ3M3C+jOKtvCN07fPcRoOvyqTXY6VaXNjCFSVZTjBZx2+laUMIVRnOKsKgOdoFbQxFSDvF2MJ4SnUVpq5Sa4vgSWMT46Ag8fSoZ76dkKvBu4+Yh85PY81pMA2AV60htyEPHHbAreOPrr7RhLK8NJawMK41Bhw1rJj04JpbPWbNZVEzsjY5LjGfb0rTeMAdiapzWEU/yugNdFPNK0d9Tjq5JQkvdujpfDt7BJHdpYXkUd9JGBbszYAOeVBPQkd6vR2GvpMsn2iVCcfM9yNq+pznmuIsPDWn+Ve3l7FM0Nqit5ULlDIxOACewpmoWtwdPkv8Aw885Nt81zp8zl2Vf+ekZ/iX1HUV0wzKMpe8rXOGplE4K0JXt8jrNfWN9ad4GRiQBIyD5WfaNxA9z/wDqorl9f8Qw6brP2QwGNBBC4PJALICT+f4UV6FPF0nFe8eZUwVZSfusthyGDdt3NOjlDl8HJ9cdaqzM8DKs6MrKDuBGKFKq2QceprwZ0nF2Z9JTrKSumWxIFcFcAEVPHLsl4Oc/xA1nPzH+7Pzqc9aesvmL+84PcVHKaOR0ENwFAIxk9/StO2lySeBk9M1yUF1tdI5HATsccCtS1u1kIEZbPuaUqWl0VCtrZnXW0vTpkVfRwWIz3zXP2lwoQFjV6CdTyGrCx1Rka6S7MY9+KmjlDOvNZaXAbOOtWorgMx4HHpRctdzURgr9cj2pJJuw+7mqZuQrpnkdDTZZDs4bAY/jVRZLTLW0OVYtuz6Vo2rFeRgLisq3kUFc5OO4q9FKAFI+X0qr2CxcYkEFscHpTJYENvvx8zdRUasMjZknqM9M1I0292zgZ5yaL3LSKskWMbx071Ru0jPIyT6CtxrdZiijc/qzcLVO6gKmQNhADgY6UGkWYDjGQABnjmqM0bEZyeePatKaNVDEc4OCTVSQfNuJyCMf/XrNmy8jJuIyuT6VWZhkjpnpV27yn8QwP1qjMRycdDmpZXqN3hjgfTFQ7ucH6U5gEORwc5GaaRufH4igaEkByrEcEYz71VmBRg3RW/nV5VMsTDoc5qvIhaJkAz3U0rAV/NKsjDgqw5qRpTHMCTwCDVYHedpzg8U5QZbCTu0JGfp60jRFp5WhuGBGAfWkkuP3UR6k5BqO5CTWlvcRuGJUB+eQelRttNqhx8wYgmpHoRi4WC/t58fdJH5ivQfDuXsWQEgzcEjqQfSvM7044J5BFeleEJNwRuDhcYqqfxET+G5NcxbN5X5R90VhXTfNtJ+b27V0mtsAG2DoPyrDs4Dcz7iDt6A46mqmuiJi9LipEwgDt17D0olUeZgjn1rSu4GSFd33SygH3rJvHIllI4GcU7WIvco38m1SF6ngVatkM1wIgf3cKjecZxWJeSkTx/xHdkAdz2re0mJtgiwWdjukwe/p+FQtXYmWxaZwUf8Ah4xj29qLYm6llc/fQKTS6gEGAhyF55GMUmlObe4Ut0l4HrTa1J6XNSJTAxZRwy/MvqKbNh5Pk5TqKbKdpCR53H8wtOjZYwOpQ/eX0NaPyHF9RrxhQVzlsfpVCYi2GMkKfTtWk4QfMOV7VQu1DKSwx6D196bLT1KUqg7XOMN/EO9QEh1yeq9BUwYQqQRujzyOuPpTVw2T1U8A1maN6Ge5IbgHB60xcHsa0ZFAGVAwah2qDQ9iOcqguuQeQaC4AwVqSYEdBVd2yuMfSsynqI+CpxwapSoBkHmre0sOAaikjG1yfSi5EkjMK/K3pSxpnAC4qxs+Y5HHpVqGAEZxyO1BmRxRFhgj3oaIKxYZqaRth47exqvI4JORg/Wgqw/ykYbgefrTWjdeA2RQhPQc+uamEiYwSM00xWKTo2SWIqJkO0nvVogFiSRj2qKRiMj8qolkdne3FjI8kJRw67HjkXcrr6EVnQ3M1peLPay+VOhJGMdD1BHce1b2l2azl5ZIfOVCqLFnAkkY4UE+nUn6VKkjT3txayJp1xHGG2xLAEEoHUIwGQcZwT1xTM5JHEeIn/tm9a7u4YhIyqhEYwBtGARRWprNlHaXpWEloJFWSNj1KMMjPv2/CileXcz9mjsr21iltSlxEkwyCNy8g+lZk3h+2dN0Tzo+xiEHI3ds55xW/Cx3AZOPLY49waVwPO6Dpj9K+0nShNe8j4WnVnD4WcVJpd7b7cxpKTwdh43Y6VRclXZZAUYdVIwRXbNzZuTyfKB59c9ap3saS2zPKiu248sMnpXDWwMLXi7HfRx878slc5RmDdCc/WnwXTREkHoeQOv1+lVZwAvA6CgdV+leXKPK7I9VPmV2dJZ3hJGMbCuRk1sWt0doAGTXGWf/AB8j8a3LJmEo5P51lUgnqbUqrT5TpIJcN8xPvWlDICcL36VgWvKjNaUZxEuPWuVo9CLNB5D8o9DUwbKqrdCciqDdvrVqH/VJ9aSZUjSiwsfH1qSOXZHtADc5HHNVf4TT4/u1QItCR2Oc4HpUyuEOTkjoKqRfcX6GnZPlvTRaN+2vFWKBpxkkEFAOlZ06u80pkbCHp64ouCQ4wf4V/lVtOc55+SnuCMeSCPY/y8Ak5Y9RWXPC3JQfL/SujIBthn1rH1HiCLHp/Wg0i2c9cqHLKOnX6VAVBC7iBkEfjV2f7xqq/wB8/Ss3oa7opzYZNp4I6Go2/wBWAudw/lTpvvfjUFwfmWkxoejbVG2mSMVwy44OcClXp+FQz8BsUgK1wiea5iJ2HOPaiYLFhoclJ49rAnowoP8ASq8v3V/66UiosSxb5JYSvPXOen4VZRSE2t0BqCH/AFpq0e9SaMzr9CATXd+CZc2cZJGcda4vUP8Aj3b6V0ng/wD5Bkf0qofEZy+E39dul2GJBliMsataVCkdvFwFZE3fiawbsn7U/wCFdA/y6OpXgkHOO/Sri/eIekUZut3oIVEJ+Ug8evrWDdzkb2OTmpZvvD/e/rWZqxOxvqaiTEiCxDXN8rj5tpwij19fwrvrC2FraBuPMYck9V9q4/wio+0DgcAV2EzN5cvJ6etVTW7JmVGUXEm3p6n0FVLqUpICDnawKn0qxaE/ZJz3z1qhef6p/qKUtiUbduGI86TOSPWnBc98YPHHNRJ2+g/lUx/pVoaK7y+W2Dkx9/b3FROwcZzkH+VNk+8PwpB938aZpYqy8bgD+NV4HETk43Rn7yjt71LN/rGqD+JvpUjexNMd3IPy1AzLkCnP1b6VCeoqWTFBMTjFVXQk+/tVuToahTrUspEaqQpLfKO9RMwfI9OM1ZuOtRQgfZxx/wAtP6UW1IeoiQbpGz0xkVLtVQNmeRzTk/8AZf60f8sBTSIZTmbDcnANV3OeeenUippfvGo5On4UluaETNjGOM9wcVExYnk5+tK3VvpTyODTsS9CFZMdRz7UNJk8/rUiqDnIFMIGDwKEyGXdIvo4HeKaQxJIVZZQufLkU5ViO46g/Wr8nlRSSXGzTbbeCGuI7kyYz1KR9cnJ+lc5ccDj0qK4ACjgUzNrUfq10l5eF4kZIlCxxIeoRRgZ9/8AGiqZ++KKVhn/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17652=[""].join("\n");
var outline_f17_15_17652=null;
var title_f17_15_17653="Silodosin: Drug information";
var content_f17_15_17653=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Silodosin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/60/33732?source=see_link\">",
"    see \"Silodosin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6813986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rapaflo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13737687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rapaflo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6822374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       1",
"      </sub>",
"      Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6822448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      BPH:",
"     </b>",
"     Oral: 8 mg once daily with a meal",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6822449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6822450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: 4 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6822451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Child-Pugh class C): Use is contraindicated (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6822456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rapaflo&reg;: 4 mg, 8 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6822372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6822453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with a meal. Capsules may be opened and the powder sprinkled onto a tablespoon of applesauce (not hot). The applesauce should be swallowed within 5 minutes without chewing and followed with 8 oz of cool water. Subdividing the capsule contents is not recommended. Do not store for future use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6822376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of signs and symptoms of benign prostatic hyperplasia (BPH)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6822370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rapaflo&reg; may be confused with Rapamune&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Silodosin may be confused with sildenafil",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6822403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Miscellaneous: Retrograde ejaculation (28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Orthostatic hypotension (3%; increased in elderly &ge;65 years up to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (3%), headache (2%), insomnia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (3%), abdominal pain (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: PSA increased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasal congestion (2%), nasopharyngitis (2%), rhinorrhea (1% to 2%), sinusitis (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Hepatic impairment, intraoperative floppy iris syndrome (IFIS), jaundice, priapism, purpura, syncope, toxic skin eruption, transaminases increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6822380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Concurrent use with strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, ketoconazole, ritonavir); severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); severe hepatic impairment (Child-Pugh class C)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to silodosin or any component of the formulation; concurrent use with other alpha-blockers (eg, prazosin, terazosin, doxazosin)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6822381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension/syncope: May cause significant orthostatic hypotension with or without syncope, especially with first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor (eg, sildenafil, tadalafil, vardenafil) is introduced although coadministration of sildenafil or tadalafil with silodosin was not associated with a clinically significant risk of orthostatic hypotension in one clinical trial (MacDiarmid, 2010). &ldquo;First-dose&rdquo; orthostatic hypotension may occur 4-8 hours after dosing; may be dose related. Patients should be cautioned about performing hazardous tasks, driving, or operating heavy machinery when starting new therapy or adjusting dosage upward.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment; contraindicated with severe impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer: It is recommended to rule out prostatic carcinoma before beginning therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate renal impairment; dosage adjustment recommended. Contraindicated in patients with severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Contraindicated in patients on strong CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; risk of orthostatic hypotension increases with increasing age. Patients &ge;65 years of age experienced an incidence of up to 5% in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Females: Not indicated for use in women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not indicated for use in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihypertensive use: Not intended for use as an antihypertensive drug.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein, UGT2B7;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6840046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6822423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: AUC decrease by 4% to 49% and C",
"     <sub>",
"      max",
"     </sub>",
"     decreased by ~18% to 43% with moderate calorie/fat meal. Management: Take once daily with a meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John&rsquo;s wort may decrease the levels/effects of silodosin; other herbal medications may have hypotensive properties. There is limited data regarding use with saw palmetto. Management: Avoid St John's wort, black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse. Avoid saw palmetto.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6822377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6822378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however, silodosin is not approved for use in women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6822452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with a meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Rapaflo Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $159.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $159.61",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6822455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; urinary symptoms",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Silodyx (BE, CZ, EE, FR, NL, PL, PT, SE);",
"     </li>",
"     <li>",
"      Thrupas (KP);",
"     </li>",
"     <li>",
"      Urief (TW);",
"     </li>",
"     <li>",
"      Urorec (EE, FR, IE, NL, PL, PT, RU, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6822426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Silodosin is a selective antagonist of alpha",
"     <sub>",
"      1A",
"     </sub>",
"     -adrenoreceptors in the prostate and bladder. Smooth muscle tone in the prostate is mediated by alpha",
"     <sub>",
"      1A",
"     </sub>",
"     -adrenoreceptors; blocking them leads to relaxation of smooth muscle in the bladder neck and prostate causing an improvement of urine flow and decreased symptoms of BPH. Approximately 75% of the alpha1-receptors in the prostate are of the alpha",
"     <sub>",
"      1A",
"     </sub>",
"     subtype.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6822428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapidly absorbed (Lepor, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 49.5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive, via CYP3A4, glucuronidation, and alcohol and aldehyde dehydrogenase pathways; KMD-3213G (active",
"     <i>",
"      in vitro",
"     </i>",
"     ) and KMD-3293 (not significant) metabolites formed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~32%; bioavailability not altered if contents of capsule sprinkled on a tablespoonful of applesauce and administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Healthy volunteers: Silodosin: ~13 hours (mean); KMD-3213G: ~24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Silodosin: ~3 hours; KMD-3213G: ~5.5 hours (Lepor, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (55%); urine (34%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chang DF and Campbell JR, &ldquo;Intraoperative Floppy Iris Syndrome Associated With Tamsulosin,&rdquo;",
"      <i>",
"       J Cataract Refract Surg",
"      </i>",
"      , 2005, 31(4):664-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/15/17653/abstract-text/15899440/pubmed\" id=\"15899440\" target=\"_blank\">",
"        15899440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lepor H and Hill LA, \"Silodosin for the Treatment of Benign Prostatic Hyperplasia: Pharmacology and Cardiovascular Tolerability,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(12):1303-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/15/17653/abstract-text/21114397/pubmed\" id=\"21114397\" target=\"_blank\">",
"        21114397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacDiarmid SA, Hill LA, Volinn W, et al, &ldquo;Lack of Pharmacodynamic Interaction of Silodosin, a Highly Selective Alpha 1a-Adrenoceptor Antagonist, With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil in Healthy Men,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 2010, 75(3):520-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/15/17653/abstract-text/20080287/pubmed\" id=\"20080287\" target=\"_blank\">",
"        20080287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9520 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17653=[""].join("\n");
var outline_f17_15_17653=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6813986\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737687\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822374\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822448\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822449\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822450\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822451\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822456\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822372\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822453\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822376\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822370\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822403\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822380\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822381\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838536\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6840046\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822423\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822377\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822378\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822452\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321883\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822455\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992808\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822426\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822428\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9520\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9520|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/60/33732?source=related_link\">",
"      Silodosin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_15_17654="T2 MRI well differentiated pancreatic neuroendocrine tumor";
var content_f17_15_17654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T2-weighted MRI image of a neuroendocrine tumor of the pancreas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pancreatic neuroendocrine tumor.",
"    <br>",
"     (A) Fat-suppressed T2-weighted image shows small high signal intensity mass (arrow) involving tail of pancreas.",
"     <br>",
"      (B) Arterial phase fat-suppressed gradient echo image from dynamic examination reveals mass (arrow) to be hypervascular.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Leyendecker JR, Brown JJ. Practical Guide to Abdominal and Pelvic MRI. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17654=[""].join("\n");
var outline_f17_15_17654=null;
var title_f17_15_17655="Orthostatic (postural) proteinuria";
var content_f17_15_17655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Orthostatic (postural) proteinuria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17655/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17655/contributors\">",
"     John T Herrin, MBBS, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17655/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17655/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17655/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17655/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/15/17655/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H188318253\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthostatic (also referred to as postural) proteinuria is characterized by an elevated protein excretion while in the upright position and normal protein excretion in a supine or recumbent position. It is the most frequent cause of isolated proteinuria in children, especially adolescents.",
"   </p>",
"   <p>",
"    The prevalence, pathogenesis, diagnosis and prognosis of orthostatic proteinuria will be reviewed here. The evaluation of proteinuria in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link\">",
"     \"Evaluation of proteinuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177347965\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177347987\">",
"    <span class=\"h2\">",
"     Normal protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are definitions for normal protein excretion in children and adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children &ndash; Urinary protein excretion in the normal child is less than 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day (&lt;4",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per hour) or a total of 150 mg per day. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link&amp;anchor=H3#H3\">",
"       \"Evaluation of proteinuria in children\", section on 'Normal protein excretion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adults &ndash; Urinary protein excretion in the normal adult is less than 50 mg per eight-hour duration or a total of 150 mg per day. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link&amp;anchor=H265924166#H265924166\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Amounts of proteinuria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188318683\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal values for protein excretion in children were developed in the 1960s and 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. During this period, studies reported a prevalence of orthostatic proteinuria between 2 and 6 percent in children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. This was best illustrated in a population-based study from the United States of 100,000 school children and adolescents conducted in 1967 and 1968 that reported 9.7 percent of the cohort had three daytime consecutive urine specimens with a protein concentration &gt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/4\">",
"     4",
"    </a>",
"    ]. Orthostatic proteinuria was detected in 210 of the 340 subjects (66 percent) with persistent daytime proteinuria who sought further medical evaluation. These two findings suggest that about 6 percent of the entire study cohort had orthostatic proteinuria.",
"   </p>",
"   <p>",
"    Over the past 20 to 30 years, there appears to be a higher reported prevalence of orthostatic proteinuria (up to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This increase may in part be due to the higher prevalence of elevated blood pressure associated with increasing body mass index (BMI) and a decrease in physical activities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/7\">",
"     7",
"    </a>",
"    ]. In one case series of 91 children (6 to 19 years of age), orthostatic proteinuria was observed in 18 individuals (20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/6\">",
"     6",
"    </a>",
"    ]. Orthostatic proteinuria was more likely in children who were boys, greater than 10 years of age, and had a BMI &gt;85 percent. However, in a multivariate analysis, only male gender remained significantly associated with orthostatic protein. In contrast, a study of 89 adolescents found orthostatic proteinuria was not associated with obesity as mean BMI percentiles for female and male subjects were 50 and 58 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Orthostatic proteinuria accounts for 60 percent of all childhood cases of persistent daytime proteinuria, and 75 percent of those observed in adolescent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/4,8-10\">",
"     4,8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link\">",
"     \"Evaluation of proteinuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Orthostatic proteinuria is uncommon in adults over 30 years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link&amp;anchor=H14#H14\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Rule out orthostatic proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms responsible for orthostatic proteinuria are not well understood; the following theories, which are not mutually exclusive, have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal variant",
"     </li>",
"     <li>",
"      Subtle glomerular abnormality",
"     </li>",
"     <li>",
"      Exaggerated hemodynamic response to the upright position",
"     </li>",
"     <li>",
"      Left renal vein entrapment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274766736\">",
"    <span class=\"h2\">",
"     Normal variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein excretion normally increases with assumption of the upright posture from a recumbent position, although total protein excretion typically remains within the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, orthostatic proteinuria may, in at least some cases, be an exaggeration of the normal response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274766751\">",
"    <span class=\"h2\">",
"     Subtle glomerular abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal biopsies have shown subtle glomerular changes in some patients with orthostatic proteinuria such as focal mesangial hypercellularity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    basement membrane thickening [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. These minor changes may require a superimposed hemodynamic abnormality to result in orthostatic proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274766729\">",
"    <span class=\"h2\">",
"     Exaggerated hemodynamic response to the upright position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increases in angiotensin II and norepinephrine release when upright may enhance glomerular permeability in susceptible individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/14\">",
"     14",
"    </a>",
"    ]. Angiotensin II release may be associated with left renal vein entrapment (referred to as nutcracker syndrome), which is discussed below. &nbsp;",
"   </p>",
"   <p>",
"    However, these observations do",
"    <strong>",
"     not",
"    </strong>",
"    have clinical significance as specific therapy of angiotensin antagonism is not warranted, because orthostatic proteinuria is a benign condition and tends to resolve spontaneously with age. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274766758\">",
"    <span class=\"h2\">",
"     Left renal vein entrapment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for entrapment of the left renal vein by the aorta and superior mesenteric artery (referred to as nutcracker syndrome) in the pathogenesis of orthostatic proteinuria is provided by observations from several small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first study, left renal vein entrapment was demonstrated by ultrasonography in 13 of 15 Japanese children with orthostatic proteinuria compared to only 9 of 80 control school children [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/17\">",
"       17",
"      </a>",
"      ]. Of the nine control children with left renal vein entrapment, six had normal protein excretion and orthostatic proteinuria was present in the other three children.",
"     </li>",
"     <li>",
"      A Korean study detected left renal venous flow abnormalities by Doppler ultrasonography in 30 of 47 children with orthostatic proteinuria compared with no detected left renal vein abnormality in 27 healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal ultrasound with Doppler flow imaging in 24 Italian or Swiss children with orthostatic proteinuria (14 girls and 10 boys) showed left renal vein entrapment in 18 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/16\">",
"       16",
"      </a>",
"      ]. In a follow-up study, orthostatic proteinuria resolved in approximately one-half of patients 2 to 15 years after diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/19\">",
"       19",
"      </a>",
"      ]. There were no differences in clinical features between those in whom the proteinuria did and did not resolve. However, increased body mass index (BMI) for age and gender appeared to be positively associated with resolution of orthostatic proteinuria. It was hypothesized that the higher BMI may increase space between the aorta and the superior mesenteric artery, thus freeing the previously entrapped left renal vein.",
"     </li>",
"     <li>",
"      A case report described a transplant donor with orthostatic proteinuria who had a kink in one renal vein [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/10\">",
"       10",
"      </a>",
"      ]. Correction of the kink at surgery was followed by disappearance of the proteinuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from an animal model suggest that renal vein constriction causes a release of angiotensin II resulting in an increase in urinary protein excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/20\">",
"     20",
"    </a>",
"    ]. In a case report, orthostatic proteinuria resolved after administration of an angiotensin converting enzyme inhibitor in a 14-year-old girl with orthostatic proteinuria, bilateral left renal vein entrapment documented by magnetic resonance imaging, and moderate mesangial hypercellularity noted on biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nutcracker phenomenon has also been implicated in the development of microscopic or gross hematuria, primarily in children in Asia and Europe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1127?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of gross hematuria in children\", section on 'Asymptomatic hematuria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=see_link&amp;anchor=H43199828#H43199828\">",
"     \"Evaluation of microscopic hematuria in children\", section on 'Nutcracker syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2881924\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with orthostatic proteinuria are asymptomatic. They generally present incidentally when a urinary dipstick is positive for protein. The urinalysis is usually performed either as a component of routine healthcare or for an unrelated condition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77439714\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of orthostatic proteinuria is made by demonstrating that the individual&rsquo;s urinary protein excretion is normal while in a recumbent position, and increased while upright. The two approaches generally used to make the diagnosis of orthostatic proteinuria are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comparison of the protein-to-creatinine",
"      <span class=\"nowrap\">",
"       (Pr/Cr)",
"      </span>",
"      ratio in urine samples collected in recumbent and upright positions. This is the most convenient standard method.",
"     </li>",
"     <li>",
"      24-hour split urine collection divided into daytime and nighttime pools.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H619742660\">",
"    <span class=\"h2\">",
"     Effect of strenuous exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relatively short period (15 to 20 minutes) of maximal exercise can lead to increased proteinuria in a substantial number of normal individuals. The increase in proteinuria is proportional to the intensity of exercise, and even a short period of intense physical activity can lead to a rise in proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/21\">",
"     21",
"    </a>",
"    ]. As a result, to avoid the risk of a false positive result, the author generally defers testing for at least 24 hours after strenuous exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77439727\">",
"    <span class=\"h2\">",
"     Urine protein-to-creatinine ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most convenient standard test to diagnose orthostatic proteinuria is to compare the",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    ratio of urine samples collected in the recumbent and upright position. The diagnosis of orthostatic proteinuria is confirmed if the recumbent urine sample has a normal",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    ratio and the upright sample has an elevated",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    ratio. The normal value for the urine",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    ratio is &lt;0.2 mg",
"    <span class=\"nowrap\">",
"     protein/mg",
"    </span>",
"    creatinine (&lt;20 mg",
"    <span class=\"nowrap\">",
"     protein/mmol",
"    </span>",
"    creatinine) in adults and children greater than two years of age, and &lt;0.5 mg",
"    <span class=\"nowrap\">",
"     protein/mg",
"    </span>",
"    creatinine (&lt;50 mg",
"    <span class=\"nowrap\">",
"     protein/mmol",
"    </span>",
"    creatinine) in infants and toddlers age 6 to 24 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of proteinuria in children\", section on 'Quantitative assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The easiest recumbent sample to obtain is the first morning void. The parents or patient should be instructed to have the patient assume a recumbent position two hours before going to bed to avoid contamination of the recumbent collection with urine formed when in the upright position. He or she should also void just before going to sleep and remain recumbent until the first morning sample is obtained. A normal urine",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    ratio on the first morning void and an elevated urine",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    ratio on a second specimen collected while the patient is upright are diagnostic of orthostatic proteinuria.",
"   </p>",
"   <p>",
"    In our practice, we generally suggest that the second (upright) urine specimen be obtained after the patient has been in an upright position for 40 to 60 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274769446\">",
"    <span class=\"h2\">",
"     24-hour urine collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternatively, a split 24-hour urine collection can be used to make the diagnosis of orthostatic proteinuria. This approach is used if the diagnosis of orthostatic proteinuria remains uncertain when a urine",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    on recumbent and upright urine samples is used. As above, this test should be deferred for at least 24 hours after strenuous exercise.",
"   </p>",
"   <p>",
"    The following protocol is used, which can be printed out and given to the patient (see",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?28/7/28799?source=see_link\">",
"     \"Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The timing of the daytime collection begins with the first morning void, which is",
"      <strong>",
"       NOT",
"      </strong>",
"      included in the collection.",
"     </li>",
"     <li>",
"      Daytime collection &ndash; The daytime collection starts with the initial void after the first morning discarded void and continues throughout the day as the patient performs their normal activities. The collection ends with inclusion of the final void when the patient is ready to go to sleep. It is important that the times of the first morning (which is not included) and final voids are noted.",
"      <br/>",
"      <br/>",
"      The patient should assume a recumbent position two hours before going to bed to avoid contamination of the recumbent (night time) collection with urine formed when in the upright position. The final void prior to going to sleep is part of the daytime collection.",
"     </li>",
"     <li>",
"      Nighttime collection &ndash; The nighttime (recumbent) collection consists of any urine collected during the nighttime after the final void prior to bedtime and the first morning void that is collected immediately upon awakening. The timing of the nighttime collection begins at the time of the void just before going to sleep (final void of the daytime collection) and ends with the first morning void.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The urinary protein excretion rate is determined for both the daytime and nighttime collections based on the urinary protein content (calculated from the urine volume and urinary protein concentration) and the duration of each of the collections.",
"   </p>",
"   <p>",
"    Orthostatic proteinuria is diagnosed if the urinary protein excretion rate is normal for the nighttime collection (for children &lt;4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per hour and for adults &lt;50 mg over an eight-hour period) and exceeds the normal rate in the daytime collection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H619742617\">",
"    <span class=\"h2\">",
"     Urinary dipstick",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary dipstick is not an accurate measurement of quantitate urinary protein excretion as it measures the urine protein concentration",
"    <span class=\"nowrap\">",
"     (mg/dL),",
"    </span>",
"    which is dependent on urine volume, as well as the degree of proteinuria. However, it may be the simplest and cheapest test to demonstrate normal urine excretion in a first morning sample. In general, a dipstick that is negative for protein is a sufficient test to demonstrate normal protein excretion, especially if the urine is concentrated with a specific gravity greater than 1.010 (which is generally the case in a first morning void) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/8\">",
"     8",
"    </a>",
"    ]. However, if there is uncertainty regarding the urinary dipstick result, a urine",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188318335\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of orthostatic proteinuria includes conditions that result in either transient or persistent proteinuria (",
"    <a class=\"graphic graphic_table graphicRef73973 \" href=\"UTD.htm?31/16/32012\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In children, transient proteinuria is the most common cause of a positive urinary dipstick for protein [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/4\">",
"     4",
"    </a>",
"    ]. It is associated with fever, vigorous exercise, or exposure to extreme cold, which may act by altering renal hemodynamics. This benign condition is distinguished from orthostatic proteinuria as proteinuria resolves when the underlying condition is no longer present, whereas in patients with orthostatic proteinuria, proteinuria is persistent when the patient maintains an upright position and resolves when",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    is recumbent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of proteinuria in children\", section on 'Approach to the child with proteinuria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link&amp;anchor=H13#H13\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Rule out transient proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent proteinuria is differentiated from orthostatic proteinuria by elevated protein excretion in urine samples collected in both the recumbent and upright positions. Non-orthostatic persistent proteinuria is a marker for renal parenchymal disease (eg, glomerulonephritis and nephrotic syndrome), and can be associated with chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11238?source=see_link\">",
"     \"Evaluation of a child with glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is particularly important to differentiate non-orthostatic persistent proteinuria with its risk for renal disease from orthostatic proteinuria. Patients with persistent non-orthostatic proteinuria require further evaluation to determine the cause of proteinuria. Thus, making the correct diagnosis of orthostatic proteinuria will prevent unnecessary and costly investigation in patients with daytime proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/8\">",
"     8",
"    </a>",
"    ]. The evaluation for persistent proteinuria in children and adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of proteinuria in children\", section on 'Approach to the child with proteinuria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link&amp;anchor=H15#H15\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Persistent isolated proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthostatic proteinuria is a benign condition with no effect on renal function based on long-term data including six individuals who have been followed for as long as 40 to 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a follow-up study of 36 of 64 original patients diagnosed with proteinuria, proteinuria resolved spontaneously in most patients being present in 50 and 17 percent of individuals at 10- and 20-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17655/abstract/24\">",
"     24",
"    </a>",
"    ]. All patients had normal renal function including those with persistent orthostatic proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77440012\">",
"    <span class=\"h1\">",
"     MANAGEMENT AND FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the benign course of orthostatic proteinuria, no intervention or further initial evaluation is recommended. The long-term follow-up care remains unclear. As noted above, the prognosis is excellent. Nevertheless, most pediatric nephrologists recommend that routine health care maintenance include testing of protein excretion of the individual while in a recumbent position (eg, first morning void) to confirm the diagnosis of orthostatic proteinuria in those who continue to have daytime proteinuria. As noted above, we suggest deferring testing for at least 24 hours after strenuous exercise. (See",
"    <a class=\"local\" href=\"#H77439727\">",
"     'Urine protein-to-creatinine ratio'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H619742660\">",
"     'Effect of strenuous exercise'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=see_link\">",
"       \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/7/28799?source=see_link\">",
"       \"Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77440030\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthostatic (also referred to as postural) proteinuria is defined as elevated protein excretion (in children &gt;4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per hour and in adults &gt;50 mg over eight hours) while in the upright position and normal protein excretion while in a supine or recumbent position. (See",
"    <a class=\"local\" href=\"#H177347965\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orthostatic proteinuria is the most common cause of isolated proteinuria in children accounting for 60 percent of all childhood cases of persistent daytime proteinuria. It is uncommon in adults over the age of 30 years. (See",
"      <a class=\"local\" href=\"#H188318683\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The underlying pathogenesis for orthostatic proteinuria is not well understood and the proposed mechanisms, which are not mutually exclusive, include variation of normal increased protein excretion while upright, minor glomerular changes, exaggerated hemodynamic response to the upright position, and the presence of left renal vein entrapment resulting in renal venous constriction and increased release of angiotensin II. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with orthostatic proteinuria are asymptomatic and generally present due to an incidental finding of a positive urinary dipstick for protein. (See",
"      <a class=\"local\" href=\"#H2881924\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of orthostatic proteinuria is made by showing that the individual&rsquo;s urinary protein excretion is normal while in recumbent position, and increased while upright. (See",
"      <a class=\"local\" href=\"#H77439714\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The standard way to make the diagnosis of orthostatic proteinuria is to measure the protein to creatinine ratio",
"      <span class=\"nowrap\">",
"       (Pr/Cr)",
"      </span>",
"      of urine samples collected in the recumbent position as a first morning void and in the upright position. The normal value for urine",
"      <span class=\"nowrap\">",
"       Pr/Cr",
"      </span>",
"      ratio is &lt;0.2 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine (&lt;20 mg",
"      <span class=\"nowrap\">",
"       protein/mmol",
"      </span>",
"      creatinine) in adults and children greater than 2 years of age, and &lt;0.5 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine (&lt;50 mg",
"      <span class=\"nowrap\">",
"       protein/mmol",
"      </span>",
"      creatinine) in infants and toddlers age 6 to 24 months. (See",
"      <a class=\"local\" href=\"#H77439727\">",
"       'Urine protein-to-creatinine ratio'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternatively a split 24-hour urine collection divided into daytime and nighttime collections can also be used. (See",
"      <a class=\"local\" href=\"#H274769446\">",
"       '24-hour urine collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary dipstick is often the easiest and cheapest test to demonstrate normal protein excretion in a recumbent urine sample. However, it is not a quantitative measure and if there is any uncertainty regarding test results, a urine",
"      <span class=\"nowrap\">",
"       Pr/Cr",
"      </span>",
"      measurement should be obtained in the recumbent sample. (See",
"      <a class=\"local\" href=\"#H619742617\">",
"       'Urinary dipstick'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing should be deferred for 24 hours after strenuous exercise, which may increase protein excretion, to avoid false positive results. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of orthostatic proteinuria includes conditions that result in either transient or persistent proteinuria (",
"      <a class=\"graphic graphic_table graphicRef73973 \" href=\"UTD.htm?31/16/32012\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H188318335\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Transient proteinuria, which is associated with fever, vigorous exercise, or exposure to extreme cold, is distinguished from orthostatic proteinuria as abnormal protein excretion resolves when the underlying condition is no longer present.",
"     </li>",
"     <li>",
"      Persistent proteinuria is differentiated from orthostatic proteinuria by elevated protein excretion in urine samples collected in both the recumbent and upright positions. It is a marker for renal parenchymal disease (eg, glomerular disease and interstitial nephritis) and can be associated with chronic kidney disease. It is important to distinguish persistent proteinuria from orthostatic proteinuria, as further evaluation is required to determine the underlying etiology in individuals with persistent proteinuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link&amp;anchor=H13#H13\">",
"       \"Evaluation of proteinuria in children\", section on 'Approach to the child with proteinuria'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link&amp;anchor=H15#H15\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Persistent isolated proteinuria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orthostatic proteinuria is a benign condition and does not affect renal function. Over time, proteinuria resolves spontaneously in most patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For individuals with orthostatic proteinuria, we recommend",
"      <strong>",
"       no",
"      </strong>",
"      further initial evaluation or intervention (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Although the long-term prognosis is excellent, we suggest periodic monitoring of protein excretion of the individual while in a recumbent position (eg, first morning void) to reconfirm the diagnosis of orthostatic proteinuria in those who continue to have daytime proteinuria (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H77440012\">",
"       'Management and follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/1\">",
"      Mahurkar SD, Dunea G, Pillay VK, et al. Relationship of posture and age to urinary protein excretion. Br Med J 1975; 1:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/2\">",
"      Milt&eacute;nyi M. Urinary protein excretion in healthy children. Clin Nephrol 1979; 12:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/3\">",
"      Robinson RR. Isolated proteinuria in asymptomatic patients. Kidney Int 1980; 18:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/4\">",
"      Dodge WF, West EF, Smith EH. Proteinuria and hematuria in schoolchildren: epidemiology and early natural history. J Pediatr 1976; 88:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/5\">",
"      Park YH, Choi JY, Chung HS, et al. Hematuria and proteinuria in a mass school urine screening test. Pediatr Nephrol 2005; 20:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/6\">",
"      Brandt JR, Jacobs A, Raissy HH, et al. Orthostatic proteinuria and the spectrum of diurnal variability of urinary protein excretion in healthy children. Pediatr Nephrol 2010; 25:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/7\">",
"      Alon US, Simon S, Hampl S, Hornberger L. Prevalence of proteinuria and its relationship to body mass in adolescents. J Am Soc Nephrol 2007; 18:338A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/8\">",
"      Sebestyen JF, Alon US. The teenager with asymptomatic proteinuria: think orthostatic first. Clin Pediatr (Phila) 2011; 50:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/9\">",
"      Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/10\">",
"      Devarajan P. Mechanisms of orthostatic proteinuria: lessons from a transplant donor. J Am Soc Nephrol 1993; 4:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/11\">",
"      Sinniah R, Law CH, Pwee HS. Glomerular lesions in patients with asymptomatic persistent andorthostatic proteinuria discovered on routine medical examination. Clin Nephrol 1977; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/12\">",
"      ROBINSON RR, GLOVER SN, PHILLIPPI PJ, et al. Fixed and reproducible orthostatic proteinuria. I. Light microscopic studies of the kidney. Am J Pathol 1961; 39:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/13\">",
"      Ha TS, Lee EJ. ACE inhibition can improve orthostatic proteinuria associated with nutcracker syndrome. Pediatr Nephrol 2006; 21:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/14\">",
"      Vehaskari VM. Mechanism of orthostatic proteinuria. Pediatr Nephrol 1990; 4:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/15\">",
"      Cho BS, Suh JS, Hahn WH, et al. Multidetector computed tomography findings and correlations with proteinuria in nutcracker syndrome. Pediatr Nephrol 2010; 25:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/16\">",
"      Ragazzi M, Milani G, Edefonti A, et al. Left renal vein entrapment: a frequent feature in children with postural proteinuria. Pediatr Nephrol 2008; 23:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/17\">",
"      Shintaku N, Takahashi Y, Akaishi K, et al. Entrapment of left renal vein in children with orthostatic proteinuria. Pediatr Nephrol 1990; 4:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/18\">",
"      Park SJ, Lim JW, Cho BS, et al. Nutcracker syndrome in children with orthostatic proteinuria: diagnosis on the basis of Doppler sonography. J Ultrasound Med 2002; 21:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/19\">",
"      Milani G, Bianchetti MG, Bozzani S, et al. Body mass index modulates postural proteinuria. Int Urol Nephrol 2010; 42:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/20\">",
"      Yoshioka T, Mitarai T, Kon V, et al. Role for angiotensin II in an overt functional proteinuria. Kidney Int 1986; 30:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/21\">",
"      Poortmans JR. Postexercise proteinuria in humans. Facts and mechanisms. JAMA 1985; 253:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/22\">",
"      Houser M. Assessment of proteinuria using random urine samples. J Pediatr 1984; 104:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/23\">",
"      Heathcote KL, Wilson MP, Quest DW, Wilson TW. Prevalence and duration of exercise induced albuminuria in healthy people. Clin Invest Med 2009; 32:E261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/24\">",
"      Springberg PD, Garrett LE Jr, Thompson AL Jr, et al. Fixed and reproducible orthostatic proteinuria: results of a 20-year follow-up study. Ann Intern Med 1982; 97:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17655/abstract/25\">",
"      Rytand DA, Spreiter S. Prognosis in postural (orthostatic) proteinuria: forty to fifty-year follow-up of six patients after diagnosis by Thomas Addis. N Engl J Med 1981; 305:618.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3111 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17655=[""].join("\n");
var outline_f17_15_17655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H77440030\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188318253\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177347965\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177347987\">",
"      Normal protein excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188318683\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274766736\">",
"      Normal variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274766751\">",
"      Subtle glomerular abnormality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274766729\">",
"      Exaggerated hemodynamic response to the upright position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274766758\">",
"      Left renal vein entrapment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2881924\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77439714\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H619742660\">",
"      Effect of strenuous exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77439727\">",
"      Urine protein-to-creatinine ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274769446\">",
"      24-hour urine collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H619742617\">",
"      Urinary dipstick",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188318335\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77440012\">",
"      MANAGEMENT AND FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77440030\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/3111\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/3111|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/16/32012\" title=\"table 1\">",
"      Causes of proteinuria children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11238?source=related_link\">",
"      Evaluation of a child with glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1127?source=related_link\">",
"      Evaluation of gross hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=related_link\">",
"      Evaluation of microscopic hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=related_link\">",
"      Evaluation of proteinuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=related_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/7/28799?source=related_link\">",
"      Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_15_17656="Anaphylaxis induced by subcutaneous allergen immunotherapy";
var content_f17_15_17656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anaphylaxis induced by subcutaneous allergen immunotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17656/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17656/contributors\">",
"     David I Bernstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17656/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17656/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17656/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/15/17656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous allergen immunotherapy (SCIT) is an essential therapy in the clinical practice of allergy. However, it can induce anaphylaxis on rare occasions. This topic reviews the frequency, risk factors, and appropriate strategies for management and prevention of anaphylaxis due to SCIT, as well as the clinical features of fatal and near-fatal allergic reactions, and systemic reactions to allergen injections.",
"   </p>",
"   <p>",
"    The indications for SCIT, the treatment of anaphylaxis, and fatal anaphylaxis due to many different causes are discussed separately. Systemic reactions to sublingual immunotherapy (SLIT) are also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1578?source=see_link&amp;anchor=H11#H11\">",
"     \"Sublingual and oral immunotherapy for allergic rhinitis\", section on 'Efficacy and safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous immunotherapy (SCIT) was introduced in the early 1900s. As early as 1916, systemic reactions were reported to occur with 3.5 percent of subcutaneous grass pollen injections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/1\">",
"     1",
"    </a>",
"    ]. In 1986, the Committee on the Safety of Medicines in the United Kingdom (UK) reported 26 SCIT-related anaphylactic deaths over a 10-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/2\">",
"     2",
"    </a>",
"    ]. This report led to adoption of a mandatory two-hour post-injection waiting period in the UK. This was difficult to implement and essentially eliminated the use of this therapy for years until a one-hour standard observation period was accepted. A 30-minute postinjection observation period is recommended in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Systemic allergic reactions to SCIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic reactions (SRs) to SCIT range from cutaneous manifestations (pruritus, urticaria, or angioedema at locations other than the site of the injection) to anaphylaxis. The World Allergy Organization has recently issued a new grading system for classifying clinical severity of SRs to SCIT (",
"    <a class=\"graphic graphic_table graphicRef85944 \" href=\"UTD.htm?42/36/43597\">",
"     table 1",
"    </a>",
"    ). The risk of experiencing SRs may vary according to potency of the injected allergens, modes of allergen preparation and modification, and dosing protocols (eg, cluster or rush regimens are associated with higher frequencies of SRs than slow build-up regimens) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic reactions of varying severity occurred with approximately 0.1 percent of all injections and in 5 percent of treated patients in two SCIT studies with alum-adsorbed extracts with a limited number of allergens [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A SR rate of 0.025 to 0.4 percent of injections and in 7 percent of treated patients was reported in two studies of SCIT with aqueous unmodified allergens using conventional build-up regimens with multiple allergens [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Most reactions were mild (generalized pruritus and urticaria only).",
"     </li>",
"     <li>",
"      Results from a small randomized trial suggest that the rate of SRs may be lower with chemically modified extracts [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SR rates were higher (4 percent of injections and in approximately 39 percent of treated patients) with accelerated dosing regimens, although severe anaphylactic reactions were still uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Patients who received only alum-absorbed extracts had lower frequency and severity of SRs. SR rates were high despite pretreatment with a regimen of H1 and H2 antihistamines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and a leukotriene antagonist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Near-fatal and fatal reactions to SCIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatal and near-fatal anaphylaxis after SCIT injections are rare events. Three retrospective surveys of fatal reactions (FRs) and one survey of near-fatal reactions (NFRs) were conducted to assess frequency and nature of life-threatening anaphylaxis related to SCIT as practiced in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Members of the American Academy of Allergy Asthma and Immunology (AAAAI) were contacted about occurrence of FRs in their practices and indirect knowledge of such events occurring in other community practices. Responders reporting anaphylactic events were requested to complete a questionnaire regarding clinical manifestations of FRs and NFRs, contributing factors, and subsequent management of anaphylactic reactions.",
"   </p>",
"   <p>",
"    Questionnaire responders reported 76 FRs to SCIT occurring between 1973 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/12\">",
"     12",
"    </a>",
"    ]. FRs were estimated to occur once in every 2 million injections from 1985 to 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/14\">",
"     14",
"    </a>",
"    ] and once in every 2.5 million injections from 1990 to 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/15\">",
"     15",
"    </a>",
"    ]. On average, fatal reactions occurred in 2 percent of allergy practices participating in the second survey, with a mean of three fatal reactions occurring annually [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/15\">",
"     15",
"    </a>",
"    ]. In the same survey, NFRs (defined as respiratory compromise, hypotension, or both, requiring emergency epinephrine treatment) were reported at a rate of five events per year or one in every 1 million injections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/16\">",
"     16",
"    </a>",
"    ]. These data may underestimate or overestimate true incidences because of a low responder rate (approximately 25 percent) as well as potential inaccuracies in recall reporting and lack of verification of events occurring in other community practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Web-based surveillance for anaphylaxis to SCIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An annual surveillance project (North American SCIT Fatality and Systemic Reaction Surveillance Project), cosponsored by the AAAAI and ACAAI, was initiated in 2008. This is a web-based surveillance program aimed to improve survey response rates and to track anaphylactic reactions with SCIT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The brief web-based survey captures data to estimate annual FRs, mean and median numbers of SCIT injections administered, as well as frequencies of mild (Grade 1), moderate (Grade 2), and severe (Grade 3) non-fatal SRs. Data captured in the first year (2008 to 2009) include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over 8 million injections were administered by 1922 prescribers.",
"     </li>",
"     <li>",
"      0.1 percent of injections elicited SRs (74 percent mild, Grade 1; 23 percent moderate, Grade 2; and 3 percent anaphylactic, Grade 3 systemic reactions) (",
"      <a class=\"graphic graphic_table graphicRef67718 \" href=\"UTD.htm?15/39/15995\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      No fatal anaphylactic reactions to SCIT were reported in the first 12 months of the surveillance study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF LIFE-THREATENING REACTIONS TO SCIT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening anaphylaxis after SCIT injections is characterized by severe bronchospasm with acute respiratory failure and hemodynamic compromise manifested by profound hypotension and associated symptoms (syncope, collapse). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H2#H2\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Definition and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link&amp;anchor=H16#H16\">",
"     \"Fatal anaphylaxis\", section on 'Clinical characteristics of fatal reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link&amp;anchor=H20#H20\">",
"     \"Fatal anaphylaxis\", section on 'Cause of death'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link&amp;anchor=H21#H21\">",
"     \"Fatal anaphylaxis\", section on 'Possible risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarities and differences in clinical presentations of FRs and NFRs were apparent from clinical data collected in two AAAAI-sponsored surveys (",
"    <a class=\"graphic graphic_figure graphicRef52921 \" href=\"UTD.htm?11/1/11294\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypotension was a common feature reported in greater than 80 percent of FRs and NFRs. Shock, syncope, or cardiac dysrhythmia occurred in 69 percent of fatal events reported in a prior fatality survey [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cutaneous manifestations (urticaria, angioedema, and pruritus) occurred at a much higher frequency in NFRs (70 percent) than in FRs (29 percent). Absence of skin manifestations may have delayed recognition and prompt treatment of FRs.",
"     </li>",
"     <li>",
"      Upper airway obstruction (eg, angioedema) and bronchospasm were reported with similar frequencies in FRs and NFRs. However, acute respiratory failure was identified in 94 percent of FRs, compared with 10 percent of NFRs. This difference probably reflects the higher prevalence of uncontrolled asthma documented among patients with FRs. All patients with FRs and NFRs who developed respiratory failure were previously diagnosed with asthma. Over half of patients with NFRs who required intubation had pre-allergen injection FEV1 (forced expiratory volume in one second) values &lt;70 percent of predicted [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of reports indicating that one-half to two-thirds of all systemic reactions (SRs) due to SCIT start within 30 minutes from the time of injection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/6,7,18-20\">",
"     6,7,18-20",
"    </a>",
"    ]. The remainder starts within six hours from the time of the injection.",
"   </p>",
"   <p>",
"    Examination of the most serious reactions reveals that nearly all reported NFRs and FRs began within 30 minutes after allergen injections in the North American surveys [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Only 4 percent of NFRs began after 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/16\">",
"     16",
"    </a>",
"    ]. Nevertheless, about 10 percent of FRs occurred 30 to 60 minutes after injections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, late reactions beginning after 30 minutes occurred more frequently among patients with asthma receiving injection of multiple allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/20\">",
"     20",
"    </a>",
"    ]. Consistent predisposing factors have not been identified.",
"   </p>",
"   <p>",
"    A post-injection waiting period of a minimum of 30 minutes is suggested, based upon these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/3,21\">",
"     3,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Biphasic anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In prospective studies, 10 to 23 percent of anaphylactic reactions to SCIT were biphasic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The second phase of these reactions was mild and did not require treatment with additional epinephrine. In one of the studies, low baseline peak expiratory flow and concomitant asthma were associated with biphasic anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FACTORS ASSOCIATED WITH FATAL AND NEAR-FATAL ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians reporting FRs and NFRs were queried about factors they believed contributed to risk for these events as part of three retrospective fatality surveys.",
"   </p>",
"   <p>",
"    A summary of responses combined from two studies is listed below (",
"    <a class=\"graphic graphic_table graphicRef53298 \" href=\"UTD.htm?20/30/20972\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fatal reactions &mdash; Based upon 34 fatal cases in these two surveys, the four most commonly implicated factors in FRs are as follows [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Uncontrolled asthma (62 percent)",
"     </li>",
"     <li>",
"      A prior history of systemic reactions (SRs) after SCIT (53 percent)",
"     </li>",
"     <li>",
"      Administration of injections during the peak pollen season (47 percent)",
"     </li>",
"     <li>",
"      Delay in epinephrine injection or failure to administer epinephrine treatment (43 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one of the above surveys, clinician responders could not identify an explanation or contributing factor in 17 percent of fatal SCIT reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Near-fatal reactions &mdash; Major factors associated with 68 cases of NFRs to SCIT included administration of injections during the peak pollen season (46 percent) and injection route or dosing errors (25 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/16\">",
"       16",
"      </a>",
"      ]. However, uncontrolled asthma was implicated in only 10 percent of events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preexisting diagnosis of asthma was more frequent among patients with FRs (88 percent) compared with those with NFRs (46 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, indicators of uncontrolled asthma were more common among patients with FRs compared with NFRs, including reports of poor asthma control, labile asthma, prior emergency room visits, and prior hospitalization (",
"    <a class=\"graphic graphic_figure graphicRef54017 \" href=\"UTD.htm?35/21/36189\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/16\">",
"     16",
"    </a>",
"    ]. The majority of patients with baseline FEV1 &lt;70 percent of predicted experienced worsening bronchospasm after allergen injections in a prospective study of rush SCIT with a standardized Dermatophagoides pteronyssinus extract, demonstrating that severe airway obstruction is a risk factor for SRs with SCIT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prior allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who had systemic reactions to SCIT were more likely to have experienced prior large local reactions (LRs) or previous injection related SRs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. In one study, the risk of an immediate SR was higher in patients who had an immediate SR with the previous dose and late SRs were associated with late LRs with the previous dose [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adjustment of subsequent allergen doses following large local reactions did not significantly reduce the risk of subsequent SRs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/27\">",
"     27",
"    </a>",
"    ]. However, more than 90 percent of allergists adjust subsequent doses (eg, repeat the same dose or decrease the dose) after large local reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Beta-adrenergic blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant treatment with beta-adrenergic blockers does not appear to increase the risk for SRs to SCIT, but may result in more protracted and difficult to treat anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Most clinicians now generally restrict beta blockers among patients initiating SCIT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H15#H15\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Concurrent medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concurrent administration of beta blockers was implicated in 2 percent of FRs, although their actual contribution to fatal outcomes was uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. A single patient with an NFR to SCIT, who was on a beta-blocker, promptly responded to epinephrine and did not require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beta blockers are relatively, but not absolutely, contraindicated in patients receiving SCIT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/3\">",
"     3",
"    </a>",
"    ]. This is most relevant to patients who have both stinging insect allergy and cardiac disease and are unable to discontinue beta blocker therapy. In these patients, the benefit of preventing life-threatening anaphylaxis from a Hymenoptera sting by treating with venom immunotherapy outweighs the theoretical risk of concomitant beta-blockade in the event of a serious SR to SCIT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4234713\">",
"    <span class=\"h2\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors impede the metabolism of vasoactive mediators, such as bradykinin, which are generated during anaphylaxis and contribute to the hypotension and hypovolemia seen in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/32\">",
"     32",
"    </a>",
"    ]. Concomitant treatment with ACE inhibitors has been associated with more severe systemic reactions during venom immunotherapy (VIT) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. However, there does not appear to be a correlation between ACE inhibitor therapy and a higher incidence of anaphylaxis, either during VIT or during other types of immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/19,36\">",
"     19,36",
"    </a>",
"    ]. The 2011 practice parameters suggest that in patients with indications for both VIT and ACE inhibitor therapy, alternatives to ACE inhibitors be considered. If no equally effective alternative medication is available, the physician should make an individualized decision about the use of ACE inhibitors, considering the risk and benefits for that patient, as well as the patient&rsquo;s preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiotensin II receptor blockers have not been associated with more severe anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combination therapy with both ACE inhibitors and beta blockers is common and patients with venom anaphylaxis may be receiving both of these medications. The decision to continue one, both, or neither of these medications must be made on an individual basis, keeping in mind that uncontrolled cardiovascular disease is a risk factor for a poor outcome from anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timely recognition of anaphylaxis and prompt injection of epinephrine are critical to good outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/13\">",
"     13",
"    </a>",
"    ]. This is consistent with reports of fatal anaphylaxis to foods, venoms, and drugs, in which epinephrine injection was often delayed or not given at all [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link&amp;anchor=H21#H21\">",
"     \"Fatal anaphylaxis\", section on 'Possible risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Favorable outcomes in patients were associated with the following (",
"    <a class=\"graphic graphic_table graphicRef53298 \" href=\"UTD.htm?20/30/20972\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Timely injection of epinephrine (delayed or not given in only 6 percent of patients with NFRs compared with 43 percent with FRs). Epinephrine was given in the first 20 minutes to 94 percent of patient with NFRs versus 82 percent of patients with FRs [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administration of SCIT and management of subsequent anaphylactic events in an",
"      <span class=\"nowrap\">",
"       allergy/immunology",
"      </span>",
"      specialist's office (93 percent of NFRs versus 59 percent of FRs) versus a primary care clinician's office, or a patient's home.",
"     </li>",
"     <li>",
"      Waiting in the office for the recommended 30 minutes after injections (3 percent of NFRs versus 12 percent of FRs left the clinic early).",
"     </li>",
"     <li>",
"      Establishment of a patent airway. Attempts at intubation or establishment of an airway were delayed or unsuccessful in 40 percent of patients with FRs [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These experiences indicate that SCIT should only be administered in a medically supervised setting. Clinics in which SCIT is administered must have protocols, medications, supplies, equipment, and trained staff in place to manage life-threatening anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, patients not responding to therapy should be promptly transferred to the emergency department. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18228?source=see_link\">",
"     \"The failed airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized study of 134 patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    60 mg pretreatment prevented severe SRs, defined as asthma exacerbations or anaphylaxis, in patients receiving tree pollen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dust mite SCIT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/38\">",
"     38",
"    </a>",
"    ]. The incidence of SRs was significantly lower in patients treated with fexofenadine versus placebo (0 percent versus 9 percent, p = 0.03). Pretreatment with an H1 antihistamine such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44757?source=see_link\">",
"     levocetirizine",
"    </a>",
"    5 mg or terfenadine (no longer available) was also effective in reducing the rate of LRs and SRs to rush Hymenoptera venom immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Premedication with a nonsedating H1-antihistamine is therefore suggested for selected patients, including those experiencing recurrent large local reactions or mild systemic reactions to prior injections. However, there is insufficient evidence to conclude that pretreatment with H1-antihistamines can effectively prevent severe near-fatal or fatal anaphylactic reactions.",
"   </p>",
"   <p>",
"    The utility of other agents, such as H2-antihistamines and glucocorticoids, as premedications prior to SCIT has not been extensively studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prevention of dosing errors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing errors were reported in 17 percent of FRs and 25 percent of NFRs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. A survey of 1717 allergists was conducted to examine the rate of dosing errors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/41\">",
"     41",
"    </a>",
"    ]. Incorrect dosing of SCIT was reported by 74 percent of responders. Dosing errors were thought to have resulted in 83 SRs that required hospital treatment, and one death was reported.",
"   </p>",
"   <p>",
"    Measures to reduce dosing errors included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Education of the staff preparing and administering SCIT injections.",
"     </li>",
"     <li>",
"      Use of patient-specific vials that are clearly labeled.",
"     </li>",
"     <li>",
"      Use of standard forms and protocols, including those recommended in the Allergen Immunotherapy Practice Parameters (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1256?source=see_link&amp;anchor=H1868053#H1868053\">",
"       \"SCIT: Standard schedules, administration techniques, and monitoring\", section on 'Total duration of therapy'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Performance of multiple identity checks (eg, name, birthday) on each patient prior to each injection.",
"     </li>",
"     <li>",
"      Allow only one patient in the \"shot room\" at a time to avoid distractions to staff administering SCIT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Allergen Immunotherapy Practice Parameter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practice parameters have been developed by a joint task force (AAAAI and ACAAI) to improve the safety of SCIT. The most recent update was published in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17656/abstract/3\">",
"     3",
"    </a>",
"    ]. This document provides specific recommendations to prevent SCIT-related anaphylaxis. Key components of these parameters include (",
"    <a class=\"graphic graphic_table graphicRef75703 \" href=\"UTD.htm?7/53/8029\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoiding SCIT injections in patients with uncontrolled asthma. Patients with asthma should be assessed prior to each injection. Asthma symptoms should be ascertained and routine preinjection measurement of lung function (eg, peak expiratory flow rate or FEV1) is suggested. SCIT should not be started until the patient's asthma has been stabilized on pharmacotherapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Factors associated with fatal and near-fatal anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selecting appropriate patients for therapy. SCIT is relatively contraindicated in medical conditions (eg severe asthma or significant cardiovascular disease) that reduce the patient's ability to survive a systemic allergic reaction.",
"     </li>",
"     <li>",
"      Establishing a 30-minute clinic observation period after injections. This waiting period is recommended in view of the finding that nearly all severe anaphylactic episodes begin within the first 30 minutes. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administering SCIT in a setting where personnel are specially trained to detect anaphylactic reactions and treat them promptly with epinephrine. Home administration of SCIT injections is not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Previous SRs are a major risk factor for FRs and NFRs. Recommendations for management of patients who experience SRs include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discontinue SCIT or lower the allergen dose(s) for the subsequent injection(s).",
"     </li>",
"     <li>",
"      If possible, administer subsequent injections in the",
"      <span class=\"nowrap\">",
"       allergy/immunology",
"      </span>",
"      specialist's office where the SCIT extracts were ordered",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prepared.",
"     </li>",
"     <li>",
"      Do NOT increase (and consider decreasing) the aeroallergen dose during a period when there is increased natural exposure to aeroallergens, because SRs are increased during peak pollen seasons.",
"     </li>",
"     <li>",
"      If SCIT is continued, train patients (particularly those who experienced late onset SRs &gt;30 minutes post-injection) on the self-administration of epinephrine in the event of a future late systemic reaction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of systemic reactions to SCIT varies according to potency of allergens, modes of allergen preparation and modification, and allergen dosing protocols (eg, cluster or rush versus slow build-up regimens). Rates of systemic reactions range from 0.1 to 4 percent of injections. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fatal and near-fatal reactions (FRs and NFRs) to SCIT are rare. Fatal reactions are estimated to occur once in every 2.5 million injections and near-fatal reactions once in every one million injections. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most serious reactions begin within 30 minutes after administration of injections. Hypotension, upper airway obstruction, and bronchospasm are common in both NFRs and FRs. Cutaneous manifestations (urticaria, angioedema, and pruritus) may be absent in FRs, and their absence potentially delays recognition of a reaction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Characteristics of life-threatening reactions to SCIT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Possible contributing factors for fatal reactions include uncontrolled asthma, history of previous systemic reactions, delayed treatment with epinephrine,",
"      <span class=\"nowrap\">",
"       dosing/injection",
"      </span>",
"      errors, and administration of pollen SCIT during the peak pollen season. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Factors associated with fatal and near-fatal anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The contribution of concurrent beta-adrenergic blocker treatment to fatal outcomes is uncertain. Beta-blocker therapy is relatively contraindicated but may be necessary in patients with cardiovascular disease who also have insect-sting anaphylactic reactions. ACE inhibitors have been associated with more severe systemic reactions in patients receiving venom immunotherapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Beta-adrenergic blockers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4234713\">",
"       'ACE inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Timely detection of anaphylaxis and prompt injection of epinephrine are critical to good outcomes. We advise that SCIT be administered in a setting where personnel are specially trained to recognize and manage anaphylactic reactions. Whenever possible, SCIT should be administered in an",
"      <span class=\"nowrap\">",
"       allergy/immunology",
"      </span>",
"      specialist's office. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Management issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with asthma who are receiving SCIT should be screened before injection(s) to determine if their asthma is well controlled. We recommend withholding injections during periods when the patient's asthma is poorly controlled (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Characteristics of life-threatening reactions to SCIT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Factors associated with fatal and near-fatal anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all patients receiving SCIT wait in the office for a minimum of 30 minutes after administration of the injection(s) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Management issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest avoiding dose increases during the pollen season in patients receiving pollen SCIT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Factors associated with fatal and near-fatal anaphylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Management issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/1\">",
"      Cooke RA, Vander-Veer A Jr. Human sensitization. J Immunol 1916; 1:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/2\">",
"      CSM Update: Desensitising vaccines. Br Med J (Clin Res Ed) 1986; 293:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/3\">",
"      Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/4\">",
"      Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol 2006; 97:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/5\">",
"      Casanovas M, Mart&iacute;n R, Jim&eacute;nez C, et al. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts. Clin Exp Allergy 2007; 37:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/6\">",
"      Nettis E, Giordano D, Pannofino A, et al. Safety of inhalant allergen immunotherapy with mass units-standardized extracts. Clin Exp Allergy 2002; 32:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/7\">",
"      Greenberg MA, Kaufman CR, Gonzalez GE, et al. Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1986; 77:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/8\">",
"      Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2007; 99:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/9\">",
"      Casanovas M, Sastre J, Fern&aacute;ndez-Nieto M, et al. Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense. Clin Exp Allergy 2005; 35:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/10\">",
"      Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/11\">",
"      Harvey SM, Laurie S, Hilton K, Khan DA. Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol 2004; 92:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/12\">",
"      Rezvani M, Bernstein DI. Anaphylactic reactions during immunotherapy. Immunol Allergy Clin North Am 2007; 27:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/13\">",
"      Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/14\">",
"      Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993; 92:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/15\">",
"      Bernstein DI, Wanner M, Borish L, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/16\">",
"      Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/17\">",
"      Bernstein DI, Epstein T, Murphy-Berendts K, Liss GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 2010; 104:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/18\">",
"      Greenberg MA, Kaufman CR, Gonzalez GE, et al. Late systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1988; 82:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/19\">",
"      Rank MA, Oslie CL, Krogman JL, et al. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc 2008; 29:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/20\">",
"      Dursun AB, Sin BA, Oner F, Misirligil Z. The safety of allergen immunotherapy (IT) in Turkey. J Investig Allergol Clin Immunol 2006; 16:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/21\">",
"      Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61 Suppl 82:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/22\">",
"      Scranton SE, Gonzalez EG, Waibel KH. Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol 2009; 123:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/23\">",
"      Confino-Cohen R, Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. Ann Allergy Asthma Immunol 2010; 104:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/24\">",
"      Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990; 85:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/25\">",
"      Moreno C, Cuesta-Herranz J, Fern&aacute;ndez-T&aacute;vora L, et al. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy 2004; 34:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/26\">",
"      Iglesias-Cadarso A, Hern&aacute;ndez-Weigand P, Rea&ntilde;o M, et al. A prospective safety study of allergen immunotherapy in daily clinical practice. Allergol Immunopathol (Madr) 2004; 32:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/27\">",
"      Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004; 92:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/28\">",
"      Coop CA, Tankersley MS. Dose adjustment practices among allergists for local reactions to immunotherapy. Ann Allergy Asthma Immunol 2007; 99:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/29\">",
"      Hepner MJ, Ownby DR, Anderson JA, et al. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol 1990; 86:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/30\">",
"      Lang DM. Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy? Curr Allergy Asthma Rep 2008; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/31\">",
"      M&uuml;ller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005; 115:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/32\">",
"      Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/33\">",
"      Tunon-de-Lara JM, Villanueva P, Marcos M, Taytard A. ACE inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet 1992; 340:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/34\">",
"      Ober AI, MacLean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol 2003; 112:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/35\">",
"      Ru&euml;ff F, Przybilla B, Bil&oacute; MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/36\">",
"      White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 2008; 101:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/37\">",
"      Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/38\">",
"      Ohashi Y, Nakai Y, Murata K. Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/39\">",
"      M&uuml;ller UR, Jutel M, Reimers A, et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol 2008; 122:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/40\">",
"      Brockow K, Kiehn M, Riethm&uuml;ller C, et al. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997; 100:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17656/abstract/41\">",
"      Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol 2004; 113:1117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 394 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.32.226.102-8F6DDF6C93-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17656=[""].join("\n");
var outline_f17_15_17656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Systemic allergic reactions to SCIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Near-fatal and fatal reactions to SCIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Web-based surveillance for anaphylaxis to SCIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHARACTERISTICS OF LIFE-THREATENING REACTIONS TO SCIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Biphasic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FACTORS ASSOCIATED WITH FATAL AND NEAR-FATAL ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prior allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Beta-adrenergic blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4234713\">",
"      ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prevention of dosing errors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Allergen Immunotherapy Practice Parameter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/394\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/394|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/1/11294\" title=\"figure 1\">",
"      Clin manif FRs NFRs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/21/36189\" title=\"figure 2\">",
"      Asthma and FRs NFRs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/394|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/36/43597\" title=\"table 1\">",
"      WAO subcutaneous immunotherapy systemic reaction grading system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/39/15995\" title=\"table 2\">",
"      Classification SRs to SCIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/30/20972\" title=\"table 3\">",
"      Risk factors FRs NFRs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/53/8029\" title=\"table 4\">",
"      SCIT practice parameter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1256?source=related_link\">",
"      SCIT: Standard schedules, administration techniques, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1578?source=related_link\">",
"      Sublingual and oral immunotherapy for allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18228?source=related_link\">",
"      The failed airway in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_15_17657="Guide for odontoid cervical spine x-ray";
var content_f17_15_17657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Guide for odontoid cervical spine x-ray",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 643px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mower WR, Hoffman JR, Mahadevan SV. Cervical spine fractures. In: Harwood-Nuss Clinical Practice of Emergency Medicine, 5th ed, Wolfson AB (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17657=[""].join("\n");
var outline_f17_15_17657=null;
var title_f17_15_17658="Common problems of breastfeeding and weaning";
var content_f17_15_17658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Common problems of breastfeeding and weaning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17658/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17658/contributors\">",
"     Jeanne Spencer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17658/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17658/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17658/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/15/17658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/15/17658/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/15/17658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding is universally recognized as the normative and preferred method of infant feeding. Mothers and infants who do not breastfeed have higher short- and long-term health risks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=see_link\">",
"     \"Maternal and economic benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although nearly 75 percent of women in the United States initiate breastfeeding, only 44 percent are still nursing at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/1\">",
"     1",
"    </a>",
"    ]. For many women, difficulties in breastfeeding result in early termination of breastfeeding before the recommended period of time. However, with accurate advice and treatment, most of these difficulties can be overcome, and breastfeeding can be successfully sustained for longer periods.",
"   </p>",
"   <p>",
"    The diagnosis and management of common problems associated with breastfeeding are reviewed here.",
"    <strong>",
"    </strong>",
"    The initiation of breastfeeding and immediate postpartum evaluation of mothers and infants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=see_link\">",
"     \"Initiation of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115298521\">",
"    <span class=\"h1\">",
"     INADEQUATE MILK INTAKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate milk intake or the perception of inadequate milk production is the most common reason for early termination of breastfeeding. Inadequate milk intake may be due to failure of the infant to extract milk or insufficient milk production, and determining the primary problem can be elusive. The inability to fully and regularly empty the breast will ultimately result in decreased milk production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4788312\">",
"    <span class=\"h2\">",
"     Etiology of inadequate intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of inadequate milk intake can be divided into insufficient milk production and failure of the infant to extract milk [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4788574\">",
"    <span class=\"h3\">",
"     Inadequate milk production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate milk production may be due to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insufficient breast development during pregnancy, which may be due to insufficient glandular tissue (eg, previous breast surgery), high androgen levels, or due to endocrine abnormalities (eg, prolactinoma).",
"     </li>",
"     <li>",
"      A delay in the usual progression of lactogenesis to stage II preventing the anticipated increase in milk production that occurs within the first five days of life. The most common reasons for such a delay include maternal pre-pregnancy obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/2\">",
"       2",
"      </a>",
"      ], pregnancy-induced hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/4\">",
"       4",
"      </a>",
"      ], polycystic ovarian syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/5\">",
"       5",
"      </a>",
"      ], as well as other complications associated with high androgen levels during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/6\">",
"       6",
"      </a>",
"      ], such as pre-eclampsia. Other less common causes are retained placental fragments and pituitary insufficiency, also known as Sheehan syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=see_link&amp;anchor=H9#H9\">",
"       \"Physiology of lactation\", section on 'Lactogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maternal drugs that may reduce milk production (eg, dopamine agonists). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H3#H3\">",
"       \"Principles of medication use during lactation\", section on 'Drug effects on milk supply'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Previous maternal breast surgery may result in poor milk production. While these mothers should be encouraged to breastfeed, the intake of their infants should be monitored closely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Following breast augmentation, lactation insufficiency is common, especially in women in whom there was a periareolar incision",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of the nipple sensation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breast reduction procedures using a pedicle technique have not been shown to significantly impair lactation. However, breastfeeding is typically not feasible in women undergoing breast reduction using the free nipple technique, in which the nipple was completely removed during the surgery, since the ducts are completely disrupted and unlikely to recanalize [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4788650\">",
"    <span class=\"h3\">",
"     Poor milk extraction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inappropriate early feeding routines are the most common cause of insufficient milk intake. They include infrequent feeding, poor latch-on (",
"      <a class=\"graphic graphic_figure graphicRef69241 \" href=\"UTD.htm?40/62/41967\">",
"       figure 1",
"      </a>",
"      ), maternal-infant separation, and the use of supplemental formula.",
"     </li>",
"     <li>",
"      Many babies are sleepy and difficult to keep awake during the first several days after birth, causing insufficient milk transfer [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/9\">",
"       9",
"      </a>",
"      ]. Less commonly, oral-motor or neurologic abnormalities may lead to insufficient emptying and milk transfer. Infants who are born at 35 to 37 weeks are considered late-preterms, and although they are often treated as term babies, they typically need supplementation and close monitoring, as they are generally weak nursers.",
"     </li>",
"     <li>",
"      Poor emptying of the breast may result in decreased milk production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382914774\">",
"    <span class=\"h2\">",
"     Assessment of intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adequacy of milk intake is assessed by the frequency and duration of feeding, infant urine and stool output, and weight of the infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=see_link&amp;anchor=H17#H17\">",
"     \"Initiation of breastfeeding\", section on 'Assessment of intake'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the first week of life, mothers with term infants generally nurse 8 to 12 times in 24 hours, and by four weeks after delivery, nursing usually decreases to seven to nine times per day.",
"     </li>",
"     <li>",
"      By the fifth day of life, infants with adequate intake urinate six to eight times daily and have three or more pale yellow and seedy stools daily.",
"     </li>",
"     <li>",
"      Term infants generally lose weight in the first three to five days of life with an average loss of 7 percent of their birth weight. They typically will regain their birth weight by one to two weeks of life. Once the mother's breasts feel full with milk by day 3 to 5, the baby should not continue to lose weight. If a baby has lost 10 percent of its weight or fails to regain birthweight appropriately, breastfeeding should be closely observed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/12/36040?source=see_link&amp;anchor=H9#H9\">",
"       \"Breastfeeding the preterm infant\", section on 'Test weighing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115298551\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of management is to increase milk production and milk transfer. Initial management is focused upon determining and addressing the cause of inadequate milk supply or transfer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough breastfeeding history may identify contributing maternal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neonatal factors. These include previous maternal breast surgeries, oral candidal infection of the infant, and the maternal use of drugs that reduce milk production. (See",
"      <a class=\"local\" href=\"#H4788312\">",
"       'Etiology of inadequate intake'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of Candida infection in neonates\", section on 'Oropharyngeal candidiasis (thrush)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H3#H3\">",
"       \"Principles of medication use during lactation\", section on 'Drug effects on milk supply'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct observation of breastfeeding may reveal either maternal or neonatal anatomical difficulties, or improper breastfeeding technique (eg, position and latch-on (",
"      <a class=\"graphic graphic_figure graphicRef69241 \" href=\"UTD.htm?40/62/41967\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef69936 \" href=\"UTD.htm?40/55/41855\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef71940 \" href=\"UTD.htm?32/12/32975\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef70124 \" href=\"UTD.htm?32/43/33471\">",
"       figure 4",
"      </a>",
"      )).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary intervention depends upon the cause but most often involves increasing the effectiveness and frequency of breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/3\">",
"     3",
"    </a>",
"    ]. Use of breast pumps or manual hand expression especially after a feeding increases stimulation and emptying of the breast, thereby enhancing milk production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115298558\">",
"    <span class=\"h3\">",
"     Galactagogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Galactagogues (or lactagogues) are medications or other substances believed to assist initiation, maintenance, or augmentation of maternal milk production. The most commonly used prescription agents are dopamine receptor antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, there are no data demonstrating that these agents are more effective than interventions focused upon increasing the frequency of breastfeeding and improving breastfeeding technique [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In the one randomized trial of mothers of term infants with inadequate milk production, there was no difference in the amount of milk production between mothers who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    at a dose of 10 mg every eight hours compared with mothers who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, the long-term effects of these medications are unknown and they may be transferred through breast milk to the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a trial of 80 mothers who were expressing breast milk to feed their infants in the neonatal intensive care unit, 10-day courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    appeared to be equally effective in increasing milk production [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/15\">",
"     15",
"    </a>",
"    ]. Although 15 percent of mothers reported side effects (eg, headaches, diarrhea, and mood swings), this may be an underestimation as a significant number of mothers withdrew from the trial (n=15).",
"   </p>",
"   <p>",
"    Data on the use of herbal galactagogues are even more limited. Fenugreek is the most widely used herbal agent, but there is a lack of published evidence regarding its efficacy and safety &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Reported side effects include diarrhea, flatulence, allergic reactions, and hypokalemia. In addition, it is not known whether components of the herb are transferred to the infant via breast milk. As with all herbal supplements, manufacturers are not required to demonstrate efficacy, and the contents of individual products vary.",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend the routine use of galactagogues. These agents should never be used in the place of an evaluation and correction of any modifiable factors such as frequency and thoroughness of breast emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. These agents should be used with caution, and mothers need to be aware of potential side effects and the lack of data supporting their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NIPPLE AND BREAST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;After insufficient milk intake, nipple and breast pain are the most common causes of premature discontinuation of breastfeeding. Causes of breast pain include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Engorgement",
"     </li>",
"     <li>",
"      Nipple injury",
"     </li>",
"     <li>",
"      Plugged ducts",
"     </li>",
"     <li>",
"      Nipple vasoconstriction",
"     </li>",
"     <li>",
"      Breast infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115298707\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of breast pain begins with a thorough history, examination of the infant and mother&rsquo;s breasts, and observation of feeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115298714\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are key elements in the history:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The onset of breast pain, as breast pain in the first days of breastfeeding is most often caused by poor latch, whereas infectious causes of breast pain occur later.",
"     </li>",
"     <li>",
"      Feeding history that includes the frequency and duration of feedings, when the milk &ldquo;came in,&rdquo; and how well the infant latches onto the breast.",
"     </li>",
"     <li>",
"      Previous breastfeeding experience.",
"     </li>",
"     <li>",
"      History of yeast infections. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Candidal infection'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Maternal breast surgeries including breast reduction, piercings and implants, or the presence of inverted nipples.",
"     </li>",
"     <li>",
"      History of nipple pain or extreme sensitivity during pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115298898\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115298905\">",
"    <span class=\"h4\">",
"     Infant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical exam of the infant should focus on the mouth. Abnormalities of the palate, frenulum, and teeth should be noted. Mucocutaneous candidiasis that involves the oral cavity (eg, thrush) or diaper area may be associated with candidal infection of the breast. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Candidal infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115298912\">",
"    <span class=\"h4\">",
"     Maternal breast exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the mother&rsquo;s breasts should identify any area of firmness or soreness, which may be found with either a blocked duct or abscess. Nipples should be inspected for erythema, scaling, cracks, fissures, or blebs (white blocked nipple pore). Blanching of the nipple can be due to primary Raynaud phenomenon but is most often caused by nipple trauma from inappropriate latch and suck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115298935\">",
"    <span class=\"h3\">",
"     Observed feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential that an episode of breastfeeding be observed because most causes of breast pain in the lactating mother are due to incorrect breastfeeding technique. Assessment of the latch and feeding technique can be directly assessed. For example, a poor latch-on may result in injury to the nipple and may interfere with the infant's ability to empty the breast, which may result in engorgement, plugged ducts, mastitis, and breast abscess. The observed feeding can be performed by either the primary care provider or a lactation consultant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=see_link&amp;anchor=H5#H5\">",
"     \"Initiation of breastfeeding\", section on 'Mechanics of feeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12479496\">",
"    <span class=\"h2\">",
"     Nipple pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sore nipples are one of the most common complaints by mothers in the immediate postpartum period. Pain due to nipple injury needs to be distinguished from nipple sensitivity, which normally increases during pregnancy and peaks approximately on the fourth postpartum day. Normal nipple sensitivity can be differentiated from the pain due to nipple trauma, the most common cause of nipple pain, by differences in their timing and course [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal sensitivity typically subsides approximately 30 seconds to 1 minute after suckling begins. It also diminishes after the fourth postpartum day and completely resolves approximately seven days after delivery.",
"     </li>",
"     <li>",
"      In contrast, pain due to trauma persists at the same or an increasing level throughout the nursing episode. Severe pain or pain that extends beyond the first postpartum week is more likely to be due to nipple injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115299012\">",
"    <span class=\"h3\">",
"     Normal nipple sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, most mothers experience nipple discomfort with breastfeeding initiation. This nipple sensitivity is usually limited to the first few suckles of the feed and is thought to be related to the negative pressure on the ductules that have not yet filled with milk [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20\">",
"     20",
"    </a>",
"    ]. This &ldquo;latch-on pain&rdquo; should not persist throughout the whole feeding and should resolve completely after the first week or two. In addition, some mothers find the &ldquo;pins and needles&rdquo; sensation of let-down to be uncomfortable, but this discomfort also resolves in the first weeks of breastfeeding. In either case, the pain is not severe in nature.",
"   </p>",
"   <p>",
"    If needed, the mother can use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    before the feeding. Nipple toughening procedures during pregnancy have not been shown to be beneficial in preventing nipple sensitivity as breastfeeding is initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115299029\">",
"    <span class=\"h3\">",
"     Nipple injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple pain due to trauma persists at the same or an increasing level throughout the nursing episode. Severe pain or pain that extends beyond the first postpartum week is more likely due to nipple injury.",
"   </p>",
"   <p>",
"    Nipple injury usually is due to incorrect breastfeeding technique, particularly poor position or latch-on. Nipple abrasion, bruising, cracking,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blistering may result when an infant fails to achieve a proper latch-on. Mothers with infants with mouth abnormalities (eg, ankyloglossia or cleft palate) are at-risk for nipple pain due to trauma. Ankyloglossia, also known as \"tongue-tie\", occurs when the frenulum connecting the tongue to the floor of the mouth is tight and limits extension of the tongue (",
"    <a class=\"graphic graphic_picture graphicRef60685 \" href=\"UTD.htm?9/0/9218\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44615?source=see_link&amp;anchor=H5#H5\">",
"     \"Ankyloglossia (tongue-tie) in infants and children\", section on 'Breastfeeding problems'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other contributing factors for nipple trauma include harsh breast cleansing, use of potentially irritating products, infant biting, and maternal skin disorders (eg, eczema) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/18\">",
"     18",
"    </a>",
"    ]. Nipple injury also is associated with plugged ducts, candidal and bacterial infections, and engorgement. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Plugged ducts'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Breast infections'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3\">",
"     'Engorgement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115299142\">",
"    <span class=\"h4\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management includes prevention of nipple injury and healing of traumatized nipples.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most effective techniques for preventing nipple trauma are a good latch-on and proper positioning of the infant.",
"     </li>",
"     <li>",
"      Avoidance of excessive moisture of the nipples and irritating cleansers. The nipples should be allowed to air dry.",
"     </li>",
"     <li>",
"      Nipple abnormalities detected in the prenatal period should be evaluated by a lactation consultant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=see_link&amp;anchor=H9#H9\">",
"       \"Initiation of breastfeeding\", section on 'Inverted nipples'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormalities of the infant&rsquo;s oral cavity (eg, ankyloglossia) should be evaluated during the birth hospitalization.",
"     </li>",
"     <li>",
"      Anticipatory guidance regarding engorgement prior to hospital discharge as nipple pain contributes to poor milk extraction resulting in engorgement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial care of the traumatized nipple consists of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assessment of infant positioning and latch-on and correction of improper technique. Nursing first on the unaffected side.",
"     </li>",
"     <li>",
"      Avoidance of excessive moisture of the nipples and irritating cleansers. The nipples should be allowed to air dry.",
"     </li>",
"     <li>",
"      Cool or warm compresses, and mild analgesics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      may be helpful.",
"     </li>",
"     <li>",
"      Although data are inconclusive, some mothers find the application of expressed breast milk, colostrum, or purified lanolin helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. Peppermint gel, which must be removed before feeding, may also be effective.",
"     </li>",
"     <li>",
"      Frenotomy decreases nipple pain and facilitates breastfeeding in infants with ankyloglossia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44615?source=see_link&amp;anchor=H10#H10\">",
"       \"Ankyloglossia (tongue-tie) in infants and children\", section on 'Breastfeeding issues'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For sore nipples that are refractory to initial measures, an infectious etiology should be considered. Unfortunately, the research in this area is inconclusive. Possible etiologies include staphylococcal and candidal infection.",
"      <br/>",
"      <br/>",
"      An antibiotic ointment, such as",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/mupirocin-drug-information?source=see_link\">",
"       mupirocin",
"      </a>",
"      &nbsp;(Bactroban&reg;), plus a combination antifungal and antiinflammatory agent (Mycolog&reg;) to eradicate presumptive",
"      <span class=\"nowrap\">",
"       skin/breast",
"      </span>",
"      bacterial or candidal infection may be used empirically. In the author&rsquo;s practice, a combination ointment that includes a mixture of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      , steroid (",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/betamethasone-drug-information?source=see_link\">",
"       betamethasone",
"      </a>",
"      &nbsp;0.1 percent), and antifungal powder (miconazole), known as \"All Purpose Nipple Ointment\" (APNO), is often administered.",
"      <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\">",
"       The US National Institute of Health LactMed website",
"      </a>",
"      recommends that visible residual APNO ointment be gently wiped off to decrease infant exposure to steroid and paraffins, and reapplied after each nursing session.",
"      <br/>",
"      <br/>",
"      Other experts in the field suggest obtaining either a swab of the skin for culture for a bacterial infection, or scraping (if possible) for examination and culture if a candidal infection is suspected. They also discourage the empirical use of ointments that contain corticosteroids when an infection is suspected. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Breast infections'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Highly concentrated vitamin E oil should",
"      <strong>",
"       not",
"      </strong>",
"      be applied to the nipples because it is readily absorbed by the infant and may be toxic at high levels [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86657159\">",
"    <span class=\"h4\">",
"     Biting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some infants cause pain to their nursing mothers by biting. Biting is typically due to a tonic bite reflex that often occurs due to infant oral defensiveness, retrognathia, and tight lingual frenulum. Natal teeth can rarely present at birth. In these neonates, the incisal edge may need to be smoothed to decrease maternal discomfort, or if they are causing great discomfort or pain they may need to be removed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=see_link&amp;anchor=H3#H3\">",
"     \"Developmental defects of the teeth\", section on 'Natal and neonatal teeth'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the normal teeth eruption at 3 to 12 months, biting may cause nipple pain and trauma. Infants usually bite more at the end of the feeding since their tongues cover the teeth during active feeding. Biting is often avoided by keeping the baby close to the breast while feeding with the mouth wide open, which prevents the baby&rsquo;s latch becoming shallow onto the nipple. Once swallowing is over and the baby is nursing for comfort, taking the baby off the breast prevents biting. If these steps are not helpful, and the baby continues to bite, the mother should say \"no\" firmly, break the suction with her finger, and put the infant on a safe surface. Mothers should avoid expressing too much emotion over the event to discourage the infant from repeating it [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/21\">",
"     21",
"    </a>",
"    ]. Most infants learn quickly not to bite. They should be offered teething rings as more suitable objects for teething.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115299157\">",
"    <span class=\"h4\">",
"     Areolar eczema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eczema of the",
"    <span class=\"nowrap\">",
"     nipple/areolar",
"    </span>",
"    complex and, less commonly, the nipple has been observed in breastfeeding women. It presents as a red, scaly rash on the",
"    <span class=\"nowrap\">",
"     nipple/areolar",
"    </span>",
"    area. Women describe sore and painful burning of the areola and nipples, and it is more common in women with a past medical history of eczema. Other contributing factors include irritant dermatitis due to soaps or fragrances, solid foods in the infant&rsquo;s diet, or allergic reaction to topical agents such as lanolin, antifungals, or antibiotics.",
"   </p>",
"   <p>",
"    During an acute presentation, vesicles, crusting, and erosions are seen in the affected areas, whereas in the chronic state, the areas are generally dry, erythematous, lichenified, and scaling [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management begins with avoidance of potential irritants and allergens. Low potency topical steroids are generally effective and should be applied after feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/26\">",
"     26",
"    </a>",
"    ]. Ointments are more easily absorbed but can expose the infant to mineral paraffins, which may be of concern [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/27\">",
"     27",
"    </a>",
"    ]. Visible topical agents should be removed before the next feeding. Expressed breast milk at the beginning of a feed is effective in their removal.",
"   </p>",
"   <p>",
"    Other conditions that may present with similar skin manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpetic infections &ndash; Women with herpetic breast lesions should not breastfeed from the affected breast until the lesions resolve because direct contact with the lesions may transmit the herpes simplex virus to her infant [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/28\">",
"       28",
"      </a>",
"      ]. Mothers should use careful hand hygiene and cover any lesions with which the infant might come into contact. Mothers can pump and the expressed milk can be given to the infant. Herpes is diagnosed by viral culture, serology, or skin scrapings. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Impetigo &ndash; Eczema can predispose a mother to impetigo. A culture should be obtained in mothers with pustules and thick adherent crusting with a characteristic golden appearance of the affected area. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=see_link&amp;anchor=H10#H10\">",
"       \"Impetigo\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86655702\">",
"    <span class=\"h3\">",
"     Nipple vasoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have Raynaud phenomenon, unusual cold sensitivity, or nipple trauma may develop cutaneous vasospasm of the nipple due to arteriolar vasoconstriction (",
"    <a class=\"graphic graphic_picture graphicRef59829 \" href=\"UTD.htm?41/18/42272\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20,29\">",
"     20,29",
"    </a>",
"    ]. In patients with Raynaud phenomenon or cold sensitivity, vasoconstriction is responsible for the classic tricolor change of pallor, followed by cyanosis, and then erythema as the circulation returns. Affected mothers typically experience pain, burning, and paresthesias with cold exposure. The vasoconstriction can be reproduced with exposure of the nipple to cold air or compresses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/30\">",
"     30",
"    </a>",
"    ]. Between episodes, the mother is asymptomatic, and the nipples are normal in appearance.",
"   </p>",
"   <p>",
"    Because of the intensity of the pain, a diagnosis of candidiasis of the nipple is often made; however, the trigger of cold exposure for the onset of pain and changes in nipple appearance can differentiate the two conditions. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Candidal infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86655811\">",
"    <span class=\"h4\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In mothers with cold sensitivity, warming the entire body appears to be helpful in reducing nipple vasoconstriction, so affected mothers should breastfeed in warm conditions (if possible) and wear warm clothing. Other interventions include avoidance of vasoconstricting medications (eg, nicotine and caffeine) and warming the nipple at the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports suggest that the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , a potent vasodilating calcium channel blocker, relieved symptoms of nipple vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Low levels of nifedipine are found in breast milk, but no adverse effects have been observed in nursing infants whose mothers have been treated with nifedipine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/14,29\">",
"     14,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Engorgement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Engorgement occurs with accumulation of excess milk that results in breast fullness and firmness, which is accompanied by pain and tenderness. Among mothers, the affected area varies with primarily areolar involvement in some mothers, more peripheral involvement in others, and in some mothers both peripheral and areolar involvement. If the areola is engorged it can impair the baby&rsquo;s ability to latch and worsen the engorgement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of engorgement may also vary.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary engorgement occurs with the onset of copious milk production (ie, lactogenesis stage II) usually between days 3 to 5 after delivery. &nbsp;It is due to interstitial edema of the breast prompted by the decrease in progesterone levels after the placenta is delivered [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Secondary engorgement typically occurs later when there is a mismatch between milk production and extraction as the mother&rsquo;s milk supply exceeds the amount of milk extracted by her infant. This occurs from excessive stimulation of milk production via pumping or taking medications to increase milk supply, or decreased milk extraction from not feeding the baby as often (eg, weaning), or during times of infant illness. (See",
"      <a class=\"local\" href=\"#H12479719\">",
"       'Routine weaning'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective management hinges on adequate removal of the milk. For primary engorgement, it is important to ensure implementation of good feeding techniques with a satisfactory latch and optimal nursing positioning.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the areola is involved, manual expression of small amounts of milk before the feeding will soften the areola and facilitate latching. Hand expression is accomplished by placing the thumb and forefingers well behind the areola toward the chest wall and then compressing them together and toward the nipple in a rhythmic fashion. Using the fingers in a similar position, the mother can present the nipple in a way that is easier to latch. Mothers can also use this rhythmic compression while the infant is suckling to enhance milk transfer (",
"      <a class=\"external\" href=\"file://newborns.stanford.edu/Breastfeeding/HandExpression.html\">",
"       Stanford video link on Hand expression of breast milk",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Some mothers may find use of a breast pump to be helpful. However, this use should be limited to immediately before a feeding to soften the breast because overuse will stimulate milk production and could increase the engorgement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence for other supportive measures is limited because engorgement usually resolves over time; therefore, it is difficult to see the effect of specific interventions. In addition, studies of these measures have included only small numbers of patients and were poorly controlled.",
"   </p>",
"   <p>",
"    This was illustrated in a systematic review that found insufficient evidence that interventions including acupuncture, cabbage leaf application, cold gel packs, ultrasound, and administration of oxytocin or protease complex (plant enzyme) were beneficial in relieving the symptoms of engorgement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/32\">",
"     32",
"    </a>",
"    ]. Results from the two studies using acupuncture showed improved symptoms in the days following treatment, but there was no difference in outcome by six days after treatment. In the single study using cold gel packs, there appeared to be improvement in symptoms, but differences between the control and intervention groups made it difficult to interpret the results.",
"   </p>",
"   <p>",
"    Nevertheless, the following interventions are often used for pain relief associated with either primary or secondary engorgement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Applying warm compresses or a warm shower enhances let down and may facilitate milk removal either by hand expression or with suckling",
"     </li>",
"     <li>",
"      After or between feedings, cold compresses may decrease the swelling and discomfort",
"     </li>",
"     <li>",
"      Analgesics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      may decrease the discomfort",
"     </li>",
"     <li>",
"      Cool green cabbage leaves",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Plugged ducts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plugged milk ducts are localized areas of milk stasis within the milk ducts that cause distention of mammary tissue. The presentation of a plugged duct typically consists of a tender and often painful palpable lump without systemic findings due to obstruction of a mammary duct [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, to a plugged mammary duct, obstruction of the nipple pore ducts (",
"    <a class=\"graphic graphic_figure graphicRef53212 \" href=\"UTD.htm?36/26/37280\">",
"     figure 5",
"    </a>",
"    ) may also occur and present as a white dot or bleb at the end of the nipple, commonly referred to as a milk blister.",
"   </p>",
"   <p>",
"    Plugged milk ducts are distinguished from mastitis and breast abscess by the absence of systemic findings, such as fever &gt;38.3&ordm; C, myalgia, chills, malaise, and flu-like symptoms.",
"   </p>",
"   <p>",
"    Predisposing factors for plugged ducts include poor feeding technique, wearing tight clothing including ill-fitting brassiere, and abrupt decrease in feeding, which leads to engorgement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Poor feeding technique (eg, poor latch-on and positioning) results in inadequate emptying and stasis that contribute to blockage of the milk ducts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management is focused on opening up the blocked milk duct and draining the area behind the blockage. The following approach is based on clinical experience and expert opinion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimize feeding technique &ndash; The most effective manner to open the blockage and drain the area of concern is by emptying of the breast with frequent feeds. The infant&rsquo;s positioning and latch should be assessed and, if needed, corrected (",
"      <a class=\"graphic graphic_figure graphicRef69241 \" href=\"UTD.htm?40/62/41967\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef69936 \" href=\"UTD.htm?40/55/41855\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef71940 \" href=\"UTD.htm?32/12/32975\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef70124 \" href=\"UTD.htm?32/43/33471\">",
"       figure 4",
"      </a>",
"      ). The mother should be encouraged to vary the position to ensure complete drainage of the entire affected breast. Some clinicians recommend positioning the infant so the chin is near the area of concern because this positioning maximizes drainage of the affected area. Pumping or hand expression after the feeding may improve the drainage. The",
"      <a class=\"external\" href=\"file://www.llli.org/faq/mastitis.html\">",
"       La Leche League site on \"My breast hurts\"",
"      </a>",
"      provides patient information on feeding techniques for a mother with a plugged duct.",
"     </li>",
"     <li>",
"      Mothers should be counseled not to stop breastfeeding since this could lead to engorgement and worsen the problem.",
"     </li>",
"     <li>",
"      Other measures that may facilitate drainage include warm compresses or showers, and manual massage [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. In the shower, the mother can massage the breast from the affected area toward the nipple to try to remove the blockage. Others recommend that the massage begin beyond the mass and toward the nipple at first to clear the duct and then to progress toward the mass, and is thought to be less uncomfortable [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Analgesics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      may decrease the discomfort.",
"     </li>",
"     <li>",
"      Plugs can often be prevented by prevention of secondary engorgement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the plugged ducts do not resolve with the above measures, additional evaluation and treatment is required.",
"   </p>",
"   <p>",
"    In some mothers with a milk blister (white bleb) on the nipple, relief may be obtained by gently opening the skin covering with a sterile needle and expressing the white cheesy substance from the nipple pore [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20\">",
"     20",
"    </a>",
"    ]. However, this procedure can be exquisitely painful and should be performed with sensitivity and caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202323719\">",
"    <span class=\"h3\">",
"     Galactoceles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Galactoceles are milk retention cysts (",
"    <a class=\"graphic graphic_picture graphicRef65929 \" href=\"UTD.htm?20/8/20623\">",
"     picture 3",
"    </a>",
"    ) that result from a blocked milk duct. They present as cystic, sometimes very large masses during pregnancy, lactation, and after weaning. Unless they are infected, they are usually painless. Initially, they contain milky fluid, but over time, contents become thicker, more creamy, or oily as the fluid is reabsorbed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound is the primary diagnostic imaging modality to distinguish galactoceles from other breast masses including adenomas, fibroadenomas, papillomas, lipomas, and fibrocystic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, although uncommon, breast malignancies can present as breast masses during lactation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On ultrasound, galactoceles appear as a well-defined lesion with thin echogenic walls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/35\">",
"     35",
"    </a>",
"    ]. The internal appearance consists of either homogeneous contents with medium-level echoes or heterogeneous contents with fluid clefts and anechoic rims, especially in galactoceles of longstanding duration. Focal echogenic areas with distal shadowing are sometimes seen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/35\">",
"     35",
"    </a>",
"    ]. On mammography they may also appear cystic, contain an air fluid level, or appear heterogenous.",
"   </p>",
"   <p>",
"    Aspiration demonstrating the characteristic milky contents confirms the diagnosis of galactocele and excludes malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832880\">",
"    <span class=\"h4\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In mothers with a diagnosis of galactocele confirmed by aspiration, repeated needle aspiration or surgical excision is only necessary if the galactocele is bothersome to the mother. Breastfeeding generally can continue during aspiration or excision. Preoperative discussion with the surgeon regarding plans to continue breastfeeding is essential. In some cases, surgery can be postponed until after the infant is weaned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     BREAST INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lactational mastitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastitis is a localized inflammation of the breast that is associated with fever, myalgias, breast pain, and redness. It can be infectious or noninfectious, although the term is usually used clinically to imply an infectious etiology. Although mastitis can occur any time during lactation, it is most common during the first six weeks postpartum.",
"   </p>",
"   <p>",
"    Lactational mastitis is often the result of the following breast problems (",
"    <a class=\"external\" href=\"file://www.bfmed.org/Media/Files/Protocols/protocol_4mastitis.pdf\">",
"     Mastitis protocol from the Academy of Breastfeeding",
"    </a>",
"    ). Effective treatment and prevention of recurrent episodes of mastitis are dependent on the resolution of the underlying condition.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Damaged nipples",
"     </li>",
"     <li>",
"      Infrequent feedings",
"     </li>",
"     <li>",
"      Inefficient milk removal",
"     </li>",
"     <li>",
"      Illness in mother or baby",
"     </li>",
"     <li>",
"      Oversupply of milk",
"     </li>",
"     <li>",
"      Rapid weaning",
"     </li>",
"     <li>",
"      Pressure on the breast (eg, tight brassiere or car seatbelt)",
"     </li>",
"     <li>",
"      Blocked milk duct",
"     </li>",
"     <li>",
"      Maternal stress or excessive fatigue",
"     </li>",
"     <li>",
"      Maternal malnutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lactation mastitis typically presents as a firm, red, and tender area of the breast with a maternal temperature that exceeds 38.5C. A tender fluctuant area is more indicative of an abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lactation mastitis and its management are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/454?source=see_link\">",
"     \"Lactational mastitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Breast abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast abscess is a localized collection of pus within the breast tissue. It is an uncommon problem in breastfeeding with a reported incidence of 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/38\">",
"     38",
"    </a>",
"    ] that increases to 3 percent of women with antibiotic treated mastitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/39\">",
"     39",
"    </a>",
"    ]. The presentation of breast abscess is similar to mastitis, with breast pain and systemic symptoms, along with a fluctuant, tender, palpable mass.",
"   </p>",
"   <p>",
"    Breast abscess in lactating women and its management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9495?source=see_link\">",
"     \"Breast abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Candidal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidal infection is widely diagnosed based on signs and symptoms as a cause of breast pain in lactating women. However, mammary candidosis is a poorly defined entity, and researchers have not been able to confirm that this is a clinically significant cause of breast pain. &nbsp;(",
"    <a class=\"external\" href=\"file://www.bfmed.org/Media/Files/Protocols/protocol_4mastitis.pdf\">",
"     Mastitis protocol from the Academy of Breastfeeding Medicine",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Based on a few small cohort studies, breast pain appears to occur more frequently in breastfeeding women with Candida albicans cultured from the nipple, breast milk, or oropharynx of their infants compared with mothers without positive candidal cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. The breast pain has been described as either burning of the nipple areola or severe deep shooting stabbing pain radiating through the breast toward the chest wall, and seems to be more severe than expected based on the findings on breast examination. However, in these symptomatic patients, it remains uncertain whether Candidal species play an important causal role in these symptoms, and further studies are needed to better understand whether there is a relationship between candidal infection and breast pain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/40,43\">",
"     40,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some human and bovine studies indicate that Staphylococcus aureus and Staphylococcus epidermidis may be the intraductal pathogens causing these symptoms, not Candida [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis of a candidal infection of the breast is challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/42,44,45\">",
"     42,44,45",
"    </a>",
"    ]. In general, mammary candidosis is diagnosed clinically based on the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Breast pain out of proportion to physical findings",
"     </li>",
"     <li>",
"      History of infant oral or diaper candidal infection or maternal vaginal candidal infection",
"     </li>",
"     <li>",
"      Physical finding of shiny or flaky skin of the affected nipple",
"     </li>",
"     <li>",
"      Exclusion of other causes of breast pain such as mastitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Often response to a trial of antifungal treatment is used to confirm the diagnosis; however, this results in a potential bias. In addition, the indiscriminate use of antifungal therapy may increase the risk of resistant Candida species to antifungal therapy, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a trial of antifungal therapy is chosen, both mother and child are generally treated. However, there are",
"    <strong>",
"     no",
"    </strong>",
"    clinical trials or good observational data on the treatment of presumed candidal infection of the nipple and breast in lactating mothers. The following approach is based on clinical experience and is used by lactation specialists (",
"    <a class=\"external\" href=\"file://www.llli.org/faq/thrush.html\">",
"     La Leche League website: Thrush",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.breastfeedingonline.com/20pdf.pdf\">",
"     file://www.breastfeedingonline.com/20pdf.pdf",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal topical care &ndash; Topical miconazole or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"       clotrimazole",
"      </a>",
"      is initially used to treat the lactating woman. These agents are preferred to topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"       nystatin",
"      </a>",
"      since there is less resistance of Candida species [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/45\">",
"       45",
"      </a>",
"      ]. Combination topical antifungal and antiinflammatory agent (Mycolog&reg;) may also be effective. Although the effects of the maternal use of topical antifungal agents in breastfed infants have not been studied, it is unlikely to be of concern during breastfeeding. However, prior to each feeding, visible residual medication should be removed and antifungal agent reapplied after each feed. If fissures are present, a topical antibiotic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      is often added. These agents are also removed prior to and reapplied after each feeding.",
"     </li>",
"     <li>",
"      One percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/5/41042?source=see_link\">",
"       gentian violet",
"      </a>",
"      &ndash; In our experience, 1 percent gentian violet in water is an inexpensive and, often effective, although messy option. It may be used if the mother&rsquo;s sore nipples are not responding to the ointments mentioned above or may be used as an initial agent if the pain is intense. The medication is applied with a Q-tip to the infant&rsquo;s mouth before a feeding. After the feeding, any areas of the",
"      <span class=\"nowrap\">",
"       nipple/areola",
"      </span>",
"      that are not purple are painted with the medication. This is repeated once daily for three to four days (",
"      <a class=\"external\" href=\"file://www.breastfeedingonline.com/6pdf.pdf\">",
"       file://www.breastfeedingonline.com/6pdf.pdf",
"      </a>",
"      ). Risks of gentian violet include mouth sores in the infant, and",
"      <span class=\"nowrap\">",
"       nipple/areolar",
"      </span>",
"      irritant dermatitis.",
"     </li>",
"     <li>",
"      Maternal oral therapy &ndash; If the mother&rsquo;s symptoms fail to resolve with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/5/41042?source=see_link\">",
"       gentian violet",
"      </a>",
"      , or if she will not tolerate its staining, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      is an alternative. In our practice, dosing for lactating mothers is 400 mg the first day followed by 200 mg per day for 14 days. At this dosage, the peak level in breast milk is 4.1",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      which is considered to be a safe level for breastfeeding infants, as the amount of drug an infant would receive from the milk is less than the amount given to treat an infant with a candida infection [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/14\">",
"       14",
"      </a>",
"      ]. In addition, this level in the milk is insufficient to treat yeast in the infant. The dose used to treat vaginal candidiasis (a single dose of 150 mg) is too low to be effective.",
"      <br/>",
"      <br/>",
"      Other experts in the field only use fluconazole with documentation of candidal infection defined as a positive breast milk culture or a potassium hydroxide (KOH) examination of skin scraping. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=see_link&amp;anchor=H6#H6\">",
"       \"Candidal intertrigo\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infant care &ndash; Although there is a lack of supportive data, the infant is typically treated for oral candidal infection with the same regimen used to treat oral mucocutaneous candidiasis. This is administered as an oral suspension of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"       nystatin",
"      </a>",
"      (100,000",
"      <span class=\"nowrap\">",
"       units/mL)",
"      </span>",
"      at a dose of 0.5 mL to each side of the mouth, given four times a day. Others in the field only administer nystatin if the infant is clinically diagnosed with oral thrush. More detailed discussions on the diagnosis and treatment of neonatal mucocutaneous candidiasis are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of Candida infection in neonates\", section on 'Oropharyngeal candidiasis (thrush)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"       \"Treatment of Candida infection in neonates\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     BLOODY NIPPLE DISCHARGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women have bloody nipple discharge during the first days to weeks of lactation. This is more common with the first pregnancy and has been called rusty pipe syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/46\">",
"     46",
"    </a>",
"    ], and it is thought to be caused by the increased vascularization of the alveoli and ducts with the onset of milk production. The color of the milk varies from pink to red and generally resolves within a few days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link&amp;anchor=H16#H16\">",
"     \"Nipple discharge\", section on 'Grossly bloody discharge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, other causes of bloody milk need to be considered including cracked nipples or, in patients with persistent milk discharge, an intraductal papilloma (tumor derived from the lining of the breast duct). If the blood is present for more than one week, evaluation including thorough breast exam and ultrasound is recommended. If the blood appears to come from a single duct, galactography is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of benign breast disease\", section on 'Intraductal papillomas'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link&amp;anchor=H9#H9\">",
"     \"Nipple discharge\", section on 'Clinical evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link&amp;anchor=H19#H19\">",
"     \"Nipple discharge\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In settings when the infant spits up blood-tinged milk or has blood in the stool, an Apt test is used to confirm whether the source of bleeding is from the mother or infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnostic approach to lower gastrointestinal bleeding in children\", section on 'Apt test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MILK OVERSUPPLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While much less common than an inadequate milk supply, some mothers experience milk overproduction, also known as hypergalactia or hyperlactation. Generally the production of milk is determined by the infant's demand, but in this case the supply exceeds demand. Milk overproduction occurs early in lactation, and more often in primigravidas, although it may worsen in affected mothers with successive pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, the rush of the milk with the mother's ejection reflex may be too forceful, and the infant may have trouble feeding. Infants may choke and cough and become irritable with feeding and may bite to clamp the nipple. Infants may either have an increased weight gain, or paradoxically, poor weight because of inadequate intake as they cannot handle the flow of milk, or because the infant is not receiving hind milk with its higher caloric content.",
"   </p>",
"   <p>",
"    Overproduction of milk typically resolves over time; however, mothers should be evaluated for drugs that increase milk production (eg, psychiatric medications that may be dopamine agonists or herbs like fenugreek) and, if it persists, for hypo- or hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9183621\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of milk oversupply",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an overactive milk ejection reflex is based on clinical experience and consists of the following (",
"    <a class=\"external\" href=\"file://www.llli.org/faq/oversupply.html\">",
"     La Leche League website: Oversupply",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nursing position &ndash; Mothers should nurse the infant in a more upright position with the mother leaning back or in the side lying position, which allows the infant to better control the flow of milk.",
"     </li>",
"     <li>",
"      Manual reduction of flow &ndash; Using a scissors-hold on the areola or pressing on the breast with the heel of the hand may restrict flow.",
"     </li>",
"     <li>",
"      Feeding strategies &ndash; Infants should be allowed to interrupt feeding as needed, and often need frequent burping.",
"     </li>",
"     <li>",
"      Pumping &ndash; Avoid pumping to avoid continued stimulation of milk overproduction. However, some mothers may find it necessary to hand express some milk at the beginning of a feeding.",
"     </li>",
"     <li>",
"      Measures to decrease breast milk leakage &ndash; Decrease leaking by applying cold water or ice to the nipples.",
"     </li>",
"     <li>",
"      Medications &ndash; The use of pharmacologic intervention is not well studied. Low dose oral contraceptives or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      may be helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20,47\">",
"       20,47",
"      </a>",
"      ]. The",
"      <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\">",
"       US National Institute of Health LactMed website",
"      </a>",
"      considers both agents to be safe in lactating mothers, although they should be used with caution due to their diminishing effect on milk production and should be avoided for the first two weeks until milk supply is well established. Pseudoephedrine may cause irritability in the infant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NEONATAL JAUNDICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding is associated with hyperbilirubinemia as two distinct entities, breastfeeding failure jaundice and breast milk jaundice, which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\", section on 'Breastfeeding failure jaundice'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\", section on 'Breast milk jaundice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     WEANING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of weaning is a personal decision made by the mother in the context of her social setting. This decision is influenced by factors including subsequent pregnancies, career choices, and maternal health. Exclusive breastfeeding is recommended by the American Academy of Pediatrics (AAP) for the first six months of life. Around six months of age, iron rich complementary foods should generally be offered to infants. The AAP recommends breastfeeding be continued for at least one year and longer as desired by the mother or child [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=see_link&amp;anchor=H5#H5\">",
"     \"Introducing solid foods and vitamin and mineral supplementation during infancy\", section on 'When to initiate complementary foods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12479726\">",
"    <span class=\"h2\">",
"     Abrupt weaning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abrupt weaning is not recommended and usually is necessitated by unanticipated maternal child separation or severe maternal illness. In this situation, engorgement is likely and steps should be taken to diminish it. The mother may experience &ldquo;milk fever&rdquo; (a condition of a flu-like illness with fever chills and malaise). This is thought to be caused by maternal reabsorption of milk products [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/20\">",
"     20",
"    </a>",
"    ]. Rapid weaning results in a rapid decrease in prolactin, and this may cause an increase in depressive symptoms. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Engorgement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12479719\">",
"    <span class=\"h2\">",
"     Routine weaning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine weaning of the infant after six months of age is most easily accomplished following the child&rsquo;s lead. After the child starts solid foods, the child will diminish breastfeeding, and gradually the weaning process begins. If the weaning is gradual, engorgement is not likely to occur.",
"   </p>",
"   <p>",
"    Strategies for weaning include dropping a breastfeeding session every two to five days, shortening each breastfeeding session, and increasing the time between breastfeeding sessions. Midday feedings are often ideal to eliminate first since the child is often active at this time and so may not become fussy. Persons other than the mother may have more success offering other feedings [",
"    <a class=\"abstract\" href=\"UTD.htm?17/15/17658/abstract/21\">",
"     21",
"    </a>",
"    ]. During the weaning process, it is important that the mother continue to maintain closeness.",
"   </p>",
"   <p>",
"    It may be challenging for exclusively breastfed infants to accommodate to bottle feeding. Older infants may be directly weaned to a cup. For infants being weaned to a bottle, varying the type of nipple may be helpful in those who are having difficulty adjusting to bottle feeding.",
"   </p>",
"   <p>",
"    If engorgement occurs during the weaning process, mothers should try to avoid pumping any more than is necessary to relieve engorgement as this will increase milk supply.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3491?source=see_link\">",
"       \"Patient information: Common breastfeeding problems (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/27/4531?source=see_link\">",
"       \"Patient information: Weaning from breastfeeding (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=see_link\">",
"       \"Patient information: Breastfeeding (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"       \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25602?source=see_link\">",
"       \"Patient information: Weaning from breastfeeding (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"       \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common problems of breastfeeding in the postpartum period are inadequate milk intake by the infant and breast pain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate milk intake may be due to failure of the infant to extract milk or insufficient milk production. Management is focused upon determining the cause of inadequate milk intake based upon a thorough history, direct observation of breastfeeding, and determination of milk volume before and after feeding. Intervention is based upon the identified specific problem. We do not suggest the use of galactagogues to increase milk production (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ), because there are no data showing they are more beneficial than interventions focused upon improving breastfeeding technique. (See",
"      <a class=\"local\" href=\"#H115298521\">",
"       'Inadequate milk intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conditions that typically present with breast pain include engorgement, nipple injury or vasoconstriction, plugged ducts, and breast infections. These problems are usually due in part to incorrect breastfeeding techniques, particularly the inability of the infant to form a good latch-on and to empty the breast. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nipple and breast pain'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Breast infections'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=see_link&amp;anchor=H7#H7\">",
"       \"Initiation of breastfeeding\", section on 'Latch-on'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The primary intervention for conditions that present with breast pain is to identify and correct any improper breastfeeding technique or routine to ensure the infant is achieving a satisfactory latch-on (",
"      <a class=\"graphic graphic_figure graphicRef69241 \" href=\"UTD.htm?40/62/41967\">",
"       figure 1",
"      </a>",
"      ) and is thoroughly emptying the breast on a regular and frequent basis.",
"     </li>",
"     <li>",
"      Other interventions of breast pain depend upon the specific condition as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Interventions for symptomatic pain relief for engorgement include cool compresses, breast massage, milk ejection between feeds, and use of analgesics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ). However, there are no data regarding their comparative efficacy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Engorgement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain due to nipple injury needs to be distinguished from nipple sensitivity, which peaks during the fourth postpartum day and then resolves. Women with nipple injury should be assessed (and if present, treated) for an underlying nipple condition, particularly for improper breastfeeding technique. Topical ointments may be applied for symptomatic relief. (See",
"      <a class=\"local\" href=\"#H12479496\">",
"       'Nipple pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial management of plugged ducts is to assess breastfeeding technique and assure that the breast is thoroughly emptied with each feed. Other interventions include massage and heat application. If there is no resolution after 72 hours, further assessment (and possible intervention) is required. Unrelieved plugged ducts may result in galactoceles (",
"      <a class=\"graphic graphic_picture graphicRef65929 \" href=\"UTD.htm?20/8/20623\">",
"       picture 3",
"      </a>",
"      ), which may need to be aspirated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Plugged ducts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of lactational mastitis and breast abscess are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/28/454?source=see_link\">",
"       \"Lactational mastitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9495?source=see_link\">",
"       \"Breast abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mammary candidosis is a poorly defined entity, and there is a paucity of data regarding its clinical significance, presentation, diagnosis, and management. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Candidal infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other common breastfeeding problems include bloody nipple discharge, milk overproduction, and neonatal jaundice. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Bloody nipple discharge'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Milk oversupply'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Candidal infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Neonatal jaundice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exclusive breastfeeding is recommended for the first six months after birth. High iron solids should be added at six months with continuation of breastfeeding until at least one year of age, and longer according to preferences of the mother and baby. Adequate intake of human milk meets all the known nutritional requirements for infants in the first six months of life and infants. After six months of age, the introduction of solid foods helps to supplement energy, iron, vitamins, and trace elements, and prepare the infant for a more diversified diet. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=see_link&amp;anchor=H23#H23\">",
"       \"Introducing solid foods and vitamin and mineral supplementation during infancy\", section on 'Self-feeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weaning can be accomplished gradually by eliminating one breastfeeding session every two to five days. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Weaning'",
"      </a>",
"      above.)",
"      <br/>",
"      The infant can be weaned to a bottle then a cup, or directly to a cup. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=see_link&amp;anchor=H23#H23\">",
"       \"Introducing solid foods and vitamin and mineral supplementation during infancy\", section on 'Self-feeding'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Drs. Richard Schanler and Debra Potak, who contributed to an earlier version of this topic review. The author acknowledges Kay Hoover IBCLC for her review and contributions to this review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     2011 CDC Breastfeeding Report Card file://www.cdc.gov/breastfeeding/pdf/2011BreastfeedingReportCard.pdf (Accessed on November 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/2\">",
"      Wojcicki JM. Maternal prepregnancy body mass index and initiation and duration of breastfeeding: a review of the literature. J Womens Health (Larchmt) 2011; 20:341.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Breastfeeding. In: Nutrition Handbook, 6th ed, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove 2009. p.29.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/4\">",
"      Leeners B, Rath W, Kuse S, Neumaier-Wagner P. Breast-feeding in women with hypertensive disorders in pregnancy. J Perinat Med 2005; 33:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/5\">",
"      Vanky E, Isaksen H, Moen MH, Carlsen SM. Breastfeeding in polycystic ovary syndrome. Acta Obstet Gynecol Scand 2008; 87:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/6\">",
"      Carlsen SM, Jacobsen G, Vanky E. Mid-pregnancy androgen levels are negatively associated with breastfeeding. Acta Obstet Gynecol Scand 2010; 89:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/7\">",
"      Michalopoulos K. The effects of breast augmentation surgery on future ability to lactate. Breast J 2007; 13:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/8\">",
"      Thibaudeau S, Sinno H, Williams B. The effects of breast reduction on successful breastfeeding: a systematic review. J Plast Reconstr Aesthet Surg 2010; 63:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/9\">",
"      Dewey KG, Nommsen-Rivers LA, Heinig MJ, Cohen RJ. Risk factors for suboptimal infant breastfeeding behavior, delayed onset of lactation, and excess neonatal weight loss. Pediatrics 2003; 112:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/10\">",
"      Sakha K, Behbahan AG. Training for perfect breastfeeding or metoclopramide: which one can promote lactation in nursing mothers? Breastfeed Med 2008; 3:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/11\">",
"      Lewis PA, Devenish C, Kahn C. Controlled trial of metocloproamide in the initiation of breast feeding. Brit J Clin Pharmacol 1980; 9:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/12\">",
"      Anderson PO, Vald&eacute;s V. A critical review of pharmaceutical galactagogues. Breastfeed Med 2007; 2:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/13\">",
"      Forinash AB, Yancey AM, Barnes KN, Myles TD. The use of galactogogues in the breastfeeding mother. Ann Pharmacother 2012; 46:1392.",
"     </a>",
"    </li>",
"    <li>",
"     US National Institute of Health LactMed. file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT (Accessed on February 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/15\">",
"      Ingram J, Taylor H, Churchill C, et al. Metoclopramide or domperidone for increasing maternal breast milk output: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2012; 97:F241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/16\">",
"      Zuppa AA, Sindico P, Orchi C, et al. Safety and efficacy of galactogogues: substances that induce, maintain and increase breast milk production. J Pharm Pharm Sci 2010; 13:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/17\">",
"      Zapantis A, Steinberg JG, Schilit L. Use of herbals as galactagogues. J Pharm Pract 2012; 25:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/18\">",
"      Committee on Health Care for Underserved Women, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 361: Breastfeeding: maternal and infant aspects. Obstet Gynecol 2007; 109:479.",
"     </a>",
"    </li>",
"    <li>",
"     The Academy of Breastfeeding Medicine www.bfmed.org (Accessed on April 14, 2009).",
"    </li>",
"    <li>",
"     Lawrence RA, Lawrence RM. Breastfeeding: A Guide for the Medical Professions, 7th ed, Elsevier Mosby, Maryland Heights 2011. p.253.",
"    </li>",
"    <li>",
"     Meek J, Tippins S. American Academy of Pediatrics New Mother's Guide to Breastfeeding, Bantam Books, 2011. p.150.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/22\">",
"      Melli MS, Rashidi MR, Nokhoodchi A, et al. A randomized trial of peppermint gel, lanolin ointment, and placebo gel to prevent nipple crack in primiparous breastfeeding women. Med Sci Monit 2007; 13:CR406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/23\">",
"      Abou-Dakn M, Fluhr JW, Gensch M, W&ouml;ckel A. Positive effect of HPA lanolin versus expressed breastmilk on painful and damaged nipples during lactation. Skin Pharmacol Physiol 2011; 24:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/24\">",
"      Dodd V, Chalmers C. Comparing the use of hydrogel dressings to lanolin ointment with lactating mothers. J Obstet Gynecol Neonatal Nurs 2003; 32:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/25\">",
"      Marx CM, Izquierdo A, Driscoll JW, et al. Vitamin E concentrations in serum of newborn infants after topical use of vitamin E by nursing mothers. Am J Obstet Gynecol 1985; 152:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/26\">",
"      Barankin B, Gross MS. Nipple and areolar eczema in the breastfeeding woman. J Cutan Med Surg 2004; 8:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/27\">",
"      Noti A, Grob K, Biedermann M, et al. Exposure of babies to C15-C45 mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol 2003; 38:317.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Tuberculosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village 2012. p.755.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/29\">",
"      Anderson JE, Held N, Wright K. Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding. Pediatrics 2004; 113:e360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/30\">",
"      Page SM, McKenna DS. Vasospasm of the nipple presenting as painful lactation. Obstet Gynecol 2006; 108:806.",
"     </a>",
"    </li>",
"    <li>",
"     Czank C, Henderson JJ, Kent JC, et al. Hormonal control of thel actation cycle. In: Textbook of Human Lactation, 1st ed, Hale TW, Hartman PF (Eds), Hale Publishing, Amarillo, Texas 2007. p.90.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/32\">",
"      Mangesi L, Dowswell T. Treatments for breast engorgement during lactation. Cochrane Database Syst Rev 2010; :CD006946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/33\">",
"      Campbell SH. Recurrent plugged ducts. J Hum Lact 2006; 22:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/34\">",
"      Baker TP, Lenert JT, Parker J, et al. Lactating adenoma: a diagnosis of exclusion. Breast J 2001; 7:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/35\">",
"      Sawhney S, Petkovska L, Ramadan S, et al. Sonographic appearances of galactoceles. J Clin Ultrasound 2002; 30:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/36\">",
"      Sabate JM, Clotet M, Torrubia S, et al. Radiologic evaluation of breast disorders related to pregnancy and lactation. Radiographics 2007; 27 Suppl 1:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/37\">",
"      Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #4: mastitis. Revision, May 2008. Breastfeed Med 2008; 3:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/38\">",
"      Dener C, Inan A. Breast abscesses in lactating women. World J Surg 2003; 27:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/39\">",
"      Amir LH, Forster D, McLachlan H, Lumley J. Incidence of breast abscess in lactating women: report from an Australian cohort. BJOG 2004; 111:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/40\">",
"      Andrews JI, Fleener DK, Messer SA, et al. The yeast connection: is Candida linked to breastfeeding associated pain? Am J Obstet Gynecol 2007; 197:424.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/41\">",
"      Francis-Morrill J, Heinig MJ, Pappagianis D, Dewey KG. Diagnostic value of signs and symptoms of mammary candidosis among lactating women. J Hum Lact 2004; 20:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/42\">",
"      Amir LH, Garland SM, Dennerstein L, Farish SJ. Candida albicans: is it associated with nipple pain in lactating women? Gynecol Obstet Invest 1996; 41:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/43\">",
"      Amir LH, Cullinane M, Garland SM, et al. The role of micro-organisms (Staphylococcus aureus and Candida albicans) in the pathogenesis of breast pain and infection in lactating women: study protocol. BMC Pregnancy Childbirth 2011; 11:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/44\">",
"      Hale TW, Bateman TL, Finkelman MA, Berens PD. The absence of Candida albicans in milk samples of women with clinical symptoms of ductal candidiasis. Breastfeed Med 2009; 4:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/45\">",
"      Wiener S. Diagnosis and management of Candida of the nipple and breast. J Midwifery Womens Health 2006; 51:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/46\">",
"      Virdi VS, Goraya JS, Khadwal A. Rusty-pipe syndrome. Indian Pediatr 2001; 38:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/47\">",
"      Wilson-Clay B. Milk oversupply. J Hum Lact 2006; 22:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/15/17658/abstract/48\">",
"      Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4996 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-BFBE39938F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17658=[""].join("\n");
var outline_f17_15_17658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115298521\">",
"      INADEQUATE MILK INTAKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4788312\">",
"      Etiology of inadequate intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4788574\">",
"      - Inadequate milk production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4788650\">",
"      - Poor milk extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1382914774\">",
"      Assessment of intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H115298551\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H115298558\">",
"      - Galactagogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NIPPLE AND BREAST PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H115298707\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H115298714\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H115298898\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H115298905\">",
"      Infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H115298912\">",
"      Maternal breast exam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H115298935\">",
"      - Observed feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12479496\">",
"      Nipple pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H115299012\">",
"      - Normal nipple sensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H115299029\">",
"      - Nipple injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H115299142\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H86657159\">",
"      Biting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H115299157\">",
"      Areolar eczema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86655702\">",
"      - Nipple vasoconstriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H86655811\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Engorgement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Plugged ducts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H202323719\">",
"      - Galactoceles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H832880\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BREAST INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lactational mastitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Breast abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Candidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      BLOODY NIPPLE DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MILK OVERSUPPLY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9183621\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NEONATAL JAUNDICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      WEANING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12479726\">",
"      Abrupt weaning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12479719\">",
"      Routine weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4996\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4996|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/62/41967\" title=\"figure 1\">",
"      Latch on PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/55/41855\" title=\"figure 2\">",
"      Cradle position PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/12/32975\" title=\"figure 3\">",
"      Cross cradle position PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/43/33471\" title=\"figure 4\">",
"      Seated nursing position for breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/26/37280\" title=\"figure 5\">",
"      Anatomy of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4996|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/0/9218\" title=\"picture 1\">",
"      Infant ankyloglossia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/18/42272\" title=\"picture 2\">",
"      Nipple vasoconstriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/8/20623\" title=\"picture 3\">",
"      Galactocele",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44615?source=related_link\">",
"      Ankyloglossia (tongue-tie) in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9495?source=related_link\">",
"      Breast abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/12/36040?source=related_link\">",
"      Breastfeeding the preterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=related_link\">",
"      Candidal intertrigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=related_link\">",
"      Developmental defects of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=related_link\">",
"      Diagnostic approach to lower gastrointestinal bleeding in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=related_link\">",
"      Initiation of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=related_link\">",
"      Introducing solid foods and vitamin and mineral supplementation during infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/28/454?source=related_link\">",
"      Lactational mastitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=related_link\">",
"      Maternal and economic benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=related_link\">",
"      Nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=related_link\">",
"      Overview of benign breast disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=related_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=related_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=related_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3491?source=related_link\">",
"      Patient information: Common breastfeeding problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25602?source=related_link\">",
"      Patient information: Weaning from breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/27/4531?source=related_link\">",
"      Patient information: Weaning from breastfeeding (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=related_link\">",
"      Physiology of lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_15_17659="Findings that increase the certainty of dx of preeclampsia";
var content_f17_15_17659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Findings which increase the certainty of the diagnosis of preeclampsia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Systolic blood pressure of 160 mm Hg or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diastolic blood pressure of 110 mm Hg or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteinuria occurring for the first time during pregnancy, especially if 2.0 g or more in 24 hours. A qualitative result of 2+ or 3+ is also suggestive.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum creatinine greater than 1.2 mg/dL (106 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet count less than 100,000 cells per cubic millimeter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence of microangiopathic hemolytic anemia (eg, elevated lactic acid dehydrogenase)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated liver enzymes (eg, alanine aminotransferase or aspartate aminotransferase)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent headache or other cerebral or visual disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent epigastric pain",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Working group report on high blood pressure in pregnancy. National Instititutes of Health, Washington, DC 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17659=[""].join("\n");
var outline_f17_15_17659=null;
var title_f17_15_17660="Types of birth control PI";
var content_f17_15_17660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F88695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F88695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of birth control",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Methods included",
"       </td>",
"       <td class=\"subtitle1\">",
"        Some information",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Barrier methods",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Male condom",
"         </li>",
"         <li>",
"          Female condom",
"         </li>",
"         <li>",
"          Diaphragm",
"         </li>",
"         <li>",
"          Cervical cap",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        These methods must be used during each sex act. They block sperm from getting into the uterus and reaching a woman's egg. Sometimes a cream or gel that kills sperm must be used along with this type of birth control. Only condoms can reduce the chance of catching a disease from sex.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Short-acting hormonal methods",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Shot/injection",
"         </li>",
"         <li>",
"          Progestin-only pill",
"         </li>",
"         <li>",
"          Estrogen-progestin pill",
"         </li>",
"         <li>",
"          Patch",
"         </li>",
"         <li>",
"          Vaginal ring",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        These methods all use hormones to cause changes in a woman's body that reduce the chance of pregnancy. The different options require a different amount of attention. For example, women having shots must see their doctor every 3 months for a shot. Women taking pills, must take a pill every day. Women using the patch or the ring must change it once a week.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Long-acting methods",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Implantable rod",
"         </li>",
"         <li>",
"          Intrauterine device (IUD) with progestin",
"         </li>",
"         <li>",
"          IUD with copper",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        The implantable rod and the IUD with progestin both use hormones to prevent pregnancy. The IUD with copper releases copper to prevent pregnancy. These stay in the body and keep working for 3 to 10 years, depending on the method chosen.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterilization",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Vasectomy (for men)",
"         </li>",
"         <li>",
"          Tubal occlusion or ligation (for women)",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        These methods involve procedures or surgery and are permanent.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17660=[""].join("\n");
var outline_f17_15_17660=null;
var title_f17_15_17661="Aspirin 325 in unstable angina";
var content_f17_15_17661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspirin is beneficial in unstable angina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 252px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Occurrence of cardiac death or nonfatal MI in 555 patients with unstable angina treated with aspirin (325 mg/day, alone or with sulfinpyrazone) or no aspirin (sulfinpyrazone alone or placebo). Aspirin led to a 51 percent reduction in cardiovascular events; sulfinpyrazone was of no benefit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Cairns JA, Gent M, Singer J, et al. N Engl J Med 1985; 313:1369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17661=[""].join("\n");
var outline_f17_15_17661=null;
var title_f17_15_17662="Oblique foot x-ray with metatarsal shaft fracture";
var content_f17_15_17662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oblique foot x-ray with metatarsal shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 206px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A&nbsp;fracture of the third metatarsal shaft is indicated by the arrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17662=[""].join("\n");
var outline_f17_15_17662=null;
var title_f17_15_17663="C neoformans Sabourauds agar";
var content_f17_15_17663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptococcus neoformans on Sabouraud's agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Culture of Cryptococcus neoformans on Sabouraud's agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_15_17663=[""].join("\n");
var outline_f17_15_17663=null;
